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The effects of betaine and neuregulin-1 on tissue, cellular and molecular changes on in 
vivo and in vitro models of nonalcoholic fatty liver disease and liver fibrosis 
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of 
chronic liver diseases in the general population. NAFLD consists of three major entities 
including steatosis, nonalcoholic steatohepatitis (NASH) and cirrhosis. The principal causes 
of steatosis are insulin resistance and hyperinsulinemia, which lead to increased lipolysis in 
adipose tissue with subsequent inflow of free fatty acids (FFA) to the liver and stimulation 
of hepatic de novo lipogenesis. Lipotoxic effects of FFAs cause mitochondrial dysfunction 
and oxidative stress that lead to the activation of inflammatory response and progression of 
steatosis to NASH. Autophagy is impaired in NAFLD and contributes to the accumulation 
of damaged organelles and proteins in hepatocytes, ultimately leading to apoptosis. Chronic 
liver injury and inflammation stimulate fibrogenic pathways and ultimately may result in 
liver cirrhosis. Hepatic stellate cells (HSCs) play a central role in hepatic fibrogenesis and 
are a major source of collagen and other extracellular matrix proteins. Transforming growth 
factor beta (TGF-β) induces a transdifferentiation of HSCs into myofibroblast-like cells 
which express collagen I gene and alpha-smooth muscle actin. Neuregulin-1 (NRG-1) 
belongs to epidermal growth factor family and is involved in cell differentiation, 
proliferation, growth and survival. Recombinant human NRG-1 (rhNRG-1) exerts 
antifibrotic effects in the heart, lungs, kidneys and skin. However, the exact role of NRG-1 
in liver fibrogenesis has not been elucidated.  
Betaine, 3-methyl glycine is a nontoxic amino acid, a methyl-group donor and exerts 
antioxidative effects by increasing the amount of sulfur-containing amino acids. 
Additionally, betaine may induce epigenetic silencing of genes involved in lipogenesis 
contributing to alleviation of steatosis. On the other hand, the effects of betaine on 
inflammation, autophagy and apoptosis, as well as on signaling pathways involved in 
NAFLD pathogenesis are still not clarified. 
The aims of the dissertation were to define the model of NAFLD using methionine-
choline deficient (MCD) diet in mice; to examine the effects of betaine on liver 
morphological and ultrastructural changes, as well as on oxidative stress, apoptosis, 
autophagy and inflammation in the liver; to study the effects of NRG-1 on connective tissue 
accumulation, gene expressions for collagen type I and III, and matrix metalloproteinases 2 
and 9 (MMP-2 and -9) in murine models of liver fibrosis induced by CCl4 and bile duct 
ligation; to examine effects of NRG-1 on TGF-β gene expression in isolated hepatocytes 
and on ErbB3 and ErbB4 receptors phosphorylation in the liver. 
To set NAFLD animal model, 8 weeks old male C57BL/6 mice (n=28) were 
randomly divided into the following groups (n=7 per group): 1. control, continuously fed 
with standard chow; 2. groups fed with MCD diet for two (MCD2), four (MCD4) or six 
weeks (MCD6). After the treatment blood samples were taken determination of 
transaminase activity and lipid profile. Liver samples were used for pathohistology and 
determination of oxidative stress parameters as well as FFA profile.  
To investigate the effects of betaine on NAFLD, animals (n=28) were on standard 
diet until the age of 8 weeks, and then they have been divided into the following groups 
(n=7 per group): 1. control – continuously on standard diet; 2. BET group – animals on 
standard diet that were treated with betaine solution in drinking water (1.5% solution ad 
libitum) for 6 weeks; 3. MCD group – animals on MCD diet during 6 weeks, and 4. 
MCD+BET group – animals on MCD diet treated with betaine in drinking water. 
Transaminase activities were measured in serum, while oxidative stress parameters, 
autophagy markers (LC3II, p62, mTOR, Beclin 1, Atg4b, Atg5, Atg7), apoptosis markers 
(Bax, Bcl2, Bbc3, Bak1) and markers of inflammation (IL-6, IL-10, TNF-α) were 
determined in liver samples. Ultrastructural changes in liver tissue were examined by using 
transmission electron microscopy. 
The effects of NRG-1 on liver fibrosis were examined on two different animal 
models. In the first model, male C57BL/6j mice (n=32) were divided into the following 
groups (n=8 per group): 1. control –corn oil i.p. 3x per week; 2. NRG-1 group –rhNRG-1 
(20 µg/kg i.p.) 5x per week; 3. CCl4 group –20% CCl4 solution (1mg/kg body weight i.p.) 
diluted in corn oil 3x per week and 4. CCl4+NRG-1 group –both CCl4 and NRG-1 in 
combination in a previously described manner. The duration of treatment in all groups was 
4 weeks. The second liver fibrosis model has been established in mice of the same strain by 
bile duct ligation. Animals (n=32) were divided into four groups (n=8 per group): 1. control 
–phosphate buffered saline (PBS) i.p.; 2. NRG-1 group –rhNRG-1 (20 µg/kg i.p.) 5x per 
week; 3. BDL group – bile duct ligation and PBS, and 4. BDL+NRG-1 group – bile duct 
ligation and rhNRG-1 (20 µg/kg i.p) 5x per week starting 24 hours after the surgery. After 
4 weeks, liver tissue was stained with Masson’s Trichrome to quantify fibrosis and 
determine gene expression for collagen type I and III, and MMP-2 and -9. The presence 
and phosphorylation of ErbB3 and ErbB4 receptors was determined in the liver of control 
and rhNRG-1-treated animals. The expression of TGF-β gene was determined in vitro on 
isolated primary hepatocytes before and 16 hours after NRG-1 stimulation. 
MCD diet for 2 weeks induced mild steatosis with focal fatty change, while after 4 
weeks steatosis was more pronounced with diffuse fatty change. However, MCD diet for 6 
weeks caused diffuse micro- and macro vesicular steatosis accompanied with inflammatory 
infiltrate indicating nonalcoholic steatohepatitis (NASH). MCD diet after 6 weeks induced 
decrease in serum total cholesterol, triglycerides and HDL and increase in LDL vs. control. 
Increase in liver oleic and linoleic acid, and a decrease in saturated and docosohexaenoic 
acid (DHA) were evident in MCD6 group (p<0.01 vs. control). 
Betaine supplementation reduced steatosis and inflammation evident on histology, 
and improved serum lipid profile by decreasing total cholesterol, LDL and increasing HDL 
level compared to MCD group (p<0.01). Betaine reduced lipid peroxidation and nitrosative 
stress that were increased in MCD group, and also improved the activity of antioxidant 
enzymes such as paroxonase, arylesterase, superoxide dismutase, catalase and glutathione 
peroxidase vs. MCD group. Besides, betaine increased liver glutathione concentration and 
reduced the activity of glutathione reductase by comparison with MCD diet-treated group. 
MCD diet for 6 weeks induced an increase in liver tumor necrosis factor alpha (TNF-
α), interleukin (IL)-6 and TGF-β expression while betaine treatment prevented this 
increase. Betaine also increased the expression of anti-inflammatory IL-10 compared to 
MCD group (p<0.05). mRNA expression of Bax was decreased and Bcl2 was increased in 
MCD+BET vs. MCD group (p<0.05). Betaine in combination with MCD diet increased 
mRNA expression of autophagy genes Atg4, Atg5, Atg7 and Beclin1 by comparison with 
control (p<0.05) and MCD group (p<0.05). Levels of SQSTM1/p62 were increased in 
MCD diet-fed mice compared to control (p<0.05), while in MCD+BET group its level was 
significantly reduced compared both with control and MCD group (p<0.05). Electron 
microscopy showed increased presence of autophagosomes and reduced apoptotic bodies in 
betaine treated mice fed with MCD diet when compared to control and MCD group.  
Histology showed severe liver fibrosis in BDL model, while CCl4 induced mild 
fibrotic changes after 4 weeks. NRG-1 treatment significantly increased fibrotic area in 
liver tissue from 1.86 to 2.65 % in CCl4 model and from 5.03 to 8.25 % in BDL-induced 
liver fibrosis (p<0.01). In the BDL model, NRG-1 treatment increased expression of col1a1 
and col3a1 vs. BDL group (p<0.05). NRG-1 treatment resulted in a significant decrease of 
MMP2 expression and there was a trend towards attenuated induction of MMP9 mRNA 
compared to group treated only with CCl4 (p<0.05). In the livers of BDL-treated animals, 
MMP 9 expression was significantly increased compared with control (p<0.01). NRG-1 
treatment increased phosphorylation of liver ErbB3 receptors to a greater extent in relation 
to the ErbB4 receptors (p<0.01). Additionally, NRG-1 treatment induced increased TGF-β 
expression in vitro on isolated hepatocytes, compared to untreated cells (p<0.01). 
Betaine exerts hepatoprotective effects by reducing lipid peroxidation and nitrosative 
stress in MCD diet-induced NAFLD through an increase in liver antioxidant enzyme 
activities and by restoring glutathione content. Betaine alleviated NAFLD by increasing 
autophagy processes in Beclin 1- and Akt/mTOR-dependent manner, but independently on 
AMPK activation. Potential additional mechanisms of betaine in MCD-diet induced 
NAFLD in mice are antiapoptotic and anti-inflammatory effects. Betaine treatment 
prevents initial fibrogenesis by decreasing TGF-β expression in the MCD diet-induced 
NAFLD. NRG-1 aggravates liver fibrosis in CCl4 and BDL mouse model by increasing 
extracellular matrix accumulation. The pro-fibrotic effects of NRG-1 could be the result of 
ErbB3 receptor phosphorylation and activation of the NRG-1/ErbB3 signaling pathway in 
the liver. Betaine delays the progression of steatosis into NASH and may be used as a 
hepatoprotective agent in NAFLD.   
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Dejstvo betaina i neuregulina-1 na tkivne, ćelijske i molekularne promene na in 
vivo i in vitro modelima nealkoholne masne bolesti i fibroze jetre 
 
Uvod 
Nealkoholna masna bolest jetre (eng. non-alcoholic fatty liver disease; NAFLD) je 
jedan od najčešćih uzročnika hroničnih oboljenja jetre u razvijenim zemljama, s obzirom na 
sve veću učestalost gojaznosti i dijabetes melitusa tipa 2 pre svega u mlađoj populaciji. 
NAFLD predstavlja hepatičnu manifestaciju metaboličkog sindroma, koja se može ispoljiti 
u tri oblika: kao masna promena jetre, nealkoholni steatohepatitis (eng. non-alcoholic 
steatohepatitis; NASH) ili ciroza jetre, sa mogućnošću progresije u hepatocelularni 
karcinom. 
Patogeneza NAFLD je kompleksna i još uvek nedovoljno rasvetljena. Savremena 
teorija ukazuje na značaj interakcije brojnih mehanizama na ćelijskom i molekularnom 
nivou u patogenezi NAFLD, tzv.teorija višestrukih udara. Smatra se da centralnu ulogu u 
njenom razvoju ima insulinska rezistencija, što uslovljava povećanje de novo lipogeneze u 
jetri, povećanje lipolize u masnom tkivu, povećan priliv masnih kiselina u jetru i nastanak 
steatoze. Slobodne masne kiseline ispoljavaju lipotoksično dejstvo i uzrokuju 
mitohondrijsku disfunkciju, oksidativni stres, kao i stres endoplazmatskog retikuluma. 
Usled povećanja permeabilnosti sluznice u digestivnom traktu i prolaska endotoksina 
bakterija crevne flore u cirkulaciju, dolazi do pokretanja zapaljenskog odgovora i 
oslobađanja proinflamatornih citokina, kao što su interleukini (IL-1, IL-6, IL-8) i faktor 
tumorske nekroze alfa (TNF-α). Oštećenja ćelija usled zapaljenja i oksidativnog strresa 
dovode do apoptoze i nekroze hepatocita. Ovi mehanizmi dovode do pogoršanja steatoze 
usled oksidativne modifikacije apoB100 i smanjenog efluksa lipoproteina veoma male 
gustine (eng. very low density lipoprotein; VLDL), kao i do progresije steatoze u NASH 
kod genetski predisponiranih osoba.Skorašnje studije ukazuju da su izmenjeni procesi 
apoptoze i autofagije verovatno uključeni u patogenezu NAFLD.  
Hronično oštećenje jetre i inflamacija podstiču razvoj fibroze posredstvom brojnih 
proinflamatornih citokina, faktora rasta i slobodnih kiseoničnih radikala. Centralna uloga u 
fibrogenezi pripada aktiviranim hepatičnim zvezdastim ćelijama, koje su glavni izvor 
kolagena i drugih proteina ekstracelularnog matriksa. Kupferove ćelije i u manjoj meri 
hepatociti i neparenhimske ćelije oslobađaju transformišući faktor rasta beta (eng. 
transforming growth factor-β; TGF-β), slobodne kiseonične radikale i citokine (IL-1, TNF-
α), koji udruženo sa oksidovanim lipoproteinima male gustine (eng. low-density 
lipoprotein; oxLDL) uzrokuju aktivaciju i transdiferencijaciju zvezdastih ćelija u 
miofibroblastima slične ćelije. Aktivirane zvezdaste ćelije eksprimiraju gen za alfa-aktin 
glatkih mišića i gen za kolagen tipa I. Faktor rasta poreklom iz trombocita (eng. platelet-
derived growth factor; PDGF) stimuliše proliferaciju i hemotaksu zvezdastih ćelija i 
sinergistički sa TGF-β podstiče fibrogenezu. Miofibroblasti takođe oslobađaju faktore rasta 
i citokine, koji autokrinim mehanizmom podstiču autoaktivaciju i vode razvoju ciroze jetre. 
Neuregulin-1 (NRG-1) pripada familiji epidermalnog faktora rasta i uključen je u 
procese ćelijske diferencijacije, proliferacije, rasta i preživljavanja. Dejstvo NRG-1 je 
posredovano ErbB3 i ErbB4 receptorima, koji nakon vezivanja liganda grade heterodimere 
sa ErbB2. Dosadašnje studije su pokazale da rekombinantni humani NRG-1 (rhNRG-1) 
igra važnu ulogu u razvoju i održanju strukture kardiomiocita i ispoljava antifibrogeno 
dejstvo u srcu, plućima, bubrezima i koži. Međutim, uloga NRG-1 u procesu fibrogeneze u 
jetri još uvek nije ispitivana. 
Za eksperimentalno izučavanje NAFLD koriste se različiti životinjski modeli, 
genetski, nutritivni kao i njihova kombinacija. Korišćenje dijete deficijentne u metioninu i 
holinu (MCD) je jedan od najčešće korišćenih nutritivnih modela, pre svega zbog 
ponovljivosti i kratkog vremenskog roka za razvoj masnih promena u jetri. Nedostatak 
holina u ishrani, remeti stvaranje fosfatidilholina u jetri, koji je neophodan za sintezu 
VLDL i time doprinosi akumulaciji triglicerida u jeti izazivajući steatozu, praćenu 
inflamacijom i oksidativnim stresom. 
Betain ili 3-metilglicin je netoksična amino kiselina koja se dobija iz različitih 
nutritivnih izvora (školjke, spanać) ili se endogeno sintetiše iz holina. Betain učestvuje u 
remetilaciji homocisteina kao donor metil grupe i ispoljava antioksidativno dejstvo u 
alkoholnoj bolesti jetre kod miševa povećanjem sadržaja aminokiselina koje sadrže sumpor. 
Osim ovog, betain ispoljava i antiinflamatorno dejstvo i smanjuje stepen steatoze u jetri 
mehanizmima nezavisnim od metabolizma homocisteina. Takođe je pokazano da betain 
povećava osetljivost tkiva na insulin kod dijabetičnih životinja delimično smanjenjem 
stresa endoplazmatskog retikuluma.S druge strane, dejstvo betaina na procese autofagije i 
apoptoze kao i na signalne puteve uključene u patogenezu NAFLD još uvek nisu u 
potpunosti razjašnjeni.  
Ciljevi istraživanja 
Definisati model NAFLD na miševima korišćenjem MCD dijete  
Ispitati uticaj betaina na morfološke i ultrastrukturne promene u jetri miševa sa 
NAFLD 
Ispitati uticaj betaina na oksidativni stres, apoptozu, autofagiju i inflamaciju u jetri 
miševa sa NAFLD 
Ispitati dejstvo neuregulina-1 na akumulaciju vezivnog tkiva, ekspresiju gena za 
kolagen tip I i III kao i na gensku ekspresiju matriksmetaloproteinaza 2 i 9, na modelima 
fibroze izazvanim podvezivanjem duktusa holedohusa i primenom ugljen tetra hlorida 
(CCl4) 
Ispitati in vitrodejstvo neuregulina-1 na ekspresiju gena za TGF-β na izolovanim 
hepatocitima 
Ispitati uticaj neuregulina-1 na fosforilaciju ErbB3 i ErbB4 receptora u tkivu jetre 
Materijal i metode 
Eksperimentalni dizajn 
Eksperimenti su izvođeni na mužjacima miševa C57BL/6 soja, prosečne telesne mase 
23±3g, uzgajanih na Vojnomedicinskoj akademiji u Beogradu. Životinje se čuvaju pod 
standardnim laboratorijskim uslovima (temperatura 22±2
o
C, relativna vlažnost 50±10%, 
ciklus svetlost/tama 12/12 h), i pre početka eksperimenta imaju ad libitum pristup 
standardnoj hrani i vodi. 
U prvom delu istraživanja, u cilju definisanja modela NAFLD, životinje (n=28) 
uzrasta 8 nedelja, su randomizacijom bile podeljene u sledeće grupe: 1. kontrola (n=7) – 
kontinuirano na standardnoj dijeti; 2. MCD2, MCD4 i MCD6 (n=7 po grupi) – grupe 
životinjana MCD dijeti u trajanju od dve, četiri i šest nedelja. Nakon tretmana uzorci krvi 
su uzeti za određivanje aktivnosti transaminaza (alanin- i aspartat-animotransferaza, ALT i 
AST) spektrofotometrijskom metodom i lipidnog profila (holesterol, trigliceridi, LDL i 
lipoproteini velike gustine /eng. high-density lipoprotein; HDL/).Uzorci jetre su korišćeni 
za patohistološku analizu stepena razvoja masnih promena u jetri i prisustva zapaljenskog 
infiltrata. Pored toga, određivani su parametri oksidativnog stresa i antioksidativne zaštite, a 
gasnom hromatografijom je određen profil zasićenih i nezasićenih masnih kiselina u tkivu 
jetre.  
Drugi eksperiment je sproveden u cilju ispitivanja efekata betaina na tok NAFLD. 
Životinje (n=28) su do 8 nedelja starosti bile na standardnoj ishrani, a potom podeljene u 
sledeće grupe: 1. kontrolna grupa (n=7) - kontinuirano na standardnoj ishrani, 2. BET grupa 
(n=7) – životinje na kontrolnoj ishrani, koje su dobijale betain rastvoren u vodi za piće 
(1,5% rastvor ad libitum), 3. MCD grupa – na MCD dijeti tokom 6 nedelja, i 4. MCD+BET 
grupa – životinje na MCD dijeti uz suplementaciju betainom u vodi za piće. Nakon 6 
nedelja, životinje su žrtvovane i za analizu su uzeti uzorci krvi i jetre. U serumu je 
određivana aktivnost transaminaza, a u tkivu jetre su određivani: 
Markeri oksidativnog stresa - koncentracija lipidnih peroksida, sadržaj redukovanog 
glutationa (GSH), aktivnost glutation reduktaze i peroksidaze (GRed i GPx), aktivnost 
superoksid dizmutaze (SOD) i njenih izoenzima, katalaze, paroksonaze (PON1), 
arilesteraze (ARE) kao i sadržaj nitrita i nitrata (NOx). 
Markeri autofagije –nivoi proteina LC3II, p62, mTOR i genska ekspresija Beclin 1, 
Atg4b, Atg5 i Atg7 
Markeri apoptoze – Bax, Bcl2, Bbc3, Bak1 
Markeri zapaljenja – IL-10, IL-6, TNF-α i profibrogeni marker TGF-β 
Transmisionom elektronskom mikroskopijom ispitivaće se ultrastrukturne promene u 
jetri 
U trećem delu istraživanja je ispitivan uticaj NRG-1 na fibrozu jetre na dva 
eksperimentalna modela. U prvom modelu mužjaci miševa C57BL/6j soja (n=32) su 
podeljeni u sledeće grupe (8 životinja po grupi): 1. kontrola –tretirana kukuruznim uljem 
i.p. 3x nedeljno; 2. NRG-1 grupa–tretirana rhNRG-1 (20 µg/kg i.p.) 5x nedeljno; 3. CCl4 
grupa –tretirana 20% rastvorom CCl4(1 mg/kgi.p.) u kukuruznom ulju 3x nedeljno i 4. 
CCl4+NRG-1 grupa – tretirana kombinacijom CCl4 i rhNRG. Drugi model fibroze je bio 
postavljen podvezivanjem ductusa choledochusa (eng. bile duct ligation, BDL) miševima 
istog soja. Životinje (n=32) su bile podeljene u četiri grupe: 1. kontrola –tretirane PBS-om 
(eng. phosphate saline buffer) i.p.; 2. NRG-1 grupa –tretirana rhNRG-1 (20 µg/kg i.p.) 5x 
nedeljno, 3. BDL – životinje kojima je podvezan žučni kanal i tretirane PBSom i 4. 
BDL+NRG-1 – životinje kojima je bio podvezan žučni kanal i tretirane su rhNRG-1 (20 
µg/kg i.p.) 5x nedeljno počev od prvog dana nakon operacije. Nakon četiri nedelje, 
životinje su bile žrtvovane u opštoj anesteziji, a uzorci krvi i jetre su bili uzeti za analizu. U 
krvi je određivana aktivnost transaminaza, a tkivo jetre bojeno Masson’s Trichrome 
bojenjem u cilju kvantifikacije fibroze. Pored toga u jetri je bila određivana ekspresija gena 
za kolagen tipa I i III i matriksmetaloproteinaze (MMP) 2 i 9. U tkivu jetre kontrolne i 
životinje stimulisane rhNRG-1, je određivano prisustvo i fosforilacija ErbB3 i ErbB4 
receptora za NRG-1. U in vitro uslovima ekspresija gena za TGF-β je određivana na 
izolovanim hepatocitima pre i 16 h nakon stimulacije NRG-1. 
Patohistološka analiza 
Uzorci tkiva se fiksiraju u 10% rastvoru formaldehida na sobnoj temperaturi. Isečci 
debljine 5 μm se prožimaju rastopljenim parafinom, potom boje hematoksilinom i eozinom 
(HE) odnosno Masson’s Trichrome bojenjem i pripremaju se za analizu svetlosnim 
mikroskopom. Preparati su analizirani i fotografisani pomoću svetlosnog mikroskopa 
(OlympusBX51 opremljenim Artcore 500 MI artray, Co.Ltd. Japan kamerom). Stepen 
fibroze je kvantifikovan pomoću ImageJ 1.42 softvera, izračunavanjem procenta pozitivno 
obojenih površina u odnosu na ukupnu površinu analiziranog tkiva. 
Transmisiona elektronska mikroskopija 
Uzorci tkiva jetre se periodu od 2h fiksiraju potapanjem u 4% rastvor  
paraformaldehida i u 2% rastvor glutaraladehida. Uzorci tkiva se zatim ponovo fiksiraju u 
1% rastvoru osmijum tetroksida, pa dehidriraju u rastvorima etanola rastuće koncentracije, 
da bi zatim ultramikrotomom bili pravljeni preseci tih tkivnih blokova (Leica Ultracut 
UCT, Beč, Austrija). Polutanki isečci (0,5 µM) se posle sečenja na ultramikrotomu, boje 
toluidin plavim i koriste se za identifikaciju oblasti od interesa.  Ultratanki isečci (70-80 
nm) se dobijaju serijskim sečenjem polutankih isečaka i boje se olovo-citratom i uranil-
acetatom radi dobijanja kontrasta. Na kraju, uzorci se posmatraju transmisionom 
elektronskom mikroskopijom (Fei, Morgagni 268D, Ajndhoven, Holandija) radi 
detektovanja ultrastrukturnih promena. 
 
Određivanje parametara oksidativnog stresa  
Uzorci jetre su homogenizovani na ledu u 0,25 M hladno puferovanom saharoznom 
medijumu, u 10 M fosfatnom puferu (0,25 M saharoze, 10 mM K/NaPO4 pufer, pH 7,0 i 1 
mmol/L EDTA). Homogenati tkiva su centrifugirani na 2000 obrtaja tokom 15min na 4
o 
C. 
Supernatanti (nadtalozi)se prebacuju u epruvete i  potom centrifugiraju na 3200 obrtaja 
tokom 30 min na 4
o 
C. Dobijeni supernatanti (nadtalozi)se čuvaju na - 70˚C i u njima je 
merena koncentracija lipidnih peroksida, GSH, GRed i GPx, SOD i njenih izoenzima, 
katalaze, PON1, ARE kao i sadržaj NOx.  
Određivanje lipidnog profila u plazmi i profila slobodnih masnih kiselina u jetri 
Nivo ukupnog holesterola u plazmi je određivan merenjem vodonik peroksida koji 
nastaje pod desjtvom holesterol oksidaze u reakciji sa 4-aminotriptinom i fenolom na 
500nm. Koncentracija LDL je određivana kombinacijom ultracentrifugiranja i precipitacije 
opisanim po Friedewaldu, dok je HDL odeđivan korišćenjem enzimske kolorimetrijske 
metode, a ukupni trigliceridi korišćenjem modifikovanog reagensa 2,4,6,-tribromo-3-
hidroksibenzoične kiseline. 
Slobodne masne kiseline u uzorcima jetre su određivane gasnom hromatografijom sa 
plamenim jonizacionim detektorom. 
Western Blot 
Uzorci tkiva jetre su najpre homogenizovani u RIPA puferu koji sadrži koktel 
inhibitora proteaza i fosfataza. Nakon centrifugiranja na 14000G tokom 5 minuta, 
supernatant (nadtalog) se uzima i koristi za dalju analizu. Iste količine proteina za svaki 
uzorak se radvajaju elektroforezom, a zatim prenose na nitrocelulozne membrane i 
inkubirajupreko noći na 4°C sa odgovarajućim primarnim antitelima: antitelo specifično za 
protein mikrotubule 1 lakog lanca 3II (LC3 II), sekvestozom (SQSTM1/p62), AMPKα1/2, 
fosfo-AMPKα1/2 (Thr172), Akt, fosfo-Akt (Ser473), mTOR, fosfo/mTOR (Ser2448), 
p70S6 kinase (S6K), fosfo-S6K (Thr389), ErbB3, ErbB4, fosfo-ErbB3,  fosfo-ErbB4, 
GAPDH i aktin. Nakon toga membrane su bile inkubirane sa kozjim ili zečjim sekundarnim 
antitelima konjugovanim peroksidazom tokom 1h na sobnoj temperaturi. Specifični proteini 
su vizuelizovani korišćenjem pojačavajućih hemi-luminscentnih reagenasa i ChemiDoc MP 
sistema. Nivoi proteina su bili kvantifikovani pomoću denzitometrije korišćenjem ImageJ 
softvera i izraženi  u odnosu na kontrolni protein aktin ili GAPDH. 
Real time PCR 
Nakon izolacije, 1µg RNK je bio korišćen za reakciju reverzne transkripcije, 
korišćenjem reverzne transkriptaze i oligo(dt) prajmera prema uputstvu proizvođača. Real 
time PCR analiza se izvodila na pločama sa 96 bunarića, pomoću TaqMan Universal 
Master Mix-a i TaqMan prajmerima za TNF-α, IL-6, IL-10, TGF-β, Bax, Bak1, Bbc3, 
Bcl2, Atg4b,Atg5, Atg7, beclin-1,  kolagen tip I (col 1a1), kolagen tip III (col3a1), MMP-2 
i MMP-9. Genska ekspresija traženih gena je bila normalizovana u odnosu na ekspresiju 
18S ribozomalne RNK (Rn18s) ili β-aktina. Real-time PCR analize su izvođene 
naRealplex
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 Mastercycler (Eppendorf, Hamburg, Germany) korišćenjem ploča sa 96 polja. 
Rezultati 
 MCD dijeta je izazvala blagu steatozu sa fokalnim masnim promenama nakon 2 
nedelje, koja je bila izraženija nakon 4 nedelje. Difuzna makro- i mikrovezikularna steatoza 
sa inflamatornim infiltratom bila je prisutna u grupi miševa na MCD dijeti tokom 6 nedelja 
ukazujući na razvijen NASH. MCD dijeta je uzrokovala promeneu lipidnom profilu u 
serumu miševa, značajno smanjujući ukupni holesterol, tigliceride i HDL i povećavajući 
koncentraciju LDLa. Značajne promene su uočene i u hepatičnom profilu slobodnih masnih 
kiselina, gde je MCD dijeta za 6 nedelja uzrokovala porast oleinske i linolne kiseline, a 
smanjenje zastupljenosti zasićenih i polinezasićenih (C 22:6n3, C 22:5n3)masnih kiselina 
(p<0,01 u odnosu na kontrolu). 
Suplementacija betainom je vidljivo ublažila steatozu i inflamaciju na histološkom 
nalazu i poboljšala lipidni profil u serumu smanjujući nivo ukupnog holesterola i LDLa, a 
povećavajući nivo HDLa u poređenju sa MCD grupom (p<0,01). Betain je takođe smanjio 
lipidnu peroksidaciju i nitrozativni stres čiji su parametri MDA i NOx bili značajno 
povišeni u MCD grupi. Takođe, betain je povećao aktivnost antioksidativnih enzima PON1, 
ARE, ukupnu SOD, katalazu i GPx u poređenju sa MCD grupom. Pored toga, betain je 
značajno povećao sardžaj glutationa u jetri i smanjio aktivnost GRed u odnosu na grupu 
hranjenu MCD dijetom (p<0,01). 
MCD dijeta u trajanju od 6 nedelja je uzrokovala porast u mRNK ekspresiji TNF-α, 
IL-6 i TGF-β, dok je suplementacija betainom sprečila ovaj porast. Betain je, takođe, 
povećao ekspresiju antiinflamatornog IL-10 u odnosu na grupu tretiranu MCD dijetom, 
koja je dovela do sniženja njegove ekspresije (p<0,05). Ekspresija proapoptotskog Bax je 
bila snižena, a expresija Bcl2, koji ima antiapoptotsko dejstvo je bila povišena u 
MCD+BET grupi u odnosu na MCD (p<0,05). 
Suplementacija betainom je dovela po povećanja expresije gena za autofagiju Atg4, 
Atg5, Atg7 i Beclin1 u poređenju sa kontrolnom i MCD grupom (p<0,05). MCD dijeta je 
izazvala povećanje nivoa SQSTM1/p62 u odnosu na kontrolu (p<0,05), dok je betain 
izazvao značajno smanjenje nivoa SQSTM1/p62 u odnosu i na kontrolu i MCD grupu 
(p<0,05). Analiza elektronsom mikroskopijom je pokazala povećano prisustvo 
autofagozoma, kao i smanjeno prisustvo apoptotskih telašaca kod miševa na MCD dijeti 
koji su bili tretirani betainom u odnosu na kontrolnu i MCD grupu. 
Histološko Masson’s trichrome bojenje je pokazalo iraženu fibrozu u BDL modelu, 
dok je CCl4izazvao blaži stepen fibroze nakon četiri  nedelje. NRG-1 tretman je statistički 
začajno pogoršao fibrozu jetre od 1,86 na 2,65% u CCl4– izazvanoj fibrozi,  od 5,03 na 
8,25% u fibrozi izazvanoj podvezivanjem žučnih puteva (p<0,01). Ekspresija gena za 
col1a1 i col3a1 nije bila promenjena pod dejstvom NRG-1 u CCl4 grupi, dok je na modelu 
izražene fibroze NRG-1 doveo do povećanja genske ekspresije za oba tipa kolagena 
(p<0,05). Pored toga, NRG-1 je indukovao značajno smanjenje ekspresije za MMP2 u 
odnosu na CCl4 grupu (p<0,05). U BDL grupi, genska ekspresija za MMP9 u jetri je bila 
značajno povišena u odnosu na kontrolu (p<0,01), dok tretman NRG-1 nije uzrokovao 
promene u ekspresiji gena za MMP2 i MMP9 (p>0,05). 
NRG-1 je izazvao povećanu fosforilaciju ErbB3 receptora u jetri miševa u mnogo 
većoj meri nego ErbB4 (p<0,01). Pored toga, NRG-1 je povećao gensku ekspresiju za TGF-
β in vitro na izolovanim hepatocitima, u poređenju sa netretiranim ćelijama (p<0,01). 
Betain ispoljava antioksidativno dejstvo smanjenjem lidpidne peroksidacije i 
nitrozativnog stresa u NAFLD izazvanoj MCD dijetom, kroz povećanje aktivnosti 
antioksidativnih enzima u jetri i obnavljanjem sadržaja GSH. Dodatno, betain snižava nivo 
triglicerida i LDL u serumu, a ujedno dovodi do povećanja nivoa HDL holesterola.  
Betain ublažava tok NAFLD potencijalno indukcijom procesa autofagije kroz 
povećanje ekspresije gena Atg4, Atg5, Atg7 i Beclin 1, nezavisno od AMPK/mTOR 
signalnog puta. Smanjenje apoptoze i inflamacije u NAFLD izazvanoj MCD dijetom, je još 
jedan potencijali mehanizam protektivog dejstva betaina. Suplementacija betainom je 
smanjila ekspresiju gena za TGF-β, ublažavajući time inicijalnu fibrozu jetre na modelu 
NAFLD.  
NRG-1 pogoršava fibrozu jetre miševa naCCl4 i BDL modelu, povećanjem ekspresije 
gena za kolagen tip I i III, potencijalno dovodeći po povećane sinteze ekstracelularnog 
matriksa. Profibrogeni efekti NRG-1 su rezultat povećane fosforilacije ErbB3 receptora i 
aktivacije NRG-1/ErbB3 signalnog puta u jetri. 
 
Ključne reči: NAFLD, betain, oksidativni stres, autofagija, fibroza jetre, neuregulin-1 
Naučna oblast: Medicina 
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1.1. Definition and epidemiological data 
NAFLD is the hepatic manifestation of metabolic syndrome, and represents a wide 
spectrum of liver diseases, ranging from simple steatosis, nonalcoholic steatohepatitis 
(NASH), and fibrosis with the potential to progress into cirrhosis and hepatocellular 
carcinoma (HCC) (1). 
NAFLD is the most common liver disease in the Western countries and is strongly 
associated with metabolic syndrome (MetS) and insulin resistance. Nowadays, NAFLD is 
considered as emerging public health issue worldwide with an increasing prevalence among 
general population, that is in the range of 20-40% (2,3). Over past two decades, the 
prevalence of type 2 diabetes mellitus (T2DM) has been increasing rapidly accompanied 
with obesity, especially among children (4). Global prevalence of NAFLD is 25.24% with 
highest values in the Middle East and South America, and the lowest in Africa. Metabolic 
comorbidities that are associated with NAFLD include obesity, T2DM, hyperlipidemia, 
hypertension and MetS (3). All these comorbidities represent risk factors for cardiovascular 
diseases, which are one of the leading cause of death in NAFLD patients (2). 
NAFLD is usually described as accumulation of fat in hepatocytes, predominantly in 
the form of triglycerides that occurs in the absence of alcohol intake. It is often without 
symptoms, and can be present for years undetected (5).  
1.2. Pathogenesis of NAFLD 
 
 According to “two-hit” hypothesis, steatosis makes liver vulnerable to various 
second-hits that lead to inflammation and further hepatocytes damage (6). Lipid 
accumulation is described as a first hit in NAFLD development. However, it is now evident 
that two-hit theory is too simplistic to describe the complexity of NAFLD pathogenesis, 
where multiple parallel factors are acting synergistically and contribute to disease 
development and progression (Figure 1.1.). That is why “multiple-hit” hypothesis is used 
today to cover all molecular mechanisms and signaling pathways that occurs in NAFLD 
(7). Steatosis is usually associated with increased secretion of hepatokines, decreased 
3 
 
glycogen synthesis, increased gluconeogenesis and inhibition of insulin signaling (8,9). 
Accumulation of excess lipids in hepatocytes causes insulin resistance that is followed by 
chronic inflammation which increases the risk of NAFLD progression into fibrosis, 
cirrhosis or eventually HCC. Besides dyslipidemia, today it is well known that adipose 
tissue dysfunction/inflammation is crucial in NAFLD pathogenesis, as well as oxidative 
stress and dysbiosis of the gut microbiota accompanied with increased absorption of 




Figure 1.1. Schematic diagram showing the course and progression of liver steatosis 
to steatohepatitis and cirrhosis. Various pathogenetic mechanisms are involved as described 
by “multiple-hit” theory, where first hit represents lipid accumulation and lipotoxicity, 





Visceral obesity is closely linked with NAFLD, which occurs in 60-95% of obese 
people. The importance of visceral fat has been shown in many experimental studies on 
obese animals (12). Visceral adipose tissue is a metabolically active and inflammatory 
organ, that can modulate the metabolism and function of liver, muscles, brain and 
cardiovascular system (13). The production of pro- and anti-inflammatory adipokines is 
imbalanced in patients with NAFLD (14). Adiponectin and leptin are the most important 
adipokines involved in NAFLD pathogenesis and have been studied the most. Leptin is an 
anorexigenic hormone that prevents lipid accumulation in non-adipose tissues, and in the 
liver this is achieved by decreasing the expression of sterol regulatory element-binding 
protein-1 (SREBP-1). In obese people, leptin levels increase as a consequence of leptin 
resistance, and it exerts pro-fibrogenic characteristics through activation of stellate cells via 
the hedgehog and mTOR pathway, as well as by stimulating Kupffer cells to produce 
transforming growth factor (TGF)-β (7,15). Adiponectin has hepatoprotective effects by its 
ability to reduce inflammation inhibiting the release of proinflammatory cytokines such as 
interleukin (IL)-6 and tumor necrosis factor (TNF)-α (15) and improving insulin resistance.  
Antifibrotic effect of adiponectin is potentially mediated by the AMP-activated protein 
kinase (AMPK) activation (7,16). Besides these two well-characterized adipokines, recent 
research revealed other adipokines with a potential role in NAFLD such as visfatin, grelin, 
resistin, chemerin, apelin, lipocalin, and retinol-binding protein (15,17). 
1.2.1. Lipotoxicity in NAFLD pathogenesis 
 
Fat accumulates in the liver predominantly in the form of triglycerides, which are 
derived from glycerol esterification and from free fatty acids. Sources of free fatty acids are 
dietary intake, lipolysis in adipose tissue and hepatic de novo lipogenesis. When free fatty 
acids reach hepatocytes, they undergo acyl-CoA synthases activity and form fatty acyl-CoA 
that can enter β-oxidation cycle or undergo esterification (7,18). Accumulation of 
triglycerides per se does not exert hepatotoxic effects. On the contrary, it can represent a 
protective mechanism to balance the excess of free fatty acids in the liver that has been 
shown in mouse models of fatty liver disease (19). However, in NAFLD, inhibition of 
triglyceride incorporation in very low-density lipoprotein (VLDL) followed by decreased 
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free fatty acid oxidation occurs simultaneously with lipotoxicity and toxic metabolites 
generation and therefore leads to more severe liver damage and worsening of steatohepatitis 
(20). De novo lipogenesis in the liver is increased by activation of transcription factors such 
as SREBP-1, carbohydrate response element-binding protein (ChREBP) and peroxisome 
proliferator-activated receptor (PPAR)-γ (21). Free fatty acids in liver cells induce 
disruption in insulin signaling pathways and contribute to insulin resistance. Insulin 
resistance is described as a condition with higher insulin levels required to achieve normal 
metabolic response and circulating glucose regulation. Insulin resistance is manifested as a 
reduced ability of insulin to inhibit glucose production in the liver and to stimulate the 
utilization of glucose in adipose tissue and skeletal muscles (22). In the state of insulin 
resistance, lipolysis in adipose tissue is impaired, which further increases free fatty acids 
efflux to the liver. Insulin resistance is a cardinal feature of NAFLD and is more prevalent 
in patients with NASH compared to simple steatosis (7). Insulin resistance increases fat 
tissue lipolysis, circulating levels of free fatty acids and decreases glycogen storage in the 
liver, which stimulates gluconeogenesis. Insulin resistance can be central (hepatic) and 
peripheral (skeletal muscle and adipose tissue). Peripheral is manifested as a reduced 
uptake of glucose from blood in muscles and fat tissue with increased efflux of free fatty 
acids, while central is manifested as uncontrolled production of hepatic glucose resulting 
from impaired suppression of gluconeogenesis and glycogen synthesis (22). Lipotoxicity 
impairs insulin signaling by promoting oxidative damage and inflammation, leading to 
steatosis progression to NASH, fibrosis and cirrhosis (23,24). It is known that lipotoxicity 
promotes cell death in NAFLD and is called hepatocytes lipoapoptosis, whose degree 
correlates with severity of NAFLD (25,26). When the lipid influx to the liver cannot be 
handled by mitochondrial or peroxisome function, respiratory oxidation processes may be 
altered and collapse with impairment of lipid homeostasis, increased generation of toxic 
lipid metabolites and reactive oxygen species (ROS). Molecular oxygen, which accepts 
electrons, is the main source of radicals. The most important are hydroxyl radical (•OH), 
nitric oxide radical (NO•) and the superoxide anion (O2•−). These unstable and reactive 
radicals are generated as products of intracellular metabolic reactions and have the ability 
toreact with proteins, free fatty acids, and DNA. Mitochondria represents the main 
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endogenous intracellular sources of ROS, but ROS are being produces in endoplasmic 
reticulum (ER), and peroxisomes as well. On the other hand, superoxide anion radicals 
(O2•−) are produced as a result of enzymatic activity, such as cytochrome P450 metabolism 
and xanthine oxidase (27).  
1.2.2. Oxidative stress in NAFLD pathogenesis 
 
Oxidative stress is recognized as a key mechanism responsible for liver damage in 
general, and is result of imbalance between prooxidant and antioxidant mechanisms in the 
favor of prooxidation. Usually it is a consequence of excessive ROS production combined 
with reduced activity of antioxidant enzymes. Altered function of mitochondria results in 
ROS overproduction leading to increased lipid and protein peroxidation that consequently 
alters lipid metabolism in the liver, playing thus significant role in steatosis and 
steatohepatitis development (28). Long-chain fatty acids contribute to generation and 
release of ROS by lipooxigenation through activity of microsomal cytochromes, CYP2E1 
and CYP4A. Microsomal and peroxisomal oxidation are normally involved in fatty acids 
metabolism, but their activity is increased when long-chain fatty acids are accumulated due 
to the decrease in CYP2E1 (28). ROS may interact with polyunsaturated fatty acids. The 
result of intracellular lipid peroxidation leads to formation of 4- hydroxy-2-nonenal (4-
HNE) and malondialdehyde (MDA). These products freely diffuse outside of cells causing 
the damage of distant cells, therefore amplifying the toxic effects of oxidative stress. All 
sources of ROS, including mitochondria, xanthine oxidase, endoplasmic reticulum, 
CYP2E1 and peroxisome can contribute to NAFLD development and progression (28). 
The major enzymes which serve as antioxidants are copper/zinc superoxide dismutase 
(Cu/ZnSOD) and manganese-superoxide dismutase (MnSOD) which promote reduction of 
O2•− toH2O2. Besides, glutathione peroxidase (GPx) is another important antioxidant 
enzyme that facilitates conversion of H2O2 into water (28). It has been proven that 
decreased antioxidant defense plays a significant role in oxidative damage in NASH, 
predominantly decreased hepatic glutathione (GSH) and decreased activity of SOD, GPx 
and glutathione transferase, which correlates with disease severity (28,29). It was observed 
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that in patients with NAFLD decreased activity of antioxidants is accompanied with 
increased serum markers of oxidative stress, while in animal models of NAFLD these 
findings are confirmed with low levels of mitochondrial GSH (28,30).  
Damaged function of mitochondrial respiratory chain is the main source of ROS, 
superoxide, hydrogen peroxide, and hydroxyl radicals. Acute oxidative stress can be a 
result of inflammation, organ infarction, reperfusion injury and shock. In the stressed 
condition, oxidative reactions such as β-oxidation, tricarboxylic acid (TCA) cycle turn 
oxidized (NAD+ and FAD) into reduced (NADH and FADH2) cofactors. After the 
oxidation of these reduced cofactors, through the respiratory chain electrons are being 
transferred to molecular oxygen. During prolonged oxidative stress, mitochondria lose their 
function of detoxification superoxide and their capacity to control the oxidative balance is 
being reduced or completely collapsed (27). Injured mitochondria become an additional 
source of excess superoxide due to electron leakage and conversion of superoxide into 
hydrogen peroxide by SOD. Hydrogen peroxide can be metabolized by GPx or catalase to 
water. Fenton and/or Haber-Weiss reactions generate highly reactive and toxic ROS and are 
mediated by iron, an inducer of oxidative stress which is found to be elevated in NASH 
(27,31,32). High plasma levels of citrate promote oxidative stress mediated by iron, by 
increasing hydroxyl radical formation. Besides, fatty acid and glucose in higher 
concentrations elevate pyruvate and acetyl-CoA increasing citrate formation. Furthermore, 
ROS can interact with polyunsaturated fatty acids and initiate lipid peroxidation and MDA 
or 4-HNE formation which can spread oxidative stress (33). β-oxidation in mitochondria is 
not inhibited until the respiratory chain is severely damaged resulting in accelerated ROS 
production, making mitochondria the major source of oxidative stress. However, ER stress 
can induce production of superoxide and hydrogen peroxide by activity of monooxygenases 
(cytochrome P450 and peroxisomes). Antioxidant defense in mitochondria is not powerful 
enough to deal with continuous and prolonged oxidative stress that results in mitochondrial 
DNA and respiratory chain damage (27,34). Mitochondrial DNA damage results in 
accumulation of mutations that cannot be repaired completely. Causing this chain reaction, 
oxidative stress is more and more pronounced and large amounts of ROS continue to be 
generated and further damage other mitochondria or organelles inducing cellular apoptosis.  
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Highly reactive ROS and lipid peroxidation products are able to diffuse into the 
extracellular space affecting neighboring Kupffer cells and hepatic stellate cells (HSC). 
Kupffer cells directly uptake free fatty acids and free cholesterol, and together with 
oxidative injury of hepatocytes induce activation of nuclear transcription factor (NF)- κB, 
that consequently increase the synthesis of TNF-α and proinflammatory cytokines such as 
IL-6 or IL-8 (27,35). Kupffer cells produce TGF-β resulting in HSCs activation and 
acquiring a fibrogenic myofibroblast-like phenotype. Exposing HSC to hydroxyl radicals 
lead to an increase in ER stress that further stimulate  autophagy and HCS activation and 
transformation to fibrogenic phenotype (27,36). Autophagy, an adaptive response to 
cellular stress is up-regulated in activated HSC in the state of liver damage (27,37). 
ROS consequently activate an inflammatory response contributing to hepatocytes 
necroinflammation and worsening of mitochondrial damage (38,39). There is a strong 
connection between the degree of oxidative stress and severity of NASH. Peroxidation of 
phospholipids on mitochondrial membranes lead to alteration of electron transportation 
system and ROS overproduction. Besides, high blood glucose level is associated with 
increased glucose autooxidation, glycation, inhibition of antioxidant enzymes, and 
mitochondrial dysfunction. In NAFLD insulin resistance contributes to the increase in 
CYP2E1 expression, which can potentiate liver injury (29).  
Increased ROS production is accompanied with a decrease in antioxidant defense, 
which is strong factor promoting oxidative stress in NASH. Decrease in SOD, catalase and 
GSH correlate with severity of the liver injury. Several mechanisms are described by which 
ROS contribute to NASH development. Free radicals cause lipid peroxidation, as well as 
oxidative modification of hepatocytes DNA and cell proteins, and mitochondrial electron 
transportation chain leading to even more increase in ROS production. Not only ROS are 
involved in oxidative damage of hepatocytes, but also it has been show that nitric oxide 
(NO) level is also increased leading to formation of reactive nitrogen species (RNS) that 




1.2.3. Inflammation in NAFLD pathogenesis 
 
ROS have strong potential to activate inflammatory cascade by the activation of the 
NF-κB followed by the increase in IL-1, IL-6, IL-8, IL-10 and IL-17 expression as well as 
TGF-β and platelet-derived growth factor (PDGF) (41). Two main inflammatory signaling 
pathways C-Jun N-terminal kinase (JNK)-AP-1 and IKK-NK-κB are predominantly 
involved in chronic inflammation process in NAFLD. Various animal studies support the 
key role of hepatic cytokines in NAFLD progression, suggesting that increased levels of 
cytokines cause typical histological changes such as necrosis and apoptosis of hepatocytes, 
neutrophil infiltration, HSCs activation and production of Mallory bodies (7). Since 
inflammation, increased TNF-α and NF-κB activation can promote liver disease 
progression, the chronic inflammatory state present in NAFLD may play an important role 
in HCC development (7,23,42).  
Recent studies have demonstrated that activity of Kupffer cells represents an 
important factor in initiation and progression of NAFLD. Kupffer cells, liver macrophages, 
are located in sinusoids, and can exhibit an M2-like phenotype in normal conditions and 
express several toll-like receptors (TLR) (43,44). After TLR ligand binding, Kupffer cells 
can induce T cell activation and cytotoxic T-lymphocytes response followed by neutrophil 
and monocytes infiltration. There is a known interaction between Kupffer cells and various 
immune cells, such as T lymphocytes, dendritic cells, HSCs and innate lymphocytes. 
Besides M2, TLRs have ability to activate Kupffer cells towards the M1 phenotype. Signals 
leading to macrophage activation converge on two main downstream pathways, NF-κB and 
JNK(43,45). The JNK pathway is activated by ROS, saturated free fatty acid, and 
cholesterol (43–45), while NF-κB acts as a key regulator of inflammation and cell death 
and is activated by various stimuli, such as TLRs, IL-1β, and TNF-α (43,46). When 
activated towards M1 phenotype, Kupffer cells produce various factors which are involved 
in inflammation and fibrosis development. IL-1 has a strong inflammatory effect and also 
can promote triglycerides synthesis in the liver by decreasing PPAR-α activity. Activated 
Kupffer cells secrete TNF superfamily ligands such as TNF-α and TNF-related apoptosis-
inducing ligand (TRAIL), therefore stimulating apoptosis and inflammation of hepatocytes. 
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Production of TNF-α contributes to monocyte infiltration, hepatocytes apoptosis and plays 
important role in NASH development (43,46,47).  
1.2.4. Apoptosis and autophagy in NAFLD pathogenesis 
 
Apoptosis represents controlled and organized process of cell death. During 
apoptosis, cells are fragmented into small apoptotic bodies that contain cleaved DNA and 
cell fragments and are removed by phagocytosis. Apoptotic processes are triggered by two 
pathways: Initiaation of extrinsic pathway is mediated by death receptors (Fas, TNF 
receptor, TRAIL) and activates proteolytic enzymes, especially caspases; and the intrinsic 
apoptotic pathway that is initiated by mitochondrial dysfunction, ER stress, lysosomal 
permeabilization and damage of DNA. In hepatocytes, the main apoptotic trigger is 
mitochondrial dysfunction, when proapoptotic proteins, such as cytochrome c and caspase 
9, are released in cytosol, where this complex activates caspases 3, 6 and 7 leading to final 
cell death. In mitochondria, apoptotic triggers are regulated by Bcl-2 proteins family that 
includes antiapoptotic proteins Mcl-1, Bcl-2ad Bcl-xL, and proapoptotic multi-domain 
Bax-like proteins, such as Bax, Bak and BH3. In NAFLD, the key trigger of apoptosis is 
lipotoxicity. Products of lipid metabolism are capable to initiate apoptotic signaling 
pathways in hepatocytes, these includes cholesterol, free fatty acids, phospho- and 
sphingolipids. Lipotoxicity is closely associated with chronic inflammatory processes that 
occurs during NASH development following obesity, diabetes and metabolic syndrome 
(48). Toxic products of lipid metabolism can damage cells through several mechanisms, by 
impairment function of endoplasmic reticulum and mitochondria, as well as other cellular 
organelles. Well-defined targets of toxic lipids are predominantly adipose tissue, skeletal 
muscle, heart and pancreas, and modulation of their response to lipid metabolites contribute 
to presentation of the complex picture of metabolic syndrome (49). 
Autophagy is an intrinsic pathway for the degradation of damaged organelles, and 
initially is a protective mechanism that is initiated by cell starvation or damage. There are 
three types of autophagy depending on the way that damaged substrate is transported to the 
lysosomes: macroautophagy, microautophagy and chaperone-mediated autophagy. The 
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major pathway is macroautophagy. The autophagosome is formed at first as a double 
membrane that enclose degradation target, then it fuses with a lysosome to form an 
autophagolysosome where recycling occurs. Lipophagy is the mechanism of lipid content 
regulation via processes of autophagy (49). Since abnormal lipid accumulation, stored in 
lipid droplets in hepatoctytes is main characteristic of NAFLD (50), it may implicate that 
autophagy processes are misfunctional. Additionally, steatosis may contribute to NASH 
development through secondary insults from oxidants and cytokines triggering oxidative 
stress and chronic inflammation (51–53).  
Macroautophagy is known as a homeostatic mechanism responsible for recycling of 
organelles and long-lived proteins (54). Lipases that are contained in lysosomes are able to 
degrade organelle-associated lipids and exogenous lipoproteins, but intracellular lipids were 
not previously considered to be a substrate for autophagic degradation (55). However, 
recent studies are suggesting that macroautophagy could have a role in the regulation of 
hepatic lipid stores (53). By genetic or pharmacological inhibition of autophagy gene Atg5, 
it was shown that cellular triglycerides content significantly increased in cultured 
hepatocytes. High amounts of triglycerides and cholesterol are still stored in lipid droplets 
because of a decreased lipolysis and reduced β-oxidation of fatty acids in cells with 
inhibited macroautophagy. Studies on laboratory animals showed that during starvation, 
macroautophagy is stimulated and recognized by increased presence of lipid 
autophagosomes (53,56). Therefore, increasing autophagy can potentially reduce the fat 
content in fatty liver disease. 
1.3. Pathogenesis of liver fibrosis 
Chronic liver injury can often result in more severe stage of liverdisease, liver fibrosis 
which precedes to the development of cirrhosis and HCC (57). The usual causes of liver 
fibrosis are viral hepatitis C and B (HCV and HBV), alcoholic steatohepatitis and NASH. 
Autoimmune hepatitis, cholestasis, metabolic disorders, primary biliary cirrhosis, drugs and 
toxins contribute to liver fibrosis development as well (58,59). 
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Fibrosis represents an excess accumulation of ECM proteins as a wound-healing 
response to chronic, repeated injury and hepatocytes death, due to failure of the 
regeneration process. In fibrosis processes, synthesis of ECM proteins is increased and 
accompanied with its decreased degradation. It results in accumulation of collagen (type I, 
III and IV), fibronectin, elastin, laminin and proteoglycans up to six times more than 
normal. Fibrotic tissue accumulates in portal area, pericentral and perisinusoidal spaces, 
with the tendency to form bridging structures and nodules in cirrhosis (60). Loss of normal 
tissue architecture followed by impaired function leads to liver insufficiency, with the only 
remaining therapy being organ transplantation. However, there is evidence suggesting that 
liver fibrosis is reversible, and it represents good therapy-targeting point to attenuate 
excessive ECM accumulation, and prevent irreversible liver damage (59,61).  
In the pathogenesis of liver fibrosis both parenchymal and nonparenchymal cells are 
involved. Activation of myofibroblasts that produce ECM proteins plays a critical role in 
the pathogenesis of liver fibrosis. Three types of cells may be transdifferentiated into 
hepatic myofibroblasts:  HSC, portal fibroblasts and bone marrow-derived collagen 
producing cells, fibrocytes. Major source of myofibroblasts, and therefore ECM proteins 
are activated HSCs. In liver injury, damaged hepatocytes and Kupffer cells trigger 
inflammatory response, release ROS and fibrotic mediators such as TGF-β (62,63). TGF-β 
is a key mediator in liver fibrogenesis and is the strongest stimulus for HSCs activation, 
their transformation into myofibroblasts and increased ECM proteins synthesis (63). So far, 
the most efficient therapy for liver fibrosis is removal of etiological agent. However, there 
is still no standard therapy for liver fibrosis. Recent studies are searching for the best 
therapeutic approach that will reduce inflammatory response, collagen amount in the liver, 
and still do not disturb normal balance of ECM proteins synthesis and degradation (64).  
1.3.1. Neuregulin-1  
 
Neuregulin belongs to epidermal growth factor family and is encoded by one of four 
genes (from NRG1 to NRG4). Neuregulin acts through activation of ErbB tyrosine kinase 
receptors (ErbB2, ErbB3 and ErbB4) and is involved in cellular proliferation, 
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differentiation, development and survival in various tissues (65). Recent studies suggest 
that neuregulin-1 may play and important role in glucose metabolism by increasing GLUT4 
content in skeletal muscles cells, indicating that prolonged treatment with neuregulin-1 
regulates glucose metabolism in muscles. However, the effects of neuregulin-1 in liver have 
not been investigated in detail, even it is well known that liver plays an important role in 
glucose metabolism. It has been shown that expression of ErbB3 receptors is more 
pronounced than ErbB4 in the liver of adult rats (66). The NRG-1/ErbB signaling is proven 
to be indispensable for normal development and growth of various organ systems including 
nervous and cardiovascular systems (67,68) . To date, many studies have shown that NRG-
1 is crucial for the maintenance of structural and functional integrity of the adult heart (69). 
Recombinant human NRG-1 (rhNRG-1) is currently being examined in clinical trials 
(phase II and III) in patients with chronic heart failure. Recent studies indicate that NRG-1 
has anti-fibrotic effects in the heart, kidney, lung, and skin (70–73). Although NRG-1 
seems to have anti-fibrotic properties in different organs, the role of NRG-1 in fibrotic liver 
diseases has not been elucidated. 
1.4. Animal models of NAFLD and liver fibrosis 
Various animal models are used for studying NAFLD and liver fibrosis. An ideal 
animal model of NAFLD should represent all manifestations that are present in human 
population. This model should demonstrate steatosis, inflammatory infiltrate near hepatic 
blood vessels and ballooning of hepatocytes. Further, it would be appropriate if a model 
develops metabolic abnormalities such as dyslipidemia, insulin resistance, obesity and 
altered adipokine profile (74). Animal models that are frequently used for studying NAFLD 
can be classified as dietary models and genetic models. Also, combination of those two is 
used as well. The complexity of NAFLD pathogenesis is the main reason why are there so 






1.4.1. Dietary models for NAFLD 
The best described dietary model is methionine-choline deficient (MCD) diet model. 
This diet is usually rich in sucrose and the fat content is about 40%. The deficiency in 
methionine and choline results in altered β-oxidation of free fatty acids and impaired 
production of VLDL, that consequently lead to fat accumulation in the liver, hepatocytes 
death, oxidative stress and inflammation (75,76). On the other hand, methionine plays 
important role as intermediate in S-adenosylmethionine (SAM) and GSH synthesis, two 
important antioxidants. The methionine deficiency contribute to oxidative stress at first, and 
afterwards to inflammation and fibrosis (77,78). This animal model is most used due to its 
reproducibility and short time required for NASH histological phenotype development, 
around six weeks, compared to high-fat diet model, that need much more time to develop 
(75). The MCD diet model induces more severe oxidative stress, inflammation, apoptosis 
and fibrosis than other nutritional NAFLD models (75). However, this model has its 
disadvantages because of its association with weight loss (around 20% after three weeks) 
and lack of insulin resistance and metabolic syndrome manifestations (74).  
High-fat diet is second widely used nutritional model that contribute to NASH 
phenotype more similar to the human disease. It is characterized by the presence of obesity, 
insulin resistance, dyslipidemia and inflammation, but without hepatocytes ballooning and 
less pronounced fibrosis after prolonged period of use (76,78). High-fat diet provides 
approximately 60% energy from fat, 20% from carbohydrates and 20% from proteins, but 
there are also many variations of this diet composition. To gather fully developed NASH 
manifestations, with complete metabolic alteration and histological changes, this model 
requires prolonged usage, around 20 weeks or even more, depending on animal strain that 
is used (75,76,79). Taken together, in rodents, high-fat diet replicates altered metabolic 
status quite similar to metabolic changes observed in humans, but histopathological 
outcome is not always fully manifested (75). 
The addition of high fructose syrup to high-fat diet has showed the development of all 
features of NASH. High-carbohydrate diet increases oxidative stress in the mice liver, 
followed my macrophage infiltration and fibrosis. This diet contribute to metabolic 
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syndrome with obesity, insulin resistance and fatty liver. Adding fructose promotes the 
development of fibrosis, adipose tissue inflammation and hepatocellular damage in mouse 
models of NASH (75). 
Besides these nutritional models, cholesterol rich diet, also called atherogenic diet 
induces progressive steatosis, inflammation and fibrosis with severe hepatocytes damage 
and ballooning after 24 weeks. Also, in this model, dyslipidemia, lipid peroxidation and 
oxidative stress are well manifested. In contrast to high-fat diet, these animals on 
atherogenic diet are more sensitive to insulin due to decreased amount of adipose tissue, 
and metabolic changes are different from human NASH (75).  
For better understanding of NASH, various genetically modified rodents are 
developed. In the most of them, genetic alteration result in fat accumulation in the liver, but 
without inflammation or fibrosis, so usually it is necessary to combine knockout mice 
model with modified diet to induce all manifestations of NASH. 
1.4.2. Genetic models for NAFLD 
Among the genetic models, mice with leptin deficiency (the ob/ob mice) have 
spontaneous point mutation in the gene coding the leptin synthesis. Leptin has role in food 
intake regulation and increases the energy storage. These mice are obese, hyperphagic, 
inactive and develop hyperglycemia, hyperinsulinemia and insulin resistance accompanied 
with hyperlipidemia (80). In this model, metabolic alterations are fully developed, but the 
inflammation in the liver tissue may be absent, so the additional stimuli are required for 
complete NASH presentation. Db/db knockout mice are carriers of leptin receptor gene 
mutation, and develop resistance to the leptin effects despite its normal or elevated 
circulating level. These mice exert similar phenotype like ob/ob mice that include obesity 
and metabolic disturbances with insulin resistance. With an additional stimulus, such as 
MCD diet, NASH can be observed with all histological signs with high potential for 
significant fibrosis development (75). 
SREBP-1c transgenic mice overexpress SREBP-1c in adipose tissue that 
consequently have impaired development and function leading to severe insulin resistance 
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and hepatic steatosis. Liver steatosis is followed by inflammation, ballooning hepatocytes 
and pericellular fibrosis. This model is a suitable model for studying lipodystrophy 
associated with NASH (75). KK-Ay/a mice that have mutation in the agouti gene, 
manifested as hyperphagia and impaired suppression of food intake. Phosphatase and tensis 
homolog  null mice results in hepatomegaly accompanied by steatosis due to increased fatty 
acid synthesis (81). There are also PPAR-α null mice, Acyl-coenzyme A oxidase null mice, 
Methionine adenosyl transferase null mice etc. (75). 
1.4.3. Liver fibrosis animal models 
In vivo models of liver fibrosis can be divided in several groups: Chemical-based 
models, diet-based models, surgery-based models and genetically modified animal models 
(82). The most used models are chemical ones that require short time of intraperitoneal 
application of specific chemicals. Ethanol is known to cause chronic liver disease that starts 
with steatosis and may progress into fibrosis and cirrhosis. However in rodent models, mere 
alcohol consumption is not enough to induce the progression of alcoholic liver disease into 
fibrosis. Therefore, it is necessary to combine alcohol intake with some specific diet, 
pharmacological agents or genetic modification. Carbon tetrachloride (CCl4) is most 
commonly used hepatotoxin in order to induce and study liver fibrosis and cirrhosis in 
rodents. In the liver, CCl4 biotransformation relies on CYP2E1 and produces 
trichloromethyl radical which is involved in lipid peroxidation and free radicals generation. 
These changes contribute to an acute phase reaction with centrilobular necrosis of 
hepatocytes, activation of Kupffer cells and inflammatory response (82,83). This model can 
be applied to both mice and rats, but using mice is more preferable due to their higher 
metabolic rate of CCl4. Since this liver fibrosis model is easy reproducible, requires 4 to 6 
weeks of administration and has low mortality rate, it is widely accepted and one of the 
most commonly used. 
Besides these two, thioacetamide, dimethylnitrosamine (DMN) and dietylnitrosamine 
(DEN) are frequently used to experimentally induce liver fibrosis in rodents. After the 
biotransformation, reactive oxygen species are produced and react with lipids, proteins and 
nucleic acid causing cell dysfunction and consequent necrosis. Numerous dietary models 
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are usually used to induce progression of NAFLD to NASH and afterwards to more severe 
stages of liver damage, such as fibrosis (82). 
Surgery-based model such as bile duct ligation (BLD) is well known to induce 
cholestatic liver injury and periportal fibrosis. The obstruction of ductus choledochus lead 
to bile accumulation in the intrahepatic bile ducts and increases biliary pressure. 
Afterwards, secretion of cytokines increases and inflammatory processes occur. This results 
in biliary epithelial cells proliferation, increased expression of fibrogenic markers such as 
TGF-β, collagen type 1, α-smooth muscle actin (SMA) and tissue inhibitor 
metalloproteinase (TIMP)-1 as well as in increased ROS production and oxidative damage 
of hepatocytes (82). Fibrosis can be studied on genetically modified models, such as 
multidrug resistance-associated protein 2 (MDR2) deficient mice and Alms1Fat ausi mutant 
mice.(foz/foz), as well as on in vitro models using HSC culture (82). 
1.5.  Betaine 
Betaine, known as trimethylglicine (N,N,N-trimethylammonioacetate) is a methyl 
derivate of glycine (Figure 1.2.) . 
 
Figure 1.2. The chemical structure of betaine 
 It represents an important nutrient that can be found in grains, spinach, shrimps and 
beet, and dietary intake is an important source of betaine, even there is endogenous 
synthesis from choline, especially in the liver and kidney (84,85). Betaine has few 
important roles in mammalian organism, especially in kidney and liver. In the kidney, 
primary role of betaine is osmoprotection in the inner medulla cells. It includes betaine 
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-dependent betaine-GABA transporter 
(BGT1) on the basal plasma membrane. Betaine balances high extracellular osmolarity and 
regulates cell volume. In the liver, betaine primarily functions as a methyl group donor. 
One-carbon metabolism is metabolic network of biosynthetic pathways in cytoplasm, 
mitochondria and cell nucleus where betaine is involved. In cell nucleus, betaine plays an 
important role in DNA replication and repairmen and in DNA methylation. In the 
cytoplasm, primary role of betaine is remethylation of homocysteine to methionine, a 
precursor to SAM, that is universal methyl group donor to more than 80 biological 
reactions of methylation in organism. Methyl groups are transferred from betaine to 
homocysteine through the methionine cycle that is catalyzed by enzyme called betaine-
homocysteine methyltranferase (BHMT). Betaine is widely used in animals and humans 
nutrition. In human population it has been used to reduce cardiovascular risk and 
complications as well as neurodegenerative diseases by lowering increased homocysteine 
levels (84). In animals, betaine is added to animal diet to increase the lean muscle mass and 
decrease the fat (86). Recently, the role of betaine in alcoholic and nonalcoholic fatty liver 
disease has been investigated. In mice that developed NAFLD by feeding with high fat diet, 
betaine supplementation increased SAM and prevented and reversed insulin resistance and 
liver steatosis by modulating pathways involved in glycogen synthesis, gluconeogenesis 
and insulin signaling (84). Similar study suggested that one of the mechanism responsible 
for betaine action was in part due to relief of ER stress (86). Effects of betaine in NAFLD 















































 To develop a NAFLD model in mice using MCD diet. 
 To examine the effects of betaine on liver morphological and ultrastructural changes in 
mice with NAFLD. 
 To examine the effects of betaine on oxidative stress, apoptosis, autophagy and 
inflammation in the liver in mice with NAFLD. 
 To examine the effects of neuregulin-1 on connective tissue accumulation, gene 
expression for collagen type I and III, and matrix metalloproteinases 2 and 9 in animal 
models of liver fibrosis induced by CCl4 and bile duct ligation. 
 To examine in vitro effects of neuregulin-1 on TGF-β gene expression in isolated 
hepatocytes. 
 To examine the effects of neuregulin-1 on ErbB3 and ErbB4 receptors phosphorylation 






































3.1. Experimental design 
 3.1.1. Setting animal model of NAFLD 
 
The experiments were performed on male C57BL/6 mice weighing on average 23±3 g 
raised at the Military Medical Academy in Belgrade. Animals were housed in controlled 
laboratory environment (temperature 22 ±2°C, relative humidity 50 10%, 12/12 h light-
dark cycle with lights turned on at 9:00 a.m.) and had free access to water and standard 
chow before the experiment.  
 Experimental animals (n=28) at the age of 8 weeks were randomly divided into the 
following groups: 1. Control (n =7) continuously fed with standard chow; 2. Groups fed 
with MCD diet for two (MCD2; n=7), four (MCD4; n=7) or six weeks (MCD6; n= 7). 
After the treatment, blood samples were taken for spectrophotometric determination of 
aminotransferase (alanine- and aspartate aminotransferase, ALT and AST), alkaline 
phosphatase (ALP) activities and lipid profile (cholesterol, triglycerides, low-density 
lipoprotein /LDL/, and high-density lipoproteins/HDL/). Liver samples were used for 
pathohistological evaluation of fatty liver change and the presence of inflammatory 
infiltrate. Besides, the parameters of oxidative stress and activities of antioxidative 
enzymes, as well as free fatty acids profile have been determined in the liver. The MCD 












Table 1. Methionine/Choline deficient diet composition (960439-MP Biomedical, CA, 
USA). Control diet had the same composition as methionine/choline deficient diet except 
2g/kg choline and 3g/kg DL-methionine were added at the expense of sucrose. 
 







Corn Oil 50 
Corn Starch 100 
Cupric carbonate 1.15 
Di-calcium phosphate  1.5 
Ferric citrate 3 
L-amino acids 85.2 
Magnesium oxide 12 
Manganese carbonate 1.7 




Potassium sulphate 26 
Sodium Chloride 37 
Sucrose 225 
Sucrose, finely powdered 55 
Vitamin mix 10 
Zinc Carbonate 8 









3.1.2. The effects of betaine on NAFLD 
 
This experiment will be performed in order to investigate the effects of betaine on 
NAFLD development in mice fed with MCD diet. Animals (n=28) will be on standard diet 
until the age of 8 weeks, and then they will be divided into the following groups: 1. control 
(n=7) – continuously on standard diet, 2. BET group (n=7) – animals on standard diet that 
will be treated with betaine solution in drinking water (1.5% solution ad libitum), 3. MCD 
group (n=7) – animals on MCD diet during 6 weeks, and 4. MCD+BET group (n=7) – 
animals on MCD diet treated with betaine in drinking water. After 6 weeks, animals will be 
sacrificed and blood and liver samples will be taken for further analysis. Aminotransferase 
activities will be measured in serum, while oxidative stress parameters, autophagy markers 
(LC3II, p62, mTOR, and gene expression for Beclin 1, Atg4b, Atg5, Atg7), apoptosis 
markers (Bax, Bcl2, caspase 3) and markers of inflammation (IL-1β, IL-6, TNF-α) will be 
determined in liver samples. Ultrastructural changes in the liver will be examined by using 
transmision electron microscopy. 
3.1.3. The role of NRG-1 on liver fibrosis on two in vivo models 
 
For this experiment, adult male C57BL/6j mice (Charles River Laboratories) average 
weight 25g were used. Animals have been housed in controlled laboratory environment 
(temperature 22 ±2°C, relative humidity 50 10%, 12/12 h light-dark cycle with lights 
turned on at 9:00 a.m.) and had free access to water and standard chow before the 
experiment.  
In the first model, mice (n=32) were divided into the following groups (n=8 per group): 
1. control –treated with corn oil (Sigma Aldrich) i.p. 3x per week; 2. NRG-1 group – 
treated with rhNRG-1 (20 µg/kg i.p., Peprotech) 5x per week; 3. CCl4 group – treated with 
20% CCl4 solution (1mg/kg body weight i.p., Sigma Aldrich) diluted in corn oil 3x per 
week and 4. CCl4+NRG-1 group – treated with both CCl4 and NRG-1 in combination in a 
previously described manner for 4 weeks.  
The second liver fibrosis model was performed by ligation of the bile duct (BDL), 
as described by Tag C. et al. (87). Animals (n=32) were divided into four groups (n=8 per 
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group): 1. control – treated with phosphate buffered saline (PBS) i.p.; 2. NRG-1 group – 
treated with rhNRG-1 (20 µg/kg i.p.) 5x per week; 3. BDL group – animals that had bile 
duct ligated and treated with PBS, and 4. BDL+NRG-1 group – animals that had bile duct 
ligated and treated with rhNRG-1 (20 µg/kg i.p) 5x for week. For bile duct ligation animals 
were anesthetized with i.p. injections of ketamine/xylazine (100mg/10mg/kg body weight). 
After making an incision at the middle abdominal line, the peritoneal cavity was opened 
and organs were exposed. Liver lobes were lifted, then the bile duct was separated from 
portal vein and ligated with two sutures. Animals were left to recover overnight before 
starting rhNRG-1 treatment. After four weeks, animals will be sacrificed in general 
phenobarbital anesthesia (150mg/kg), and blood and liver samples have been taken for 
analysis. Transaminase activities were measured in serum, while liver tissue was stained 
with Masson’s trichrome in order to determine and quantify the fibrosis. In the liver tissues, 
gene expression for collagen type I and III, and matrix metalloproteinases 2 and 9 will be 
determined. The presence and phosphorylation of ErbB3 and ErbB4 receptors will be 
determined in the liver of control and rhNRG-1-treated animals by Western blot.  
3.1.4. The effects of NRG-1 on TGF-β expression in vitro on isolated hepatocytes 
 
Primary hepatocytes were isolated from mouse liver by two-step liver perfusion as 
previously described (88) with minor modifications. Liver was perfused by cannulating  
inferior cava vein, while portal vein was cut for drainage. Solution 1 was PBS without 
calcium and magnesium (6 min perfusion at 5mL/min); Solution 2 contained collagenase P 
(Roche, Germany) dissolved in Dulbecco's Modified Eagle Medium, DMEM (Invitrogen) 
in concentration 40mg/mL (7 min perfusion at 5mL/min). Liver was collected in 30mL of 
solution 2 on ice, and transferred in Petri dish under sterile conditions. 20mL of DMEM 
were added in Petri dish, and hepatocytes were scraped from liver. Tissue was held with 
tweezers and shaken well to release more cells. The solution got blurry, and the rest of the 
tissue was discarded. Cell suspension was filtered through 75µm cell strainer into 50mL 
tube and centrifuged on 50G for 4 minutes, then washed twice with 30 mL of DMEM (4 
min on 50G centrifugation). Hepatocytes were cultured in DMEM containing 10% heat-
inactivated fetal bovine serum (Invitrogen), 100 U/mL penicillin, and 100 μg/mL 
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streptomycin in two 6-well plates, in a humidified 5% CO2 incubator at 37°C. Cells were 
used 24 hours after culturing and were serum-starved for 12 hours prior to experiments. 
Primary hepatocytes were stimulated with rhNRG-1β (20 ng/mL) for 16 hours. Cells were 
collected for mRNA isolation and relative mRNA expression for TGF-β was measured by 
quantitative polymerase chain reaction (qPCR).  
The expression of TGF-β gene will be determined in vitro on isolated primary 
hepatocytes before and 16 hours after NRG-1 stimulation. 
 
3.2. Histopathology analysis 
Liver tissue was sectioned and incubated in 10% formalin solution at room 
temperature. After fixation, the liver samples were processed by the standard method. 
Tissues were incorporated in paraffin, sectioned at 5 μm and then stained with 
Hematoxylin-Eosin (HE). The sections were analyzed and photographed using an Olympus 
BX51 (Olympus, Tokyo, Japan) light microscope equipped with Artcore 500 MI (Artray, 
Co. Ltd., Tokyo, Japan) camera. 
The right liver lobe was fixed in 4% buffered formalin and embedded in paraffin. 
Sections were stained with Masson’s trichrome, according to the manufacturer’s 
instructions. Images were acquired with an Olympus U-TU1X-2 microscope and analyzed 
with ImageJ 1.42 software. Liver fibrosis was quantified by calculating the percentage of 
positively stained ECM area to total tissue area in digitalized microscopic images. 
Quantification was performed by a person blinded to the treatment protocol.  
 
3.3. Transmission electron microscopy (TEM) 
The liver tissue was fixed by immersion in a 3% solution of glutaraldehyde (Agar 
Scientific Ltd., Stansted, UK) in a 0.1 mol/L cacodylic buffer (pH = 7.4) over night at 
+4
o
C. The tissue was then postfixed with 1% solution of osmium tetraoxide (Merck, 
Darmstadt, Germany) in a 0.1 mol/L cacodylic buffer, followed by overnight incubation at 
+4°C in a 4.8% aqueous solution of uranyl acetate (Serva, Heidelberg, Germany). The 
samples were embedded in a four-component embedding medium made up of the epoxy 
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embedding medium, dodecenyl succinic anhydride, epon hardener methyl nadic anhydride 
(all from Fluka Chemika, Buchs, Germany), and epon hardener accelerator N-
benzildimethylamine ( Agar Scientific Ltd., Stansted, UK). Semi-thin sections were cut 
from the blocks of embedded tissue, stained with toluidine blue, and analyzed under the 
Olympus BX41 microscope (Olympus GmbH, Hamburg, Germany). All slides were photo-
documented with the Olympus C5060-ADU wide zoom camera and the Olympus DP-Soft 
Image Analyzer program (Olympus GmbH, Hamburg, Germany). Ultra-thin sections were 
treated with uranyl acetate and lead citrate ( Alkaloid, Skopje, FYRM), and analyzed on a 
transmission electron microscope (Fei Morgagni 268D, Eindhoven, the Netherlands) 
equipped with a MegaViewIII Soft Imaging System digital camera (Olympus Soft Imaging 
Solutions GmbH, Münster, Germany). 
3.4.  Biochemical analysis 
3.4.1. Determination of hepatic enzymes in the serum 
 
Liver damange was biochemically confirmed by determination of the activity of 
serum alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase. 
Activities of these enzymes were measured spectrophotometrically at photometer BTS-330 
according to the manufacturer’s instruction using special kits containing 2- oxoglutarate 
(Sigma Aldrich, St. Louis, MO) for ALT and AST and a kit containing 4-nitrophenyl 
phosphate (Sigma Aldrich) for ALP determination. 
3.4.2. Determination of acute phase proteins 
 
 The concentration of C-reactive protein (CRP) and ferritin was determined 
turbidimetrically, based on agglutination of latex particles coated with antibodies on CRP and 
ferritin (BioSystems, Barcelona, Spain). The concentration of serum transferrin was determined 
turbidimetrically, based on precipitation in the reagent contains antitransferin antibodydisolved in 
imidazole buffer (1 ml/L) and sodium azide (0.95 g/L, pH 7.5). All analyses were carried out on 





3.4.3. Serum lipid profile determination 
 
Lipid concentrations in plasma (total cholesterol, triacylglycerol [TAG] and HDL) 
were measured by enzymatic colorimetric methods. Cholesterol and triglyceride assay kits 
were purchased from Abcam (Cambridge, UK, Cholesterol Assay Kit, ab65390; Triglyc- 
eride Quantification Kit, ab65336). Total plasma cholesterol concentration was determined 
by measuring hydrogen peroxide generated by cholesterol oxidase in oxidative coupling 
reaction with 4-aminoantipyrine and phenol at 500 nm (89). Plasma LDL concentration was 
obtained by a combination of ultracentrifugation and precipitation procedure according to 
Friedewald et al (90). Plasma HDL concentration was determined by using enzymatic 
colorimetric method (Roche Diagnostics, Basel, Switzerland). In the presence of double 
positively charged anions, the HDL fraction was measured after selective LDL precipitation 
by polyanion sulfates (dextran sulfate and magnesium sulfate) in accordance with the 
Centers of Disease Control and Prevention (Atlanta, GA: Lipid Reference Section). After 
centrifugation, HDL fraction was determined directly in the supernatant by the PAP 
method. Modified cholesterol-oxidase reagent by inclusion of 2,4,6-tribromo-3-
hydroxybenzoic acid was used to measure plasma TAG concentration by enzymatic 
colorimetric method. 
3.4.4. Free fatty acid analysis 
 
Lipids for fatty acid analysis were extracted from the liver according to the Bligh 
and Dyer method (91). The fatty acid methyl esters (FAMEs) from the lipid extract were 
transesterified with HCl in methanol according to the method as described by Ichihara and 
Fukubayashi (92). FAMEs were quantified using an Agilent Technologies 7890A Gas 
Chromatograph with a flame ionization detector. Separation of the FAMEs was performed 
on a 112-88A7, HP-88 capillary column (100 m x 0,25 mm x 0,2 μm) using He as a carrier 
gas at a flow rate of 105 ml/min. The samples were injected at a starting oven temperature 
of 175˚C, injector temperature was 250˚C and detector temperature was 280˚C. The oven 
temperature was programmed to increase from 175˚C to 220˚C at 5˚C/min. Fatty acids were 
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identified by their retention time with reference fatty acid standards (SupelcoTM FAME 
Mix, USA) and were expressed as a percentage of total fatty acids in the liver. 
 
3.4.5. Oxidative stress parameters determination 
 
Lipid peroxidation in liver homogenates was measured as MDA production, 
assayed in the thiobarbituric acid reaction as described by Girotti et al (93). The results are 
expressed in nanomoles per milligram of proteins in liver homogenates. 
Nitrite concentration (NO2
-
) in liver homogenates was determined by using Griess 
reagent on ELISA reader at 540 nm (Plate reader, Mod. A1, Nubenco Enterprises, 
ICN)(94). Results are shown in nmol/mg proteins. 
SOD activity was determined in liver homogenates according to the method of Sun 
and Zigman by measuring the absorbance change during epinephrine autooxidation into 
adrenochrome at 340 nm (95). Commercial SOD from human erythrocytes (Sigma Aldrich, 
Germany) was used as a standard for the evaluation of total SOD activity. One unit (U) of 
enzyme activity changes the absorbance for 0.001 per minute (ΔA/min) under the test 
conditions. Samples for manganese SOD (MnSOD) activity determination were previously 
treated with 8 mM KCN (Sigma Aldrich) and then analyzed as previously described (95). 
The activity of copper-zinc-SOD (Cu/Zn SOD) was calculated as a difference between the 
activities of total SOD and MnSOD.  
Activity of GRed in liver homogenates was determined spectrophotometrically 
according to the method of Carlberg and Mannervik (96). Absorbance change was 
measured during oxidation of NADPH in the presence of dithiobis (2-nitrobenzoic acid) at 
340 nm. Human recombinant GRed (Sigma Aldrich) was used as a standard for the 
evaluation of total GRed activity. One unit (U) of enzyme activity catalyzes the 
transformation of one µmol of DTNB per minute under the test conditions. 
Activity of GPx in liver homogenates was determined spectrophotometrically according to 
the method of Wendel (97). Absorbance change was measured during oxidation of NADPH 
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at 340 nm. Commercial GPx from human erythrocytes (Sigma Aldrich) was used as a 
standard for the evaluation of total GPx activity. One unit (U) of enzyme activity catalyzes 
the transformation of one µmol of hydrogen peroxide per minute under the test conditions.  
Catalase (CAT) activity in liver homogenates was assayed by means of UV-kinetic 
method in the presence of H2O2 (98). Activity was expressed as U/mg proteins. 
Reduced glutathione (GSH)  was determined spectrophotometrically with DTNB 
following the Ellman΄s method at 412 nm (99). Results were shown in nmol/mg proteins. 
Proteins were determined by the Lowry method using bovine serum as the standard 
(100). All spectrophotometric measurements were performed with Cecil CE 2021UV/VIS 
spectrophotometer. 
PON1 activity was assayed by using synthetic paraoxon (diethyl-p-nitrophenyl 
phosphate) as a substrate in the assay mixture containing 2.0mM paraoxon, 2.0mM CaCl2 
and 40μL of liver homogenates in 100mM Tris-HCI buffer (pH 8.5). PON1 activity was 
determined by measuring the initial rate of substrate hydrolysis to p-nitrophenol, which 
absorbance was monitored at 412nm (101).  
Phenylacetate was used as a substrate for the determination of arylesterase activity 




) produced in this 
reaction (101). 
 
3.5. Western Blot 
 
The liver tissue was homogenized on ice in RIPA buffer containing 
protease/phosphatase inhibitor cocktail (all from Sigma-Aldrich, St. Louis, MO). The 
homogenates were centrifuged at 14000 g for 15 min at 4°C, and the supernatants were 
collected.  Protein concentrations were determined using the method described by Bradford 
(102), using bovine serum albumin as a standard (Sigma). Equal protein amounts from each 
sample (30 μg) were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
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After membrane blockade with 5% powder milk or 5% bovine serum albumin in Tris-
buffered saline (TBS) Tween 10, membranes were incubated with primary antibodies at 
4°C overnight. The membranes were then washed and incubated with secondary antibodies 
at room temperature for 1h. Rabbit polyclonal primary antibodies used were anti-
microtubule-associated protein 1 light chain 3B (anti-LC3B), anti-sequestosome 1 (anti-
SQSTM1/p62), anti-AMPKα1/2, anti-phospho-AMPKα1/2 (Thr172), anti-Akt, anti-
phospho-Akt (Ser473), anti-mTOR, anti-phospho/mTOR (Ser2448), anti-p70S6 kinase 
(S6K), anti-phospho-S6K (Thr389), anti-ErbB3, anti-ErbB4, anti-phospho-ErbB3,  anti-
phospho-ErbB4 (all from Cell Signaling Technology, Beverly, MA), anti-actin and anti-
GAPDH (Santa Cruz Biotechnology). Anti-actin and anti-GAPDH were diluted in 1:3000, 
while other primary antibodies were diluted in 1:1000. Goat anti-rabbit peroxidase-
conjugated IgG was used as a secondary antibody (Jackson IP Laboratories, West Grove, 
PA) in a dilution 1:3000. After washing, specific protein bands were visualized using 
enhanced chemiluminescence reagents (Amersham Pharmacia Biotech, Piscataway, NJ) 
and ChemiDoc MP System (Bio-Rad, Hertfordshire, UK). The protein levels were 
quantified by densitometry using ImageJ software (NIH, Bethesda, MD) and expressed 
relative to actin or GAPDH as a loading control. The results were presented as fold change 
in signal intensity, which was set to 1 in untreated controls.  
 
3.6. Real time PCR 
 
Total RNA from liver tissue was extracted using TRIZOL reagent according to the 
manufacturer's instructions. Approximately 1 μg of RNA was used in the reverse 
transcription reaction using M-MuLV reverse transcriptase and random hexamers 
according to the manufacturer's instructions. Real-time PCR was performed in a 
Realplex
2
Mastercycler using 96-well reaction plates, TaqMan Universal PCR Master Mix, 
and TaqMan primers/probes for mouse TNF-α, IL-6, IL-10, TGF-β, Bax, Bak1, Bbc3, 
Bcl2, Atg4b, Atg5, Atg7, beclin-1, collagen type I (col 1a1), collagen type III (col3a1), 
MMP-2, MMP-9, Rn18s, and β-actin. mRNA levels were expressed relative to Rn18s or β-
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actin as a loading control and the results were presented relative to the control value, which 
was arbitrarily set to 1. 
 
3.7. Statistical analysis 
 
Normal distribution of parameters was checked by Kolmogorov-Smirnov test. 
Depending on distribution, the statistical difference among groups was determined using 
analysis of variance (ANOVA) with Tukey post hoc test, Student’s t-test or Kruskall-
Wallis with Mann-Whitney nonparametric test. All statistical analysis were performed 
using GraphPad Prism 6 or SPSS 15.0 software. The difference was considered 






































4.1 The effects of MCD diet on biochemical and histological changes in mice liver 
4.1.1. The effects of MCD diet on mice body/liver weight ratio 
 
MCD diet induced a significant decrease in body weight after two (17.29 ± 1.41g; 
p<0.01), four (15.86 ± 1.16g; p<0.01) and six weeks (15.00 ± 1.00g; p<0.01) by 
comparison with control (22.86 ± 1.77g). The lowest body weight was observed in MCD6 
group. Also, the liver/body weight ratio was significantly lower in all MCD diet-treated 
groups in comparison with control. However, the most prominent decrease in this ratio was 




Figure 4.1. The effects of methionine/choline-deficient (MCD) diet on animal body 
weight and body/liver weight ratio 2, 4 and 6 weeks after beginning of treatment (MCD2, 
MCD4 and MCD6 groups respectively).  
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The significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test (*p<0.05, **p<0.01 vs. control). The data are 
presented as mean ±SD. 
 
4.1.2. The effects of MCD diet on histological changes 
 
No pathological changes were found in control group (Figure 4.2.A). MCD diet 
caused hepatic steatosis in mice, which was evident in all experimental groups. Mild 
hepatic steatosis with focal fatty change was found in MCD2 group in the form of 
microvesicular steatosis (Figure 4.2.B). Within four weeks MCD diet induced moderate 
steatosis with diffuse fatty change in mice liver (Figure 4.2.C). In MCD6 group the 
presence of severe macrovesicular steatosis with intralobular inflammatory infiltrate 
indicates NASH. Ballooning degeneration of hepatocytes and cell swelling were observed 












Figure 4.2. Histological findings of liver tissue in MCD diet-fed mice (Hematoxylin 
& Eosin, magnification x 40).  
A. Control group shows normal morphology of the liver.  
B. In MCD2 group focal fatty changes are evident (mild steatosis).  
C. In MCD4 group diffuse fatty change is evident (more severe steatosis).  
D. In MCD6 group steatosis with prominent inflammatory infiltrate, cell swelling 
and ballooning degeneration of hepatocytes are evident. Apoptotic bodies may 
also be seen. 
 
4.1.3. The effect of MCD diet on serum biochemical parameters 
 
Our study has shown that serum ALT activity was significantly increased in all 
experimental groups (MCD2: 492.32±61.10 U/L, MCD4: 510.15±63.51 U/L and MCD6: 
537.09±77.32 U/L) in comparison with control group (66.05±19.22 U/L) (p<0.01). No 
significant difference in ALT activity was evident among MCD diet-treated groups. AST 
activity was significantly increased in MCD2 (642.87±42.24 U/L), MCD4 (669.65±86.21 
U/L) and MCD6 (896.45±121.22 U/L) group in comparison with control (69.43±16.01 
U/L). However, the most pronounced increase was observed in MCD6 group, while 
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between MCD2 and MCD4 no significant difference was evident. On the other hand, MCD 
diet did not cause the change in serum ALP activity in all experimental groups when 
compared with control (Figure 4.3.A). Accordingly, AST/ALT ratio was significantly 
increased in MCD diet-treated groups (MCD2: 1.30±0.04, MCD4: 1.31±0.05) in 
comparison with control (1.04±0.05) (p<0.05). However, the highest ratio was evident in 
MCD6 group (1.67±0.08) (p<0.01) (Figure 4.3.B). 
Serum total cholesterol level was significantly decreased in MCD diet-treated group 
at all time points in comparison with control (2.34±0.25 mmol/L) (p<0.01). The most 
prominent decrease was observed in MCD6 group (1.16±0.14 mmol/L) compared with 
MCD2 (1.57±0.15 mmol/L) and MCD4 groups (1.33±0.16 mmol/L) (p<0.01). 
Analysis of serum cholesterol fractions has shown that MCD diet induced a 
progressive decline in serum HDL level. While an initial decline was evident in MCD2 
(1.17±0.09 mmol/L) when compared with control group (1.57±0.20 mmol/L) (p<0.01), 
serum HDL level was significantly lower in MCD4 (0.28±0.07 mmol/L) and MCD6 
(0.18±0.08 mmol/L) groups in comparison with MCD2 group (p<0.01). 
In contrast, serum LDL level was significantly elevated in MCD4 (0.49±0.10 
mmol/L) and MCD6 (0.73±0.10 mmol/L) groups in comparison with control (0.07±0.03 
mmol/L) (p<0.01). Difference in serum LDL level between MCD6 and MCD4 group was 
also highly significant (p<0.01) (Figure 4.4.A). 
Serum triglyceride level was significantly decreased in all experimental groups 
(MCD2: 0.75±0.10 mmol/L, MCD4: 0.7±0.14 mmol/L and MCD6: 0.48±0.05 mmol/L) in 
comparison with control group (1.52±0.12 mmol/L) (p<0.01). The decrease was more 
prominent in MCD6 group compared to MCD4 and MCD2 groups (p<0.05) (Figure 4.4.B). 
 
Concentration of CRP and ferritin was significantly increased (p<0.01), while the 
concentration of transferrin was significantly lower (p<0.05) in MCD6 group when 





Table 2. Concentration of acute-phase proteins in serum of mice fed with MCD diet 
during 2, 4, and 6 weeks (MCD2, MCD4, MCD6, respectively) 
 Group 
Parameter Control MCD2 MCD4 MCD6 
CRP 0.17±0.04 0.16±0.06 0.21±0.03 0.43±0.05** 
Ferritin (g/L) 87.20±6.83 92.62±10.10 95.84±10.40 135.02±23.94** 
Transferrin (g/L) 0.09±0.02 0.07±0.02 0.08±0.01 0.04±0.01* 
 
CRP: C-reactive protein 
Significance of the difference was estimated by using one-way analysis of variance 






Figure 4.3. The effects of MCD diet on serum enzymes (ALT, AST and ALP) activity 
(A), and AST/ALT ratio (B). 
Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (*p<0.05, **p<0.01 vs. control; ††p<0.01 
vs. MCD4). 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, 
alkaline phosphatase 






Figure 4.4. Time dependent effects of MCD diet on serum lipid profile: total 
cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL) (A) and 
triglyceride level (B). 
Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (*p<0.05, **p<0.01 vs. control; #p<0.05, 
##p<0.01 vs. MCD2; †p<0.05, ††p<0.01 vs. MCD4). 
For further information see Fig. 1. 
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4.1.4. The effects of MCD diet on free fatty acid profile in the liver 
 
MCD diet induced a significant decrease in liver palmitic acid (C16:0) proportion at 
all time points and in stearic acid (C18:0) proportion only 2 and 4 weeks after beginning of 
the diet in comparison with control group (p<0.01). While oleic acid (C18:1 n9) was 
significantly higher, oleic acid isomer (C18:1 n7) was significantly lower in all 
experimental groups when compared with control (p<0.01). Linoleic acid (C18:2 n6) was 
significantly higher in all experimental groups vs. control with the highest proportion in 
MCD2 group. After this period linoleic acid (C18:2 n6) proportion progressively declined 
and in MCD6 group it was significantly lower than in MCD2 group (p<0.05). When 
compared with control group, arachidonic acid (C20:4 n6) was significantly lower (p<0.05) 
and docosapentaenoic acid (DPA, C22:5 n3) was significantly higher (p<0.01) only 2 
weeks after the beginning of the MCD diet. At other time points no significant change was 
found. In contrast, liver docosahexaenoic acid (DHA, C22:6 n3) proportion was 













Table 3. The effect of MCD diet on liver free fatty acid profile. The duration of MCD diet was 2, 4 or 6 weeks (MCD2, MCD4 
and MCD6 respectively)  
 
Significance of the difference was estimated by using one-way ANOVA with Tukey’s post hoc test 
 (**p<0.01, *p<0.05 vs. control; #p<0.05 vs. MCD2 group) 
Abbreviations: C 16:0 – palmitic acid; C 18:0 – stearic acid; C 18:1 n9 – oleic acid; C 18:1 n7 – oleic acid isomer; C 18:2 n6 – 
linoleic acid; C 20:4 n6 – arachidonic acid; C 22:5 n3 - docosapentaenoic acid (DPA); C 22:6 n3 - docosahexaenoic acid (DHA). 
 
Group Free fatty acid (%) 
 
C 16:0 C 18:0 C 18:1 n9 C 18:1 n7 C 18:2 n6 C 20:4 n6 C 22:5 n3 C 22:6 n3 
Control 21.9±0.78 13.24±0.73 10.11±0.67 2.33±0.37 18.47±0.76 15.53±0.62 0.54±0.05 10.09±0.44 
MCD2 16.66±1.17** 9.00±1.65** 14.44±1.94** 0.91±0.19** 26.07±2.54** 12.20±2.21* 1.23±0.24** 9.13±0.76 
MCD4 15.66±0.49** 10.47±1.08** 15.43±2.22** 0.89±0.27** 22.86±1.87* 14.51±1.90 0.44±0.15 7.16±0.95** 




4.1.5. Association between free fatty acid and lipid status 
 
Assessments by the Pearson correlation coefficients revealed significant correlation 
between liver DHA proportion and serum LDL (r = -866, p<0.001), total cholesterol 
(r=813, p<0.001) and triglyceride level (r=695, p<0.001), (Figure 4.5.). 
 
 
Figure 4.5. Association between hepatic DHA and serum LDL (A), total cholesterol 
(B) and triglycerides (C). Correlation was estimated by using Pearson’s correlation 
coefficient r.  
 
4.1.6. The effects of MCD diet on oxidative stress parameters in the liver 
 
 Liver MDA concentration was significantly increased in all experimental groups 
(MCD2: 364.30 ± 63.8, MCD4: 332.14 ± 32.00, and MCD6: 48.57 ± 49.98 nmol/mg  
proteins) compared with control group (189.3 ± 43.9 nmol/mg  protein; p<0.01). However, 
no significant difference in MDA concentration was observed between groups (p>0.05; 
Figure 4.6.A). 
 The MCD diet induced a significant increase in liver NOx levels in all experimental 
groups in comparison with control (19.15 ± 5.95 nmol/mg  protein, p<0.01). NOx level was 
significantly higher in MCD6 (52.4 ± 11.45 nmol/mg  protein) compared to MCD2 (33.03 
44 
 
± 15.18 nmol/mg  protein) and MCD4 (37.98 ± 5.05 nmol/mg  protein, p<0.05; Figure 
4.6.B). 
 The activity of total SOD activity in the liver was significantly decreased in MCD2 
(3.42 ± 0.77 U/mg protein) as compared to control (27.5 ± 2.67 U/mg protein, p<0.01). 
During time, the total SOD activity continue to decrease in MCD4 (1.32 ± 0.18 U/mg 
protein) and MCD6 (1.68 ± 0.32 U/mg protein) and it was significantly lowerc in 
comparison with MCD2, p<0.01 (Figure 4.6.C). Activities of MnSOD and Cu/ZnSOD 
followed the changes of total SOD in all groups, where the values in MCD4 and MCD6 
groups were significantly lower than in MCD2 (p<0.05). 
 Catalase activity in the liver was significantly reduces in all MCD diet- treated 
groups in comparison with control (147.14 ± 22.25 U/mg protein, p<0.01). However, the 
most pronounced decrease in CAT activity was observed in MCD4 group (31.07 ± 6.93 
U/mg protein) compared to MCD2 (55.71 ± 14.00 U/mg protein, p< 0.05, Figure 4.6.D). 
 MCD diet induced a significant decrease in liver GSH level in MCD4 (95.3 ± 25.11 
nmol/mg  protein) in comparison with control group (123.34 ± 32.12 nmol/mg  protein, 
p<0.05). The most prominent decrease was evident in MCD6 (78.08 ± 28.13 nmol/mg  
















Figure 4.6. The effects of MCD diet on liver MDA level (A), level of NOx (B), activity of 
total SOD, MnSOD and Cu/ZnSOD (C), and the catalase activity and GSH content (D) in 
mice liver after 2, 4, and 6 weeks.  
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Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (*p<0.05, **p<0.01 vs. control; #p<0.05, 
##p<0.01 vs. MCD2; †p<0.05). 
SOD: superoxide dismutase, MnSOD: manganese superoxide dismutase, Cu/ZnSOD: 
cooper/zinc superoxide dismutase, CAT: catalase. 
4.2. The effect of betaine on biochemical, molecular and morphological changes in 
NAFLD mouse model 
 
4.2.1. The effects of betaine on animal body and liver weight 
 
Animal body weight was measured at the beginning of experiment, and animals 
weighted average 23±3g. After six weeks of experiment, in control and BET groups, animal 
weight was significantly increased (30.10±2.86g and 28.65±3.69g, respectively) by 
comparison with initial weight (p<0.05). In contrast, in MCD group animal weight was 
significantly decreased (16.43±1.82g) when compared to the weight at the beginning of the 
experiment (p<0.01). Also, body weight at the end of experiment was significantly reduced 
in MCD+BET group by comparison with initial weight (p<0.01; Figure 4.7.). On the other 
hand, body/liver weight ratio did not significantly differ between all experimental groups 






Figure 4.7. Animal body weight before and after the experiment. Animals were on MCD 
diet and treated with betaine for 6 weeks. Betaine was dissolved in drinking water (1.5% 
w/v) and animals had free access to betaine-contaning water during the whole experiment. 
Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (**p<0.01 vs. control, †p<0.05, ††p<0.01 
vs. the same group at the beginning of experiment). The data are presented as means ±SD. 
Groups: Control – mice fed with standard chow, BET – mice fed with standard chow and 
was on betaine supplementation, MCD – mice on methione, choline-deficient diet, 
MCD+BET – mice on methionine, choline-deficient diet with betaine supplementation. 
 
4.2.2. The effects of betaine on serum biochemical parameters 
 
MCD diet induced a significant increase in serum ALT activity (304.19±14.59 U/L) 
by comparison with control (29.71±4.72 U/L; p<0.01). Betaine alone did not cause a 
significant change in ALT activity when compared to control (p>0.05), while in 
combination with MCD diet, betaine caused a significant decrease in ALT activity 
(29.33±8.33 U/L) vs. MCD group (p<0.01). Similar to ALT, serum AST activity was 
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significantly increased in MCD group (321.74±27.01 U/L) when compared with control 
(130.00±30.16 U/L) (p<0.01), while in MCD+BET group this enzyme activity (71.33±7.31 
U/L) was significantly reduced vs. MCD group (p<0.01). Betaine alone did not induce 
significant change in AST activity (Figure 4.8.A). 
 While total serum cholesterol level was significantly decreased by MCD diet 
(0.69±0.19 mmol/L) when compared with control (2.41±0.20 mmol/L; p<0.01), betaine 
supplementation induced a significant increase in MCD+BET group (1.14±0.18 mmol/L) 
by comparison with MCD group (p<0.01). Analysis of serum cholesterol fractions has 
shown that MCD diet induced a significant decrease in HDL level (0.36±0.20 mmol/L) 
when compared with control (2.27±0.16 mmol/L) (p<0.01). Serum HDL level was 
significantly higher in MCD+BET (1.07±0.14 mmol/L) when compared with MCD group 
(p<0.01). 
On the other hand, serum LDL level was significantly increased by MCD diet 
(1.25±0.13 mmol/L) by comparison with control (0.08±0.01 mmol/L; p<0.01), while 
betaine treatment in combination with MCD diet significantly reduced LDL level 
(0.08±0.01 mmol/L) vs. MCD group (p<0.01). Similar to LDL, MCD diet induced a 
significant increase in serum triglyceride level (0.36±0.05 mmol/L) by comparison with 
control group (0.74±0.08 mmol/L; p<0.01). Triglyceride level in MCD+BET group 
(0.80±0.11 mmol/L) was significantly decreased by comparison with MCD group (p<0.01). 
However, betaine administered alone did not induce significant changes in serum lipid 
concentrations (total cholesterol, HDL, LDL, triglycerides) when compared with control 








Figure 4.8. Effect of betaine on serum biochemical analysis in mice with NAFLD induced by MCD diet: A) aminotransferase 
activities (ALT, AST); B) HDL and LDL level and C) cholesterol and triglycerides level. 
Significance of the difference was estimated by using one-way analysis of variance (ANOVA) with Tukey’s post hoc test 
(*p<0.05, **p<0.01 vs. control, ##p<0.01 vs. MCD). The data are presented as means ±SD. 
For further information see Figure 1
B A C 
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4.2.3. Pathohistological findings 
 
No pathological changes were found in control group (Figure 4.9.A), as well as in 
BET group (Figure 4.9.B). Hepatic steatosis with diffuse fatty change in the form of micro- 
and macrovesicular steatosis was found in MCD group, accompanied with mild 
perivascular inflammation (Figure 4.9.C). However, in MCD+BET group steatosis and 
inflammation were less prominent than in MCD group with few fat droplets seen 
occasionally in hepatocytes (Figure 4.9.D). 
 
Figure 4.9. The effects of betaine and MCD diet on liver morphology (Hematoxylin-eosin 
staining, magnification x10) 
(A) No pathological changes were found in control group  
(B) Normal liver morphology with preserved tissue architecture and lobular 
organization in BET group 
(C) Hepatic steatosis with diffuse fatty change in the form of micro- and macrovesicular 
steatosis associated with mild perivascular neutrophil infiltration in MCD group.  
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(D) In MCD+BET group steatosis and inflammation were less prominent than in MCD 
group with few fat droplets seen occasionally in hepatocytes without inflammation 
For further information see Figure 1. 
4.2.4. The effects of betaine on oxidative stress parameters 
 
Our results have shown that MDA concentration was significantly increased in 
MCD group (581.80±153.40 nmol/mg prot.) by comparison with control (160.70±49.87 
nmol/mg prot.; p<0.05). However, in MCD+BET group, MDA concentration 
(192.00±104.4 nmol/mg prot.) was significantly decreased vs. MCD group (p<0.05). 
 Liver nitrites concentration was significantly increased in MCD diet-treated group 
(30.32±8.96 nmol/mg prot.) in comparison to control group (11.87±0.71 nmol/mg prot.; 
p<0.05). Similar to MDA, significant decrease in liver nitrites was evident in MCD+BET 
(12.36±1.7 nmol/mg prot.) when compared to MCD group (p<0.05; Figure 4.10.A and B).  
Liver PON1 activity was significantly decreased in MCD group (58.20±4.12 U/mg 
protein) by comparison with control (118.60±33.48 U/mg protein; p<0.05). However, 
betaine supplementation caused an increase of its activity in MCD+BET (94.59±23.26 
U/mg protein) vs. MCD group (p<0.05). 
Betaine and MCD diet induced similar changes of liver ARE activity, and MCD diet 
significantly reduced its activity (465.80±75.78 U/mg protein) vs. control group 
(797.80±210.70 U/mg protein; p<0.05). In MCD+BET group ARE activity (692.50±187.40 
U/mg protein) was significantly higher compared with MCD group (p<0.05; Figure 4.10. C 
and D). 
Liver tSOD activity was significantly reduced in MCD (65.11±12.09 area/mg 
protein) by comparison with control group (94.36±8.11 area/mg protein) (p<0.01). Betaine 
in combination with MCD diet induced a significant increase in tSOD activity 
(111.10±15.58 area/mg protein) when compared to MCD group (p<0.01). Similar increase 
was evident in BET group (114.20±7.27 area/mg protein) vs. control (p<0.01). Apart from 
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total SOD, activities of its isoenzymes were significantly reduced in MCD diet-treated 
group (Cu/Zn SOD: 24.50±5.88, and MnSOD: 40.60±6.80 area/mg protein) by comparison 
with control (34.64±4.40 and 58.95±5.62 area/mg protein, respectively) (p<0.01). Betaine 
administered alone, as well as in combination with MCD diet induced a significant increase 
in MnSOD activity (BET: 74.98±3.95 and MCD+BET: 73.00±3.41 area/mg protein) by 
comparison with control (p<0.01). On the other hand, no significant difference was evident 
in Cu/Zn SOD activity between MCD and MCD+BET group (p>0.05; Figure 4.11.). 
Liver CAT activity was significantly decreased in MCD diet-treated group 
(91.50±18.23 U/mg prot.) by comparison with control (159.90±4.79 U/mg prot.; p<0.01). 
However, in MCD+BET group, activity of this enzyme was significantly increased 
(124.60±32.96 U/mg prot.) when compared with MCD group (p<0.01), but still it was 
lower by comparison with control (p<0.05). Similar changes in liver GSH level were 
observed in experimental groups. MCD diet significantly reduced liver GSH content 
(97.48±11.08 nmol/mg prot.) by comparison with control (126.70±20.25 nmol/mg prot.; 
p<0.01), while betaine supplementation accompanied with MCD diet induced a significant 
increase in GSH content (165.20±33.92 nmol/mg prot.) vs. MCD group (p<0.01) and 
control (p<0.05). On the other hand, GRed activity was significantly increased in BET and 
MCD group (12.28±3.02 and 15.70±1.83 U/mg prot., respectively) by comparison with 
control (7.06±0.53 U/mg prot.; p<0.01). In MCD+BET group, GRed activity was 
significantly decreased (8.38±1.56 U/mg prot.) compared to MCD (p<0.01). Liver GPx 
activity was significantly decreased in MCD group when compared to control (p<0.01). 
Betaine administered alone significantly increased liver GPx activity vs. control (p<0.01). 
Liver GPx activity in MCD+BET group was significantly increased by comparison with 
MCD and control group (p<0.01; Table 4). 
Correlations  
By using Pearson correlation test, we found that in MCD group PON1 significantly 
correlated with tSOD (r=0.864; p<0.05), GSH (r=0.866; p<0.05) and MDA (r= - 915; 
p<0.05). Similarly, ARE was found to correlate significantly with tSOD (r=0.894), GSH 
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(r=0.864) (p<0.05), MDA (r= -0.964) (p<0.01), but also with GR (r=0.818) (p<0.05), CAT 
(r=0.962), and nitrites (r= -0.947) (p<0.01).  
 
 
Figure 4.10. Effect of betaine on liver MDA, marker of lipid peroxidation (A), nitrites 
concentration that represents nitrosative stress (B), PON1 activity (C) and ARE activity (D) 
in NAFLD induced by MCD diet. 
Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (*p<0.05 vs. control, #p<0.05 vs. MCD). 
The data are presented as mean ±SD. 
MDA – malondialdehyde, PON1 – paroxonase-1, ARE – arylesterase. For further 
information see Figure 1. 
 






Figure 4.11. Effect of betaine on liver total SOD activity (A) and its isoenzymes activities 
(B) in NAFLD induced by MCD diet. 
Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (**p<0.01 vs. control, ##p<0.01 vs. MCD). 
The data are presented as mean ±SD. 
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Table 4. Effect of betaine on liver GSH content, GRed, GPx and CAT activity in MCD diet 
induced NAFLD 
 
Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (*p<0.05, **p<0.01 vs. control, ##p<0.01 
vs. MCD). The data are presented as mean ±SD. 











 Control BET MCD MCD+BET 
GSH (nmol/mg 
prot.) 
126.70±20.25 136.70±12.71 97.48±11.08** 165.20±33.92*## 
GRed (U/mg prot.) 7.06±0.53 12.28±3.02** 17.70±1.83** 8.38±1.56## 
GPx (U/mg prot.) 20.83±5.46 74.39±14.98** 12.87±3.33** 67.34±9.64**## 
CAT (U/mg prot.) 159.90±4.79 127.60±29.17* 91.50±18.23** 124.60±32.96*## 
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4.2.5. The effects of betaine in hepatic expression of inflammation and apoptosis 
markers in MCD diet-induced NAFLD 
 
Our results indicate that MCD diet induced a significant increase in expression of 
inflammatory marker genes TNF (p<0.05) and IL-6 (p<0.05) vs. control with more 
prominent increase in TNF. Besides, in MCD group expression of anti-inflammatory 
cytokine IL-10 and fibrogenic mediator TGF-β were increased by comparison with control 
group (p<0.05). 
The expression of TNF and IL-6 mRNA was significantly lower in MCD+BET 
compared to MCD group (p<0.05). Betaine treatment in combination with MCD diet 
further increased expression of IL-10 mRNA compared to MCD group (p<0.05). In contrast 
to MCD group, no significant difference in TGF-β expression was evident between 
MCD+BET and control group (p>0.05; Figure 4.12.A.). 
The mRNA levels of both proapoptotic protein Bax and antiapoptotic protein Bcl-2 
were significantly upregulated in MCD group by comparison with control group (p<0.05). 
On the other side, betaine supplementation in combination with MCD diet significantly 
reduced expression of Bax mRNA (p<0.05) and increased the expression of Bcl-2 mRNA 
when compared with MCD group (p<0.05). The levels of mRNA encoding the proapoptotic 
factors Bbc3 and Bak1 did not display significant differences between thecontrol and 
experimental groups (Figure 4.12.B). 
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Figure 4.12. Effect of betaine on liver mRNA levels of (A) cytokines and (B) 
apoptotic proteins in MCD-fed mice. 
The mRNA expression of selected cytokines and apoptotic mediators was analyzed 
by quantitative RT-PCR in liver tissue from different treatment groups (n = 7 per group). 
Animals in control group were fed with control diet. MCD group was fed with MCD diet 
for six weeks. BET group was on control diet followed by betaine supplementation (1.5% 
solution in drinking water) and MCD+BET that was on MCD diet combined with betaine 
treatment for six weeks. 
Significance of the difference was estimated by using one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used (*p<0.05, vs. control, #p<0.05 vs. MCD). 
The data are presented as means ±SD. 
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4.2.6. The effects of betaine supplementation on autophagy and Akt/mTOR signaling 
in MCD diet-induced NAFLD 
 
The protein levels of LC3-II, the lipidated form of LC3 that is incorporated in, and 
degraded by autophagosomes (103) were increased in all three treatment groups (BET, 
MCD, and MCD + BET) compared to control (p<0.05) without the difference among those 
three groups. While the level of SQSTM1/p62, a protein selectively degraded by autophagy 
(104), was increased in MCD-fed mice by comparison with control (p<0.05), betaine 
supplementation significantly reduced its levels compared to both control and MCD group 
(p<0.05).  
MCD diet did not affect the mRNA levels of autophagy activators Atg4b, Atg5, 
Atg7, and beclin 1. On the other hand, betaine treatment alone significantly increased Atg4 
and beclin 1 mRNA expression by comparison with control (p<0.05). Betaine treatment in 
mice fed with MCD diet significantly increased the mRNA levels of Atg4b, Atg5, Atg7, 
and beclin 1 by comparison with control (p<0.05).  
The phosphorylation of mTOR, its substrate S6K, and its upstream activator Akt, 
was significantly upregulated in BET compared to control group (p<0.05). While no 
difference in p-S6K, p-mTOR and p-Akt expression was found in MCD vs. control group 
(p>0.05), in MCD + BET group the expression of phosphorylated forms of S6K, mTOR 
and Akt was significantly increased compared to both control and MCD group (p<0.05). 
However, no significant differences were observed between the four groups in the 
phosphorylation of the mTOR inhibitor AMPK (Figure 4.13.). These data indicate that 
betaine-mediated increase in autophagic response and Akt/mTOR signaling in the liver 
might contribute to its beneficial action in MCD-induced NAFLD.       
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Figure 4.13. Effect of betaine on autophagy and mTOR signaling in MCD-fed mice. 
 The expression of Atg4, Atg5, Atg7, and beclin 1 mRNA was analyzed by quantitative 
RT-PCR in liver tissue from different treatment groups, while LC3 conversion, p62 
accumulation, and the phosphorylation of mTOR, S6K, Akt, and AMPK were assessed by 
immunoblotting. Significance of the difference was estimated by using one-way analysis of 
variance (ANOVA) with Tukey’s post hoc test was used (n = 7 per group; *p < 0.05 
compared to control; 
#
p < 0.05 compared to MCD group; representative blots are shown). 
For further information see Figure 4.11. 
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4.2.7. The effects of betaine on ultrastructural changes in the liver 
 
In the control group, the analysis with electronic microscope showed normal liver 
ultrastructure, while in BET group normal liver tissue architecture was found with evident 
autophagosomes and mitochondria of different sizes within HSCs. In MCD diet-treated 
group diffuse fatty change that disrupts normal liver architecture was found with occasional 
apoptotic bodies in endothelial cells, enlarged mitochondria, hepatocytes and 
myofibroblasts surrounded with collagen fibers. In MCD+BET group steatosis and 
autophagosomes were clearly evident and accompanied with mitochondria of different sizes 











Figure 4.14. Effect of betaine on liver ultrastructure in MCD-fed mice evaluated on 
TEM. 
Liver tissue sections from control (A), betaine-treated (B), MCD-fed (C), and MCD + 
betaine-treated mice (D) were analyzed by TEM. White arrows point at autophagic vesicles 
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4.3. The effects of NRG-1 on animal models of liver fibrosis and isolated hepatocytes 
 
4.3.1. The effects of NRG-1 on hepatocyte damage in CCl4 and BDL-induced liver 
fibrosis 
Serum aminotransferase activities, ALT (CCl4, 96.96±40.0 U/L and BDL, 
239.17±103.46 U/L) and AST (CCl4, 81.87±25.81 U/L and BDL 437.30±171.58 U/L) were 
significantly increased in both liver fibrosis models, compared to control group (ALT, 
57.98±39.00 and AST 71.35±36.42 U/L) (p<0.01).  However, NRG-1 treatment did not 
induce any significant changes in transaminase activities, (Figure 4.15.). 
 
Figure 4.15. The effects of neuregulin-1 (NRG-1) on serum alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) activity in mice with liver fibrosis.  
 A) Mild liver fibrosis model induced by CCl4 i.p. injections for 4 weeks and B) severe 
liver fibrosis developed 4 weeks after bile duct ligation (BDL). NRG-1 was 
administered 5 times a week i.p. (20µg/kg body weight). Significance of the difference 
was estimated by two way analysis of variance (ANOVA) with Tukey’s post hoc test (* 
p<0.05, ** p<0.01).Data are presented as mean±SD. 
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4.3.2. The effects of NRG-1 treatment on fibrotic changes in the liver tissue 
 
 Masson trichrome staining showed significantly increased accumulation of ECM 
proteins in both models by comparison with control group (p<0.01). However, NRG-1 
treatment significantly increased liver fibrosis from  1.86 to 2.65 % in CCl4 model and from 











Figure 4.16. Histological findings in liver tissue (Masson’s trichrome staining, scale 
bar 100µm, quantification of percentage of fibrotic area). Effects of neuregulin-1 (NRG-1) 
on fibrotic tissue accumulation in A. Mild liver fibrosis model induced by CCl4 i.p. 
injections for 4 weeks and B. severe liver fibrosis developed 4 weeks after bile duct ligation 
(BDL). NRG-1 was administered 5 times a week i.p. (20µg/kg body weight). Significance 
of the difference was estimated by two way analysis of variance (ANOVA) with Tukey’s 
post hoc test (** p<0.01). Data are presented as mean±SD. 
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4.3.3. The effects of NRG-1 on collagen 1, collagen 3, MMP2 and MMP9 mRNA 
expression in the liver fibrosis 
 
In addition to histological findings, relative mRNA expression of collagen type 1 
and 3 (Col1a1 and Col1a3) was significantly increased in CCl4 group when compared with 
control, while in CCl4+NRG group no significant difference was observed when compared 
to CCl4 group. On the other hand, in BDL group there was no change in mRNA expression 
for collagen type 1 and 3 compared to control. In contrast to CCl4 model, NRG-1 treatment 
significantly increased mRNA expression for both types of collagen in BDL+NRG-1 group, 
compared to BDL group (p<0.05, Figure 4.17.A). 
In CCl4-induced liver fibrosis, relative MMP2 and MMP9 mRNA expression was 
significantly increased by comparison with control (p<0.05). NRG-1 caused a decrease in 
these MMPs expressions, but only significant is the decrease in MMP2 mRNA expression 
compared with CCl4 group (p<0.05). Besides, MMP-9 expression was significantly higher 
in BDL-treated vs. control group (p<0.01). However, NRG-1 did not cause a significant 
change in MMP2 and MMP9 expression either in control or BDL group by comparison 
with vehicle-treated groups (p>0.05, Figure 4.17.B). 
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Figure 4.17. Effects of neuregulin-1 (NRG-1) on relative collagen 1 and 3 (col1a1 
and Col3a1) expression (A) and matrix-metalloproteinases (MMP) 2 and 9 (B) in both liver 
fibrosis models. 
Mild liver fibrosis model induced by CCl4 i.p. injections for 4 weeks and  severe 
liver fibrosis developed 4 weeks after bile duct ligation (BDL). NRG-1 was administered 5 
times a week i.p. (20µg/kg body weight). Significance of the difference was estimated by 
two way analysis of variance (ANOVA) with Tukey’s post hoc test (*p<0.05, 
**p<0.01).Data are presented as mean±SD. 
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4.3.4. The effects of NRG-1 on total and phosphorylated ErbB3 and ErbB4 
receptors in the liver  
 
Western blot analysis did not show significant differences in total amount of ErbB3 
and ErbB4 NRG-1 receptors in healthy mouse liver. However, 30 minutes after NRG-1 
stimulation, Western blot showed a significantly increased phosphorylation of ErbB3 
receptors when compared with control (p<0.01), while ErbB4 phosphorylation was not 
significantly different between NRG-1 and control group (p>0.05; Figure 4.18.).  
 
Figure 4.18. Neuregulin-1 (NRG-1) receptors in mouse healthy liver (Western blot 
analysis with primary antibodies ErbB3, ErbB4, phosphor-ErbB3, phospho-ErbB4 and GAPDH, 
all diluted at 1:1.000). A. Total amount of ErbB3 and ErbB4 receptors in mouse liver. B.  
Liver ErbB3 and ErbB4 receptors phosphorylation 30 minutes after NRG-1 i.p injection. 
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Significance of the difference was estimated by two way analysis of variance (ANOVA) 
with Tukey’s post hoc test. Data are presented as mean±SD. 
4.3.5. The effects of NRG-1 treatment on TGF-β mRNA expression on isolated 
hepatocytes 
 
In vitro NRG-1 (20ng/ml) stimulation lasting 16 hours induced a significant 
increase in relative TGF-β mRNA expression in primary isolated mouse hepatocytes, 
compared to control cells (p<0.01). After the same period of stimulation with three 
different doses of NRG-1, Western blot did not show a significant difference in total 




Figure 4.19. Effects of NRG-1 on TGF-β mRNA expression on isolated 
hepatocytes  
RT-PCR analysis of relative TGF-β mRNA expression in primary isolated 
hepatocytes treated with NRG-1 (20ng/ml) for 16 h. Significance of the difference was 
estimated by Student’s t test (**p<0.01). Data are presented as mean±SD. 
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NAFLD represents one of the leading health problems in the world, predominantly 
in well-developed countries with prevalence of 20-30% due to rapidly increasing 
prevalence of obesity and diabetes mellitus type 2 especially among young population (4). 
Despite all the efforts and numerous groups of research to find an adequate therapeutic 
solution, NAFLD still remains too complex for targeting all pathogenetic pathways at the 
same time. Therefore, the best solution is to improve prevention, or to reduce all risk 
factors before the development of the disease. In order to test all substances that could 
potentially be used for prevention and treatment of NAFLD, it is necessary to use an 
adequate animal model that can meet all the requirements in order to cover all changes and 
disturbances that occurs in human NAFLD.  
Various rodent models of NASH have been described, but no single animal model can 
completely reflect the range of pathohistological and pathophysiological features associated 
with human NASH. Ob/ob mice that are obese and diabetic develop with increased leptin 
levels develop severe type 2 diabetes and also obesity due to a functional defect in the long-
form leptin receptor. High fat diet-fed mice develop MetS, are obese with hyperinsulinemia 
and glucose intolerance with developed insulin resistance, similar to NAFLD in humans, 
but histological changes are often not completely developed (74,105).  
NAFLD induced by using MCD diet is a commonly used animal model since it is 
reproducible, changes in the liver develop rapidly and are quite similar to those observed in 
humans (106). In MCD diet-induced NAFLD, animals do not develop insulin resistance, 
and lipid profile is different than in human population. This model of NAFLD is associated 
with characteristic changes in serum lipid profile. Serum triglycerides progressively 
decreased and showed the lowest value after six weeks of MCD diet when compared to 
control and MCD2 and MCD4 groups (Fig. 4.4B). Similar finding was evident in study by 
Park et al. (107) where plasma triglycerides decreased even after one week of MCD diet 
with more pronounced decrease after six weeks. Low triglyceride level in plasma, as a 
measure of liver VLDL secretion, can be a consequence of increased hepatic fatty acid 
uptake and decreased VLDL secretion from the liver (108). Besides, total serum cholesterol 
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decreased, but it does not imply an anti-atherogenic effect of MCD diet, since LDL 
cholesterol was increased and HDL decreased. This indicates that MCD-induced model can 
be potentially used for studying the link between atherogenic dyslipidemia and NAFLD.  
However, this model is associated with changes in liver structure and function, thus it is 
appropriate for studying pathogenetic mechanisms of NAFLD progression. In our study, 
MCD diet after two weeks induced initial fatty changes in mice liver with progressive 
intensification and the development of inflammation with ballooning degeneration of 
hepatocytes after 6 weeks of feeding with MCD diet. Fat accumulation in liver tissue was 
evident histologically (Figure 4.2.B) as a simple steatosis after 2 weeks. Although 
inflammation was not developed, oxidative stress and lipid peroxidation in the liver 
associated with reduced activity of antioxidative enzymes was evident 2 weeks after MCD 
diet (109). These findings indicate that MCD treatment for two weeks may be a suitable 
model for investigation of early fatty changes and oxidative damage in initial stage of 
NAFLD.  
In contrast to early changes in liver tissue, 6 week-treatment with MCD diet induced 
liver steatosis accompanied with inflammation and apoptosis that were evident on histology 
(Figure 4.2.D). The presence of inflammation in 6 weeks of MCD diet model was also 
confirmed by increased levels of acute phase proteins in serum, CRP and ferritin (Table 2). 
Fat accumulation in the liver was obvious even macroscopically and it caused the increase 
in the liver weight that made liver/animal weight ratio even higher, since MCD diet caused 
weight loss in experimental animals (Figure 4.1.). The increase in serum transaminases 
(Figure 4.3.A) also confirmed hepatocyte damage in this animal model. Histological and 
biochemical analysis confirm that feeding with MCD diet for 6 weeks is an appropriate 
model for studying pathogenetic mechanisms that may contribute to NASH development or 
its progression.  
It is well known that FFAs, especially saturated FFAs exert hepatotoxic effects and 
contribute to the progression of steatosis to NASH (110–113)(114,115). Mechanisms 
involved in the lipotoxicity of FFAs include mitochondrial dysfunction and increased ROS 
production as well as ER stress and activation of inflammatory and cell death pathways 
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(116). Saturated fatty acids can act as a ligand for TLR-4, that leads to the activation of 
proapoptotic and proinflammatory pathways (117). Intracellular FFA accumulation is 
associated with increased synthesis of IL-6, IL-8 and TNF-α (112) as well as profibrogenic 
growth factors (113). Also, fatty acids can destabilize lysosomal membrane and cause a 
release of cathepsin B that also activate apoptotic pathway (118). Lipotoxic effects of FFAs 
have been also confirmed in cultured hepatocytes which exibit inflammatory and fibrogenic 
response similar to NAFLD in human population when exposed to high concentration of 
free fatty acids (110). Also, Jun et al. (111) showed that stimulation of HepG2 cells with 
free fatty acids resulted in hepatic lipotoxicity due to disrupted fatty acid oxidation in 
hepatocytes. In this context esterification of FFAs in the form of triglycerides as well as 
intracellular fatty acid binding to specific fatty acid binding protein (FABP) can be 
considered a protective response that prevents lipotoxic injury of the liver.   
Based on previous data, this study is one of the first that determined fatty acid profile in 
MCD diet model of NAFLD. Our study has shown a decrease in hepatic palmitic and oleic 
acid isomer proportions, whereas the proportions of oleic and linoleic acid were elevated. 
In addition, increase in hepatic linoleic acid proportion was most pronounced in MCD2, 
whereas the highest oleic acid proportion was evident in MCD4 group (Table 2). Other 
fatty acids showed characteristic time-dependent changes. Stearic acid was decreased after 
2 and 4 weeks of MCD treatment, while after 6 weeks it returned to basal values. Since the 
hepatotoxic effects of saturated fatty acids are well known (117), accumulation of palmitic 
and stearic acid clearly did not contribute to the liver injury caused by MCD diet in the 
present study. On the other hand, DPA level was increased and arachidonic acid level was 
decreased after 2 weeks of MCD diet, and both fatty acids returned to basal values after 4 
and 6 weeks of MCD diet. The significance of this finding is still not established. Lipid 
mediators derived from n-6 PUFAs are bioactive and may exert proinflammatory, 
atherogenic and pro-thrombotic effects. Linoleic acid is the direct precursor for generation 
of its oxidized metabolites (OXLAMs) that are actually bioactive lipids. Similarly, 
arachidonic acid can also serve as a substrate for oxidized metabolites, which together with 
OXLAMs are associated with steatosis markers, liver oxidative injury and insulin resistance 
 
   74 
 
(119). However, only linoleic acid, but not arachidonic acid seems to contribute to the 
NASH development and progression in the present study.  
On the other hand, lipid metabolites generated from n-3 PUFAs (protectins, maresins 
and resolvins) are anti-inflammatory and pro-resolving mediators which are also able to 
decrease lipogenesis (116,120). It has been shown that high n-6/n-3 PUFA ratio in 
hepatocytes and in circulation correlates with NAFLD severity (119). MCD diet used in 
present study caused the decrease in n-3 PUFA such as DHA (Table 2), and the ratio 
between n-6 and n-3 PUFAs was increased in liver tissue. These changes in hepatic free 
fatty acid profile in NAFLD, even in the initial phase, may represent an important 
triggering factor for promotion of oxidative stress and inflammation that will contribute to 
NAFLD progression. Supplementation with DHA and diet with lower n-6 PUFAs content 
may potentially be used for alleviation of liver steatosis and prevention of its further 
progression.  
The relevance of this finding in human NAFLD remains questionable, since MCD diet 
does not induce insulin resistance and metabolic syndrome. Other human and experimental 
studies support this claim, since they have shown contradictory findings related to FFA 
profile in the liver and serum. In contrast to our model, high-fat diet was found to induce an 
increase in liver DHA level (121). Studies on patients with NAFLD and NASH have shown 
that hepatic FFAs were unchanged across the spectrum of liver injury (122), whereas 
plasma FFA levels were significantly increased in NAFLD and were suggested to be the 
primary source for TAG synthesis in hepatocytes. Within TAGs and diacylglycerols, the 
saturated palmitic acid and the monounsaturated oleic acid were elevated, reflecting, 
perhaps, their greater availability in the circulating FFA pool (123,124). Other studies have 
demonstrated elevated levels of circulating oleic and palmitic acid in patients with NAFLD 
(110). The precise effect of DHA supplementation should be further investigated. 
There is a possible association between serum free fatty acids and cardiovascular risk 
factors such as dyslipidemia, insulin resistance and body mass index, that are also present 
in NAFLD (125). However, in our animal NAFLD model, a significant negative correlation 
between hepatic DHA and serum LDL level may indicate a potential role of DHA 
 
   75 
 
supplementation in prevention of atherogenic lipid profile in patients with NAFLD. In 
addition, DHA+EPA diet was found to decrease hepatic total cholesterol content (126),  
whereas our study suggests that DHA may have an opposite influence on serum cholesterol 
level because there was a significant positive correlation found. Supplementation with n-3 
polyunsaturated fatty acids in humans decreases serum triglyceride level (127). A 
significant decrease in serum triglycerides in our animal NAFLD model probably is not 
caused directly by decreased hepatic DHA despite their positive correlation, but due to 
specific lipid metabolism in rodents than in a human population.  
 MCD diet after 6 weeks of consummation induced an increase in unsaturated fatty acids 
such as oleic acid, and n-6 polyunsaturated fatty acids (PUFA), linoleic and arachidonic 
acid.  
An inflammatory response that occurs in the liver is an important driving force of 
NAFLD progression, since inflammation processes may contribute to hepatic fibrogenesis 
which ultimately leads to cirrhosis (116). In our study we showed increased expression of 
proinflammatory cytokines TNF and IL-6, which confirm the presence of inflammatory 
processes evident on histology, making this model suitable for NASH studying. 
Inflammation is the process that occurs after the second hit, oxidative stress and free 
radicals accumulation that cause cell damage. MCD diet for six weeks caused increased 
lipid peroxidation that was evident as an increase in MDA as well as in nitrosative stress 
(Figure 4.10.). Besides, the activity of enzymes responsible for antioxidant defense was 
decreased (Figure 4.10. and 4.11., Table 3). Oxidative injury and damage of cells and 
organelles is responsible for triggering inflammation and subsequent the autophagy to 
remove damaged cell particles or cell death processes apoptosis and necrosis (29). Our 
results indicate that there was an increase in pro-apoptotic markers expression suggesting 
that there is an increase in cell apoptosis in NASH, as suggested in previous studies, both 
clinical and experimental (128–130). In contrast to increased apoptosis, autophagy markers 
were significantly reduced in MCD group, due to decreased removal of damaged 
organelles, and more pronounced cell death. 
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Betaine represents an important human nutrient and is present in almost all tissues, but 
the liver, kidney and testes are organs with the highest concentration of betaine. Dietary 
intake is a major source of betaine, but it can also be synthesized from choline in the liver 
and kidney (131). Recent data highlight the potential therapeutic use of betaine, with the 
specific focus on its mechanisms which could possibly attenuate liver injury. Our results 
showed that betaine supplementation improved histological findings in the liver in animals 
fed with MCD diet. Steatosis was reduced and inflammation less prominent than in MCD 
group (Figure 4.9.). This finding was also confirmed by significant decrease in ALT and 
AST activities in serum (Figure 4.8.), thus indicating that betaine has aprotective role in 
NAFLD. Other studies that investigated betaine effects on fatty liver, have obtained similar 
results (132). Methyl donors are described to have the ability to reduce fat deposition in the 
liver by decreasing free fatty acid levels and preventing further triglyceride accumulation. 
Additionally, it has been shown that betaine can potentially increase insulin sensitivity in 
mouse models of NAFLD (133,134). On the other hand, betaine supplementation 
significantly increased serum HDL and decreased LDL concentration, and also increased 
serum triglyceride content by comparison with MCD group. Wang et al. (135) suggested 
that betaine alleviated hepatic fat accumulation by the activation of AMPK system and 
inhibition of de novo lipogenesis in the liver. Besides, betaine may reduce liver steatosis by 
improving adipose tissue function and stimulation of adiponectin secretion. Study on high-
fat diet-induced NAFLD showed that betaine improved insulin sensitivity and adipokine 
production what is considered as one of the protective effects of betaine (136). 
Hepatoprotective effect of betaine evident as a decerease in serum aminotransferase 
activities was also confirmed in human NAFLD (136). Altered lipid profile in patients with 
NAFLD usually increases the risk of cardiovascular diseases, suggesting that betaine 
treatment may reduce this risk by improving serum HDL level and reducing LDL.  
These mechanisms of steatosis and lipid profile improvement are not sufficient to 
explain all beneficial effects of betaine in NAFLD. Therefore we examined the effects of 
betaine supplementation on oxidative stress, inflammation, apoptosis and autophagy in the 
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liver in MCD-diet induced NAFLD. An imbalance between oxidative stress and 
antioxidative protection has been implicated in the etiology of various disorders such as 
cancers, renal diseases, atherosclerosis, diabetes mellitus and liver diseases (137). 
Oxidative stress has been described as the major component of the “second hit” that is a 
key point in aggravation of fatty liver and its progression (28,29,138–140) Our study 
confirmed this finding, since MCD diet induced oxidative damage of the liver with 
increased lipid peroxidation evident as an elevation of MDA level (Figure 4.10.A). In our 
model oxidative stress could be explained by decreased activity of liver SOD and its 
isoenzymes, especially MnSOD in mitochondria that will lead to accumulation of 
superoxide anion, which has an ability to build peroxynitrite in reaction with NO. Similar to 
this, in MCD group catalase activity was decreased. These findings are in accordance with 
one of our previous studies (41) where dynamics of oxidative stress was observed in MCD 
diet-induced NAFLD. Liver GSH decreased in MCD group with increased nitrites (Figure 
4.10.). This decline could be a consequence of methionine deficiency, and subsequent 
decreased cysteine production which is necessary for GSH synthesis (141). Also, there is 
increased utilization of GSH during the neutralization of free radicals, which can 
additionally explain low GSH level in our model (41). GSH decrease in MCD group was 
followed by reduced GPx activity in the absence of substrate, while activity of glutathione 
reductase was increased, probably in order to restore GSH. MnSOD was decreased in MCD 
group by comparison with control, and this was confirmed in various studies, both 
experimental and clinical (142,143). It has been shown that MnSOD expression negatively 
correlates with steatosis grade and MnSOD amount negatively correlates with triglycerides, 
indicating the relationship between fat accumulation in the liver and low levels of MnSOD 
(142).  
Betaine exerted antioxidative effects in the present study, evident as a decrease in lipid 
peroxidation (Fig.4.10.A) and nitrozative stress (Fig.4.10.B), as well as an increase in 
antioxidative enzymes. Previous in vivo studies have shown that betaine exerts its 
antioxidative effect by two mechanisms: directly as a “free radical scavenger” and 
indirectly by improving the antioxidant defense, including enzymatic antioxidants like GPx, 
catalase, SOD, and nonenzymatic GSH (41,143). Betaine supplementation in our study also 
 
   78 
 
significantly increased the activities of SOD, catalase, GPx, and GSH content in the liver. 
Superoxide anion can be detoxified by SOD in mitochondria into hydrogen peroxide, which 
can be further metabolized into water by the activity of GPx. For the normal function of 
GPx, the adequate amount of GSH is necessary in mitochondrial matrix. On the contrary, 
depletion of GSH content leads to mitochondrial dysfunction and cell death. Additionally, 
catalase has detoxifying effects against excess accumulation of hydrogen peroxide, and 
therefore represents another mechanism of antioxidant defense in the cell. Additionally, 
betaine increases the supply of substrate for GSH synthesis, by taking part in SAM 
synthesis, therefore making betaine an important factor for regulation of the metabolism of 
sulfur-containing amino acid (143,144).  
Study by Ganesan et al. (145) investigated antioxidant effects of betaine in lymphoid 
organs during induced restraint stress in rats. This research group showed that betaine 
supplementation reduces lipid peroxidation that is in accordance with our results in the 
liver. It can potentially be explained by inhibition of ROS production that damage proteins, 
DNA and lipids. Due to its lipotropic properties, betaine can easily pass through lipid 
bilayer in cell membrane and diffuse into all parts of the cell and exert its antioxidant 
activity. Balkan et al. (146) suggested that betaine prevented lipopolysaccharide-induced 
necrosis in the liver by inhibition of Kupffer cell activity and through antioxidative effect. 
On the other hand, betaine exert its antioxidant properties by increasing GSH content in 
the liver that was accompanied with increased GPx activity (Table 3). Recent study showed 
that 1.8% betaine solution increased activities of SOD and the GSH content in blunt snout 
fish fed with high-fat diet (147). Study by Ganesan et al. (145) showed that betaine 
supplementation prevented depletion in GSH in spleen of rats as well as activity of GPx 
and glutathione S transferase. It is suggested that betaine play role in membrane 
stabilization and protect membrane proteins from denaturation (148). In hydroxyl free 
radical, there is an unpaired electron that is mostly responsible for membrane damage and 
lipid peroxidation. With betaine, this electron might be trapped and dismuted by betaine, 
which may represent one of its antioxidant mechanism (149,150). Besides, betaine 
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indirectly increases GSH content by restoration of SAM that is a contributor to an increase 
in substrate required for GSH synthesis (145).  
Main antioxidant enzyme that is present in cell cytoplasm and mitochondria is SOD 
with its isoenzymes Cu/ZnSOD and MnSOD and together with catalase they play an 
important role in neutralization of O2
-
 into H2O2. Study by Alirezaei et al. (151) showed 
that betaine reduced lipid peroxidation and increased the activity of SOD, catalase and GPx 
in ethanol-induced oxidative stress in rat brain. In the same study it has been showed that 
betaine treatment reduced the content of H2O2 by elevation of catalase activity in betaine 
treated group as well as in ethanol + betaine group (151). In our study, we have notice the 
same changes in catalase activity. Its activity has been decreased in MCD diet-treated 
group, while betaine administered alone, and in combination with MCD diet significantly 
improved catalase activity (Table 3), suggesting that this can potentially be additional 
mechanism for ROS neutralization besides SOD. Comparing the activities of Cu/ZnSOD 
and MnSOD, it can be noticed that betaine exerts its antioxidant activity by increasing 
MnSOD activity in a higher extent than Cu/ZnSOD. This makes MnSOD predominant 
antioxidant that is being activated after betaine supplementation. MnSOD has been 
increased in betaine group, as well as in betaine+MCD, while that is not the case with 
Cu/ZnSOD. (Figure 4.11.). Liu et al. (152) conducet a study that examined effects of 
betaine on oxidative stress and survival of yeast exposed to H2O2. Their results suggest that 
betaine treatment alone and in the state of oxidative stress have ability to improve activity 
of SOD, catalase and GPx. Similar results have been reported in man studies. Hagar et al. 
showed that betaine improved SOD activity in cisplatin-induced nephrotoxicity, as well as 
the activity of catalase, GPx and the GSH. Total antioxidant status was also increased by 
betaine (153). Total oxyradical scavenging capacitywas significantly reduced in high-fat 
diet-induced NAFLD in rats, while betaine supplementation increased this capacity in the 
reaction with hydroxyl and peroxyl radicals (154). Similar study on animal model of 
alcoholic liver injury showed that betaine supplementation improved total oxyradical 
scavenging capacity in the liver by regulation the metabolism of sulfur amino acid (155). 
Recent study showed that betaine attenuated oxidative stress, reduced CYP450 activity, 
improved GSH-transferase acitivity in liver of radiation-exposed animals (156). 
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In addition, this study examined the effects of betaine on liver PON1 activity, which 
was significantly reduced in MCD diet model of NAFLD. Many studies assert the role of 
PON1 in atherogenesis and its correlation with increased serum lipids (157,158), while 
fewer studies have investigated the role of this enzyme in liver diseases such as NAFLD 
(159–161). Serum PON1 is liver-produced HDL-associated peroxidase and it was shown to 
possess antioxidative properties, which are probably attributed to the enzyme’s capability to 
protect HDL and LDL from oxidation (162–164). In PON1 deficient mice, higher serum 
oxidative stress was shown and HDL was no longer able to protect LDL from oxidation 
(165). In the present study, betaine supplementation in NAFLD mice prevented triglyceride 
accumulation in the liver, reduced steatosis and also improved serum lipid status by 
decreasing LDL and increasing HDL content. This finding can be in part explained by 
improved PON1 activity in betaine-supplemented mice, since some studies have found 
significant correlation between PON1 activity and serum lipids (166,167). Elevated serum 
LDL and decreased HDL might have a causal role in the pathogenesis of NASH (160), and 
beneficial effects of betaine on serum lipid profile might be one of the mechanisms by 
which betaine alleviates fatty liver disease. Study on db/db mice has shown that betaine 
increased fatty acid oxidation by increasing PPARα and carnitine palmitoyltransferase 1α 
(CPT1α) mRNA levels, indicating a possible mechanism of betaine action in the alleviation 
of hyperlipidemia (168).  
Activity of liver PON1 in the present study was significantly reduced in mice with 
MCD diet-induced NAFLD with negative correlation with liver MDA, which has also been  
confirmed by similar studies (169,170). In addition, it has been shown that oxidative stress 
can affect PON1 activity and its expression (171). However, it has been shown that mRNA 
and protein expression of PON1 were both elevated in human NASH livers (161). This 
discrepancy could be related to the differences in investigated species or to the diffrences in 
oxidized lipids that are able to inactivate PON1 (172). Interestingly liver PON1 activity was 
found to positively correlate with SOD activity and GSH content. This finding may suggest 
that betaine improves GSH and SOD directly, and probably to a lesser extent by 
modulating liver PON1 activity. Similar correlations were found in study on diabetic 
patients where serum PON1 was inversely correlated with parameters of insulin resistance, 
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chronic inflammation and with markers of oxidative stress, inversely with MDA, and 
directly with SOD and GPx (173). The same study has shown significantly increased GRed 
activity in group of subjects with metabolic syndrome (173), what is also in accordance 
with our results in animal model of NAFLD. We observed that PON1 activity was 
significantly decreased in NAFLD compared to control group, while betaine improved its 
activity in the liver. PON1 plays a role in the lipid metabolism and generation of VLDL in 
the liver (174), and liver dysfunction can potentially be caused by decreased PON1 activity. 
The putative function of PON1 in the liver is to provide hepatic protection against oxidative 
stress (172), while low activities of PON1 are associated with diabetes mellitus,oxidative 
stress, increased cholesterol levels,  cardiovascular diseases, and sepsis (175,176). Our 
results are in accordance with these findings, since decreased PON1 activity and increased 
oxidative stress were evident as well as correlations between PON1 and MDA and nitrites.  
Inflammatory response in the liver is an important factor leading to NAFLD 
progression and development of steatohepatitis. However, as in other chronic liver diseases 
the presence of chronic inflammation precedes NASH and is the key mechanism 
contributing to liver fibrosis (177). Oxidative stress is considered to be an important trigger 
for inflammatory processes in NAFLD. Earlier studies showed that H2O2 is able to rapidly 
and potently activate NF-kB in human T-cells. Further studies reported that various 
oxidants may directly activate NF-kB, while antioxidants have ability to inhibit its activity 
(178). NF-kB is an important transcription factor involved in immune response and 
inflammation. Under normal conditions, this factor is in the cytoplasm and is bound to 
inhibitory kB (I-κB), which then inhibits translocation of NF-kB into cell nucleus. 
Increased ROS production in cells activates redox sensitive kinase that phosphorylates I-
kB, leading to its degradation and NF-kB translocation to the nucleus with subsequent 
upregulation of proinflammatory genes, such as TNF-α and IL-6 (24,179). In our study 
apart from increased oxidative stress, in the liver tissue, the mRNA expressions of 
inflammatory mediators were increased. Inflammation in the NAFLD may be induced by 
few mechanisms, but oxidative stress is considered to be the main factor contributing to 
inflammation and NASH development (23,24,180). Therefore, increased inflammation 
verified on histology and by increased expression of proinflammatory cytokines could be 
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the consequence of prolonged oxidative injury of hepatocytes. In the present study the 
mRNA expression of TNF-α and IL-6 were significantly increased in MCD diet-fed mice, 
as well as IL-10 (Figure 4.12.). Increased expression of anti-inflammatory IL-10 is 
probably a compensatory response of liver tissue on increased inflammation. Similar to 
oxidative stress, free fatty acids are also triggers for synthesis of proinflammatory 
cytokines, and in our model, we have shown increased long chain fatty acids in the liver 
(Table 2). It has been shown that increased levels of linoleic acid promotes the synthesis of 
tissue arachidonic acid and both are able to induce synthesis of  inflammatory eicosanoids 
and reduce conversion of alpha linoleic acid into EPA and DHA (181), which were 
significantly reduced in our NAFLD model (Table 2). Impaired free fatty acid profile, 
together with oxidative stress potentially represent important mechanisms leading to 
inflammation and steatosis progression to NASH.  
TNF-α represents a proinflammatory cytokine derived from various organs, including 
adipose tissue, skeletal muscles and liver, and its increased production occurs as a 
consequence of metabolic disturbances and is closely related to insulin resistance in obese 
animals. TNF-α is expressed to a higher extent in patients with NASH than with simple 
steatosis. Recent study by Ceccarelli et al. (182) have showed that lipopolysaharide-
induced TNF-α synthesis represents a key regulator of proinflammatory and profibrogenic 
response in the liver in NAFLD examined in clinical study and in HSC cell line. Betaine 
supplementation reduced inflammation that was evident on histology (Figure 4.9.), but also 
confirmed by decreased mRNA expression of TNF-α and IL-6, as well as TGF-β (Figure 
4.12.) in the liver. Betaine was confirmed to decrease the mRNA expression of TNF-α  and 
IL-6 in colonic mucosa in mice and also down-regulated lipopolysaharide-induced 
inflammatory response (183). Prevention of inflammation by betaine treatment may be 
partly explained by suppression of NF-kB activation that was confirmed in the aging and 
oxidative injury (184). In addition, betaine was shown to inhibit generation of ROS and 
activation of NF-kB in endothelial cells, and it is capable of restoring the redox balance by 
moderation thiol homeostasis (183–185). Increase in IL-10 mRNA expression contributes 
to the anti-inflammatory effects of betaine in our model of NAFLD.  
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Betaine has been shown to attenuate alcoholic liver disease by elevation of SAM 
concentration in liver tissue (186). Previous studies (186) suggest that SAM may attenuate 
liver injury by increasing IL-10 concentration and decreasing TNF-α concentration. 
Investigation conducted on macrophage cell line obtained that SAM and its metabolite 5’-
methylthioadenosine (MTA) significantly decreased lipopolysaharide-inducible NF-kB 
transcriptional activity and consequently the expression of TNF-α. Besides, SAM leads to 
the increase in intracellular adenosine concentration that may increase IL-10 expression. 
Examination SAM role on macrophage cell line showed that SAM binding to the adenosine 
A2 receptor is the mechanism of IL-10 expression modulation (187–189). High-fat diet for 
6 weeks in IL-10
-/-
 mice induced a significant increase in hepatic triglyceride content 
compared to control animals, which suggest that IL-10 can protect liver against steatosis. 
Besides, inhibition of IL-10 in another NAFLD animal model aggravated hepatic 
inflammation by increasing IL-6 and TNF-α  expression in liver (190). 
Apoptosis represents an important mechanism that contributes to the progression of 
various liver diseases and if uncontrolled it can trigger liver fibrogenesis (128,130,191). 
Numerous studies confirmed a significant role of apoptosis in NAFLD development and 
progression to liver fibrosis (129,180,192,193).  
Oxidative injury and increased influx of free fatty acids are considered to be main 
mechanisms that trigger hepatocyte apoptosis in NAFLD. Oxidative stress can damage cell 
structure and function on every level, but the most significant is mitochondrial dysfunction. 
Since mitochondria are the major source of ROS, they are most susceptible to oxidative 
injury and peroxidation of membrane lipids that have PUFAs as essential components of 
phospholipids (194). Free radicals react with PUFAs damaging mitochondrial membrane 
and also inactivate antioxidant enzymes such as SOD. Oxidative injury leads to the 
inhibition of electron-transport chain in mitochondria, which ultimately increases 
production of ROS. It is known that ROS damage mitochondria DNA, so taken together 
prolonged oxidative stress leads to mitochondrial dysfunction starting vicious cycle in ROS 
production and oxidative damage (180,195–197). Altered electron transport chain 
accompanied with defective ATP production and disrupted ultrastructure such as 
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mitochondrial enlargement, membrane crystalline inclusions and loss of cristae are 
indicators of mitochondrial dysfunction. Under normal conditions, damaged cell 
components and organelles are being removed by degradative processes such as autophagy. 
However, prolonged oxidative injury without adequate repair lead to cell death by 
apoptosis and necrosis (180). Initiation of apoptosis by dysfunctional mitochondria starts 
with cytochrome C release, which forms an activation complex with apoptotic protein 
activation factor-1 and caspase 9. This complex further activates effector caspases 3, 6 and 
7, which execute final apoptotic changes. Proapoptotic protein Bax can integrate into outer 
mitochondria membrane following apoptotic stimuli, while antiapoptotic protein Bcl-2 is 
localized predominantly in mitochondria (128,180,193).  
Our results presented on Figure 4.12.B showed increased mRNA expression of both 
proapoptotic Bax and antiapoptotic Bcl-2 protein in NAFLD model. This paradoxical 
finding can be explained by different time frame when these proteins are expressed in 
hepatocytes after proapoptotic stimulus. However, histological and TEM analysis suggest 
increased apoptosis in NAFLD as a presence of apoptotic bodies (Figure 4.9. and 4.14.). 
Figure 4.14. shows the ultrastructure of hepatocytes, where enlarged and mega-
mitochondria were observed suggesting their impaired structure, and probably the function 
as well. Apoptosis in NAFLD can be partly explained by increased oxidative stress and 
lipid peroxidation (Figure 4.10. and 4.11.) and consequent mitochondrial dysfunction. On 
the other hand, several studies point to the role of free fatty acid profile in apoptotic 
processes in NASH. Lipotoxicity mediators, saturated fatty acids and free cholesterol are 
important triggering factors that activate specific signaling pathways leading to apoptotic 
cell death (128,198). Accumulation of free fatty acids, especially saturated, induces ER 
stress in hepatocytes, that activates signaling pathways causing apoptotic cell death (199).  
Betaine supplementation in MCD diet-fed mice significantly reduced apoptosis by 
decreasing expression of Bax and increasing Bcl-2. Besides, by decreasing levels of lipid 
peroxidation and oxidative stress, betaine can indirectly reduce apoptosis through its 
antioxidant effects. Similar to our results, apoptosis induced by bile duct ligation in rats, 
was significantly reduced after betaine supplementation in study by Graf et al. (200). In 
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animals exposed to ionizing radiation, betaine treatment significantly reduces the activity of 
caspase-3 in the liver (156). Betaine effects on apoptosis were examined on isolated 
hepatocytes where betaine prevented the activation of caspase 3, 8 and 9, as well as an 
increase of cytochrome C in the cytoplasm, suggesting that antiapoptotic effect of betaine is 
predominantly at the mitochondria level (200). Another in vitro study on isolated 
hepatocytes treated with adenosine to induce cell damage analogous to alcoholic liver 
injury showed that betaine reduced the caspase-3 activity in hepatocytes via methylation 
reaction catalyzed by betaine-homocysteine methyltransferase (201). 
Autophagy represents a “housekeeper” process, which major role is to remove damaged 
or dysfunctional cellular contents and organelles and to provide substrates for energy 
production during starvation. So far known facts about the autophagy make it an important 
factor in maintaining normal cell function (202,203). Autophagy can be induced in stressed 
conditions such as oxidative or metabolic stress (202). In NASH, which is characterized 
with hepatocyte injury and inflammation, degradation and dysfunction of cells and 
organelles is increased. Since damaged organelles are removed by autophagy, alteration in 
this process could lead to aggravation of cellular injury. First described forms of autophagy 
in the liver were mitophagy and lipophagy (202). Autophagy has an important role in 
removing dysfunctional mitochondria, which occurs in aging, neurodegenerative disease, 
terminal differentiation of blood cells or prolonged oxidative stress, and is called 
mitophagy (202,204). Besides cytosolic lipases, autophagy is involved in regulation of cell 
content of lipids, by process called macrolipophagy (205,206), which represents the most 
important role of autophagy in fatty liver disease, since it could regulate the process of lipid 
accumulation in hepatocytes (202). Study on Atg7
-/-
 mice showed a significant increase in 
triglyceride accumulation in the liver indicating that defective autophagy promotes 
development of steatosis (202,203). This is in accordance with our results, where 
autophagy was decreased in MCD diet fed mice. Similarly, inhibition of Atg5 in 
hepatocytes also results in lipid droplets accumulation in the liver (203). MCD diet in our 
NAFLD model increased the levels of SQSTM1/p62 in the liver, suggesting that 
autophagic flux is decreased. This finding is followed by increased amount of LC3-II 
protein, marker of autophagosomes, which is degraded by autophagy. The study on patients 
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with steatosis and NASH showed accumulation of p62 and LC3-II that may indicate that 
autophagy was decreased (207), which is in accordance with our results.  In clinical studies 
on patients with liver steatosis, accumulation of autophagy cargo p62/SQSTM1 was evident 
suggesting decrease autophagy activity. This finding support the proposition that level of 
autophagy inversely correlate with liver fat content (208). The role of autophagy in the 
progression of steatosis is not completely elucidated. Alteration in lipid metabolism, 
increased oxidative stress, inflammation and apoptosis are usually associated with the 
modulation of autophagy process as a protective response against stress and cell injury 
(207,209). Pharmacological inhibition of autophagy induced an elevation of triglyceride 
content in the liver, possibly due to impaired lipolysis and not by increased synthesis of 
lipids (203). It has been shown that autophagy is an important mechanism in regulation of 
hepatic intracellular lipid metabolism and participates in lipid droplet degradation, 
therefore, dysfunctional autophagy is a potential pathogenic mechanism involved in fatty 
liver disease (210). Our results are in accordance with these findings, since in our NAFLD 
model, there was increased fat accumulation in the liver and decreased autophagy. 
On the other hand, betaine increased the expression of Atg4, Atg5 and Atg7 in mice on 
MCD diet (Figure 4.13.A), suggesting that another mechanism of protective effect of 
betaine against fat accumulation is the stimulation of lipophagy. Besides, betaine 
supplementation increased the content of LC3II accompanied with low levels of p62, 
suggesting that betaine increased autophagy (Figure 4.13.B). Increased LC3-II levels was 
probably due to increase in LC3-II synthesis, rather than decrease in its degradation, since 
betaine stimulated degradation ofp62 and the expression of Atg4b, Atg5, Atg7, and beclin 
1. Besides, there were increased autophagic vesicles in the mice liver on MCD diet, evident 
on TEM. Ultrastructural analysis using TEM showed decreased steatosis, presence of 
autophagosomes in MCD+BET group, with rare megamitochondira and few apoptotic 
bodies (Figure 4.14.D) confirming increased autophagy and decreased steatosis after 
betaine supplementation.  
It has been reported that ROS are important inducers of autophagy during starvation 
and nutrient deficiency. It is proposed that O2
-
 is the primary radical involved in autophagy 
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(211). However, increased oxidative injury can reduce autophagic function in hepatocytes 
and contribute to ROS accumulation due to increasing number of dysfunctional 
mitochondria. Our results have shown that betaine exerts antioxidant activity by reducing 
lipid peroxidation and increasing the activity of antioxidant enzymes, we may suggest that 
modulation of oxidative stress by betaine supplementation, can be additional mechanism by 
which betaine stimulates autophagy leading to diminished lipid content in hepatocytes and 
removal of dysfunctional mitochondria. There are evidence that increased oxidation of 
GSH is able to induce autophagy even there are not present any other autophagy stimuli 
(212).With decreased lipid peroxidation, we may assume that betaine treatment increases 
oxidation of GSH to reduce the amount of hydrogenperoxide, catalyzed by GPx, suggesting 
that this antioxidative effect of betaine is also trigger mechanism of autophagy (211). 
Recent studies in the past five years suggest that NO and nitrosylation process have the 
role in autophagy inhibition. It is demonstrated that NO donors or an increase in NO 
synthase in cell culture results in autophagy prevention by inhibition of c-Jun-N-terminal 
kinase 1 and IkB kinase β that regulate Beclin 1 and AMPK activation (211,213). Increased 
production of reactive nitrogen species, evident in our MCD model of NAFLD (Figure 
4.10.B) are at least partly responsible for decreased autophagy. Sarkar et al. (213) have 
showed that NO donors can also inhibit autophagy by upregulation classical mTOR 
pathway with increased p-s6K and mTOR activity in HeLa cells, suggesting that NO 
impairs autophagy by two independent mechanisms via JNK1-Bcl2-Beclin1 and 
AMPK/mTOR pathways. In our model, reactive nitrogen species didn’t modulate 
autophagy via classical AMPK/mTOR signaling pathway, but possibly by activating JNK1-
Bcl2-Beclin1 pathway. Similar to ROS, betaine treatment also diminished the content of 
reactive nitrogen species, which could be another linking mechanism between nitrosative 
stress and autophagy. Sine it has been shown that NO donors may inhibit autophagy, 
decrease in reactive nitrogen species by betaine may be additional probable cause of 
increased autophagy in our study. 
Apoptosis, process that is important for cell and organelles turnover and is in tight 
interaction with autophagy (214). Apoptosis and autophagy usually occurs in the same cell, 
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with the autophagy preceding the apoptosis. Initial stress stimulates and autophagic 
response, but when stress exceeds a critical duration or intensity, apoptotic pathways of cell 
death are activated. In the most cases, autophagy tends to suppress apoptosis or increase 
stress threshold before apoptosis occurs and therefore to reduce tendency of cells to die. 
This autophagy-apoptosis crosstalk seems to be anti-apoptotic rather than pro-apoptotic. 
However, in the condition of intense and prolonged cell injury that reach the cell limit, 
adaptive mechanisms, including autophagy are being overwhelmed and apoptotic cell death 
pathway is activated. Activated caspases digest proteins that are essential for autophagy, 
and hence inhibit the autophagic programme, probably in order to interrupt its protective 
function and accelerate cell death. The main targets for caspases are Atg3 and Beclin 1, 
making them to lose their ability to stimulate autophagyand convert proautophagic proteins 
into pro-apoptotic ones (215–217). This interaction between apoptosis and autophagy is 
perhaps additional mechanism of cell damage in our MCD-diet induced NAFLD. Our 
results indicate increased mRNA expression of pro-apoptotic Bax and Bcl-2 (Figure 4.12.) 
and the presence of apoptotic bodies in MCD-diet fed mice liver (Figure 4.14.). Increased 
apoptotic response in the hepatocytes may be the possible inhibitor of autophagy in our 
model. Caspase 10 is also being showed to degrade Bcl-2-associated transcriptional factor 
(BCLAF1), preventing BCLAF1 to interact with Bcl-2 and cause disruption of Bcl2-Beclin 
1 complex that will formation of Beclin-1-C fragments that further promote release of pro-
apoptotic factors, activating autophagy. Besides, activation of caspases inhibits Beclin 1-
induced autophagy by as cytochrome c by mitochondria (215,216,218,219). Increased 
autophagy flux (Figure 4.13.) by betaine supplementation is one possible mechanism that 
protected cells from apoptotic death. The major mechanisms by which autophagy reduces 
chances of cells to undergo apoptosis is mitophagy (215). Damaged and dysfunctional 
mitochondria are particularly able to activate apoptosis, so their removal by autophagy can 
postpone cell death by increasing the threshold for the induction of apoptosis (215). 
Another protective role of autophagy is removal of pro-apoptotic proteins in cytoplasm and 
decreasing their amount. It has been shown that autophagy mediates the removal of caspase 
8 in colon cancer cells (220). Study on Atg7 knockout animals registered increased caspase 
8 activity in TNF-induced apoptosis in hepatocytes (221). In addition, autophagy decreases 
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the SQSTM1 abundance, a protein that stimulate ROS production and cell death if it 
overexpressed (222).  
Since autophagy occurs before the apoptosis, it plays an important role in suppression 
of inflammation activated by death cells by increased recruitment of macrophages and 




, death cells 
with defective exposure of lysophosphatidylcholine on its surface accumulate and promote 
inflammation (215,223). This may be the linking mechanism between autophagy and 
inflammation, and may be applied to our results, where betaine supplementation reduced 
inflammation, that can be at least partly by increased autophagy.  
Through stimulation of autophagy, betaine exert additional hepatoprotective effects by 
dereasing fat content in the liver, reducing oxidative stress, inflammation and apoptosis, 
besides modulating these processes directly. 
Our results indicate that betaine may potentially have antifibrotic effects by down-
regulation of TGF-β expression. MCD diet induced an increase in TGF-β expression, while 
betaine prevented this increase. (Figure 4.12.). Similar results were obtained in high-
fat+CCl4 model of liver fibrosis in rats. Bingul et al. (224) showed that betaine 
supplementation reduced the expression in profibrotic markers such as TGF-b, a-SMA and 
Col1a1 in the liver, suggesting that betaine may directly affect the activity of HSCs. 
However, our model is predominantly NAFLD model, and the process of fibrogenesis is 
probably in early initial phase. Therefore, betaine could potentially be used for prevention 
of fibrosis development by modulation of TGF-β mRNA expression. 
 
Recent studies reported benefitial effects of NRG-1, especially in heart failure but also 
in lung fibrosis, nephropathy, nerve regeneration processes and insulin resistance (71,225–
228). Clinical trials in patients with chronic heart failure showed that rhNRG-1 treatment 
caused improvements in cardiac function (65,229–232). The effects of rhNRG-1 on liver 
physiology or pathopysiology is currently unknown. Previous studies have shown that 
rhNRG-1 prevents cardiac, kidney, skin, and lung fibrosis (71,72). The anti-fibrotic effects 
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of rhNRG-1 on fibroblasts are mainly mediated by the ErbB4 receptor (71). In this study, 
we examined the effects of NRG-1 on liver fibrosis. Two different murine models for liver 
fibrosis were used; CCl4 induced mild fibrosis and BDL induced severe liver fibrosis 
(Figure 4.16.). Surpisingly, the present study shows increased liver fibrosis in mice that 
were treated with NRG-1. Furthermore, we showed that the expression of the pro-fibrotic 
factor TGF-β is increased in isolated hepatocytes after stimulation with NRG-1 (Figure 
4.19). Therefore, the increased ECM accumulation in the liver in the NRG-1-treated 
animals could be due to increased TGF-β expression in hepatocytes by NRG-1.   
 MMPs represent extracellular endopeptidases that are involved in ECM regulation and 
degradation and may have both inhibitory and stimulatory role in fibrogenesis (233). In the 
CCl4 model, our results indicated increased expression of liver MMP2 and MMP9 (Figure 
4.17.). This increase is a consequence of a compensatory tissue response to hepatocyte 
damage, and overproduction of ECM proteins consistent with other studies (234–236). In 
the NRG-1 treated group, a significant decrease in liver MMPs expression was observed, 
which may represent an additional pro-fibrotic mechanism of NRG-1. On the other hand, in 
BDL model with severe liver fibrosis, no significant change in MMP2 and MMP9 mRNA 
expression between BDL and BDL+NRG-1 groups was evident, that may suggest that 
fibrogenesis in BDL occurs via a different mechanism. 
So far, various studies pointed out the importance of NRG-1/ErbB4 signaling pathway, 
suggesting that in cardiovascular system, NRG-1 exerts its effects predominantly by 
phosphorylation of ErbB4 receptors (65,237). ErbB2 and ErbB4 receptors are required for 
normal cardiac function, since their absence leads to embryonal lethality because of 
deficient cardiac morphogenesis (238). In contrast to the heart, ErbB3 receptors are known 
to be highly expressed in the liver, while ErbB2 and ErbB4 are expressed in small amounts 
(239,240). Pro-fibrotic effects of NRG-1 in the liver could be explained by predominantly 
activating ErbB3 in hepatocytes. Indeed, we observed a significant increase in ErbB3 
phosphorylation in liver tissue after NRG-1 exposure (Figure 4.18.), while ErbB4 was not 
phosphorylated by NRG-1. In contrast to the anti-fibrotic effects of NRG-1 in heart, kidney, 
lung and skin through NRG-1/ErbB4 signaling, in the liver NRG-1 exerts its activity 
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predominantly by activation of ErbB3 receptors. In addition to our research, Scheving et al.  
(240) pointed out a significant role of ErbB3 receptors in liver fibrosis development, and 
therefore pro-fibrotic effects of NRG-1 in the liver can be explained by NRG-1/ErbB3 
pathway. They showed that mice lacking ErbB3 and both ErbB3/EGF receptors develop 
less pronounced fibrosis after CCl4 injections compared to wild type mice, which indicates 
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1. Based on our results, it can be concluded that MCD die tinduces initial fatty change 
within 2 weeks with progression to more diffuse fatty change at 4 weeks and NASH 
in 6 weeks accompanied by apoptosis and inflammation. MCD diet is an appropriate 
model for investigation of the histological, biochemical and molecular changes 
where metabolic syndrome, and the role of adipose tissue are not reflected. 
2. Betaine exerts antioxidative effects by reducing lipid peroxidation and nitrosative 
stress in MCD diet-induced NAFLD. Anttioxidative capacity of the liver is enhanced 
by an increase in GSH level and activity of PON1, total SOD and its isoenzymes, 
CAT and GPx.  
3. Additionally, betaine improved serum lipid profile by reducing serum triglyceride 
and LDL level, and increasing HDL concentration.  
4. Betaine potentially alleviates the course of NAFLD by stimulation of autophagy 
through an increase in Atg4, Atg5, Atg7 in Beclin 1- and Akt/mTOR-dependent 
manner, but independently on AMPK activation.  
5. Betaine exerts antiapoptotic effect in MCD-diet induced NAFLD by lowering Bax 
and by increasing Bcl2 mRNA expression. 
6. Betaine alleviates inflammatory response in MCD-diet fed mice, by reducing the 
expression of TNF, IL-6 and by increasing anti-inflammatory IL-10. 
7. Betaine treatment prevents initial fibrogenesis by decreasing TGF-β expression in 
the liver that was increased in NAFLD model. 
8. NRG-1 aggravates liver fibrosis in CCl4 and BDL mouse model by increasing ECM 
accumulation. The pro-fibrotic effects of NRG-1 could be mediated by ErbB3 
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The Effects of a-Lipoic Acid on Liver Oxidative Stress and Free Fatty Acid
Composition in Methionine–Choline Deficient Diet-Induced NAFLD
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ABSTRACT Development of nonalcoholic fatty liver disease (NAFLD) occurs through initial steatosis and subsequent
oxidative stress. The aim of this study was to examine the effects of a-lipoic acid (LA) on methionine–choline deficient
(MCD) diet-induced NAFLD in mice. Male C57BL/6 mice (n = 21) were divided into three groups (n = 7 per group): (1)
control fed with standard chow, (2) MCD2 group—fed with MCD diet for 2 weeks, and (3) MCD2 + LA group—2 weeks on
MCD receiving LA i.p. 100 mg/kg/day. After the treatment, liver samples were taken for pathohistology, oxidative stress
parameters, antioxidative enzymes, and liver free fatty acid (FFA) composition. Mild microvesicular hepatic steatosis was
found in MCD2 group, while it was reduced to single fat droplets evident in MCD2 + LA group. Lipid peroxidation and
nitrosative stress were increased by MCD diet, while LA administration induced a decrease in liver malondialdehyde and
nitrates + nitrites level. Similary, LA improved liver antioxidative capacity by increasing total superoxide dismutase (tSOD),
manganese SOD (MnSOD), and copper/zinc-SOD (Cu/ZnSOD) activity as well as glutathione (GSH) content. Liver FFA
profile has shown a significant decrease in saturated acids, arachidonic, and docosahexaenoic acid (DHA), while LA treatment
increased their proportions. It can be concluded that LA ameliorates lipid peroxidation and nitrosative stress in MCD diet-
induced hepatic steatosis through an increase in SOD activity and GSH level. In addition, LA increases the proportion of
palmitic, stearic, arachidonic, and DHA in the fatty liver. An increase in DHA may be a potential mechanism of anti-
inflammatory and antioxidant effects of LA in MCD diet-induced NAFLD.
KEY WORDS:  antioxidant  DHA  FFA  lipid peroxidation  lipotoxicity  liver  mice  steatosis
INTRODUCTION
Methionine–choline deficient (MCD) diet iswidely used for the development of nonalcoholic fatty
liver disease (NAFLD) and nonalcoholic steatohepatitis
(NASH) animal model.1 NAFLD includes a wide spectrum
of liver diseases ranging from simple steatosis to steatohe-
patitis and cirrhosis, which often progress to hepatocellular
carcinoma (HCC).2 The earliest stage of NAFLD is simple
hepatic steatosis, which is characterized by deposition of
triglycerides in more than 5% of hepatocytes. Hepatic stea-
tosis can progress to NASH and about 20% of patients with
NASH develop cirrhosis, while about 28% of patients with
NASH-induced cirrhosis develop hepatocellular carcino-
ma.3 Nowadays, the prevalence of NAFLD increases rapidly
parallel with obesity and diabetes.
Mechanisms involved in the progression of steatosis to
NASH are complex and not completely understood. Insulin
resistance, oxidative stress, inflammation, and innate im-
mune system activation contribute to the development of
NAFLD through steatosis and inflammation in the liver.4
Although still poorly understood, the pathogenesis of
NAFLD is widely explained by a two-hit model theory in
which the first hit is an initial metabolic disturbance that
increases the inflow of free fatty acids (FFAs) and de novo
lipogenesis, leading to steatosis. Triglyceride accumulation
in hepatocytes increases the sensitivity of the liver to sec-
ondary insults (the ‘‘second hit’’), which include oxidative
stress, decreased hepatic ATP production, and induction of
proinflammatory cytokines.5,6 Many studies on animals and
humans have shown correlation between severity of NASH
and oxidative stress degree.7,8
Various animal models of NAFLD/NASH were used in
previous studies, and they may be classified into genetic
models, nutritional models, and their combinations. Al-
though numerous animal models are used, neither com-
pletely reflects pathophysiology and liver histopathology of
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human NAFLD/NASH.9 One commonly used model is
treatment with CCL4 (carbon-tetrachloride). CCl4-induced
toxicity and its mechanisms have been extensively investi-
gated after oral administration to rodents. A large number of
rat models have been reported to develop both liver cirrhosis
and HCC using CCl4 or diethylnitrosamine.
10 CCl4 is a
well-known compound for the production of chemical he-
patic injury which is mediated by metabolites that react with
antioxidant enzymes, such as glutathione (GSH), catalase
(CAT), and superoxide dismutase (SOD), and increase the
level of inflammatory cytokines,11 which make this model
of liver injury suitable for investigation of antioxidant ac-
tivity in vivo.
Recently, the role of lipotoxicity was emphasized in the
pathogenesis of NAFLD. Lipotoxicity is known to promote
hepatocyte death, which in the context of NAFLD is termed
lipoapoptosis.12 Lipoperoxides generated by the reaction of
free radicals with membrane fatty acids can induce hepa-
tocyte membrane damage. The fatty acid profile may in-
fluence the formation of lipoperoxides, as it is known that
unsaturated fatty acids are more susceptible to oxidative
modification than are saturated fatty acids.
a-Lipoic acid (LA) is a natural compound, chemically
named 5-(1,2-dithiolan-3-yl) pentanoic acid, that is also
known as thioctic acid. In humans, LA is synthesized in the
liver and other tissues with high metabolic activity, such as
the heart and kidney. It is also synthesized in small amounts
by plants.13 Previous studies have suggested that LA can
improve liver antioxidant defense in rats.14 LA has reactive
oxygen species scavenging capacity, the capacity to regen-
erate endogenous antioxidants, such as GSH, and vitamins E
and C, and a metal-chelating capacity.15 Unlike other anti-
oxidants, LA is both water and lipid soluble and, therefore,
can cross biological membranes easily and has its antioxi-
dant action both in the cytosol and in the plasma
membrane.16
Although the direct antioxidative role of LA was con-
firmed, its indirect effects on the course of NAFLD through
changes in liver fatty acid profile are not completely clear. A
possible link between fatty acid profile and antioxidative
properties of LA may have potential beneficial effects in the
prevention of steatosis progression into NASH. Therefore,
the aim of this study was to examine the effects of LA
treatment on liver oxidative stress parameters, FFA com-




The experiment was performed on male C57BL/6 mice,
weighing on average 23 – 3 g, raised at Military Medical
Academy in Belgrade. Animals were housed individually in
a controlled laboratory environment (temperature 22C –
2C, relative humidity 50% – 10%, 12/12 h light-dark cycle
with lights turned on at 9:00 h a.m.). All experimental pro-
cedures were in full compliance with Directive of European
Parliament and of the Council (2010/63EU) and approved
by the ethics committee of the University of Belgrade
(no. 695/2).
All animals (n = 21) were on standard chow before the
experiment. At the age of 8 weeks, they were randomly
divided into the following groups: (1) control (C; n = 7)—
continuously fed with standard chow; (2) MCD2 group
(n = 7)—fed with MCD diet for 2 weeks, and (3) MCD2 +
LA group (n = 7)—fed with MCD diet and simultaneously
treated with a-LA (100 mg/kg daily i.p.) for 2 weeks.
Control diet contained 2 g/kg choline chloride and 3 g/kg
methionine, while MCD diet (MP Biomedicals) had the
same composition as control standard chow without methio-
nine and choline with the expense of sucrose (22.76%). Before
administration, LA (Sigma-Aldrich) was dissolved in saline in
a concentration of 10 mg/mL (injection volume 0.01 mL/g
body weight). All animals had free access to adequate food
and water during the experiment. During the diet, daily food
intake was measured, while body weight was measured
weekly and compared with liver weight after sacrifice.
After the treatment, animals were sacrificed by exsan-
guinations in ketamine (100 mg/kg i.p.) anesthesia. On the
day before sacrifice, mice were fasted overnight. Liver
samples were collected for pathohistological analysis, FFA
level measurement, determination of oxidative stress pa-
rameters, and antioxidative enzymes activity.
Sample preparation
Liver samples for biochemical analysis were homoge-
nized on ice in cold buffered 0.25 M sucrose medium
(Serva, Feinbiochemica) that contained 10 M phosphate
buffer (pH 7.0) and 1 mM EDTA (Sigma Chem. Co.). The
homogenates were centrifuged at 2000 g for 15 min at 4C.
Crude sediments were dissolved in a sucrose medium
and centrifuged. The supernatants were transferred into the
tubes and centrifuged at 3200 g for 30 min at 4C. Obtained
sediments were dissolved in deionized water. After 1 h of
incubation, the samples were centrifuged at 3000 g for
15 min at 4C, and supernatants were stored at - 70C.
Supernatants obtained were combined after three rounds of
centrifugation. Proteins were determined by the Lowry
method using bovine serum albumin as the standard.17
Biochemical analysis
Total SOD (tSOD; EC1.15.1.1) activity in the liver was
measured spectrophotometrically, as an inhibition of epi-
nephrine autooxidation at 480 nm. After the addition of
10 mM epinephrine (Sigma), an analysis was performed in
the sodium carbonate buffer (50 mM, pH 10.2; Serva,
Feinbiochemica) containing 0.1 mM EDTA (Sigma). Sam-
ples for manganese SOD (MnSOD) were previously treated
with 8 mM KCN (Sigma) and then analyzed as previously
described.18 Activity of copper/zinc-SOD (Cu/ZnSOD) was
calculated as a difference between the activities of total
SOD and MnSOD.
Lipid peroxidation in the plasma and liver homogena-
tes was measured as malondialdehyde (MDA) production,
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assayed in the thiobarbituric acid.19 The results are ex-
pressed as nM/mg protein in liver homogenates.
The concentration of nitrites + nitrates (NOx) as a mea-
sure of nitric oxide (NO) production was determined by
using Griess reagent. With nitrites, Griess reagent forms a
purple azo dye, which can be measured spectrophotomet-
rically at 492 nm.20
Reduced GSH was determined using 5,5-dithiobis-2-
nitrobenzoic acid (36.9 mg in 10 mL of methanol), which
had reacted with aliphatic tiol compounds in Tris-HCl buffer
(0.4 mol, pH 8.9), thus making yellow-colored p-nitrophenol
anion. Spectrophotometric measurement of GSH concen-
tration at 412 nm was proportioned to color intensity of the
chemical compound produced.21
CAT activity in the liver was determined spectrophoto-
metrically at 240 nm on the basis of decline of hydrogen
peorxide absorbance and was expressed as units per mg of
proteins in the sample.21,22 One unit was defined as a re-
duction of 1 lM H2O2 per minute at 25C, pH 7.
Pathohistological analysis
Liver tissue was sectioned and incubated in 10% formalin
solution at room temperature. After the fixation, the liver
samples were processed by the standard method. Tissues
were incorporated in paraffin, sectioned at 5 lm, and then
stained with hematoxylin–eosin. Then, they were prepared
for light microscopy analysis. All samples were evaluated
by an experienced pathohistologist who was blinded to
the experiment. Preparations were analyzed and photo-
graphed using a combined photobinocular light microscope
Olympus BX51-equipped Artcore 500 MI Artray, Co. Ltd.,
Japan Camera.
FFA analysis
Lipids for further fatty acid analysis were extracted ac-
cording to the Bligh and Dyer method.23 The methyl esters
of the fatty acids (FAMEs) from the lipid extract were
transesterified with HCl in methanol according to the
method described by Ichihara and Fukubayashi.24 FAMEs
were quantified using an Agilent Technologies 7890A Gas
Chromatograph with a flame ionization detector. Separation
of the FAMEs was performed on a 112-88A7, HP-88 cap-
illary column (100 m · 0.25 mm · 0.2 lm) using He as a
carrier gas at a flow rate of 105 mL/min. The samples were
injected at a starting oven temperature of 175C, injector
temperature was 250C, and detector temperature was
280C. The oven temperature was programmed to increase
from 175C to 220C at 5C/min. Fatty acids were identified
by their retention time with reference fatty acid standards
(Supelco FAME Mix) and were expressed as a percentage
of total fatty acids in the liver.
Statistical analysis
Results are expressed as means – SD. Since the normal
distribution of parameters was confirmed by Kolmogorov–
Smirnov test, one-way analysis of variance (ANOVA) with
Tukey’s post hoc test was used for testing the difference
among groups. The difference was considered statistically
significant if P < .05. Computer software SPSS 15.0 was
used for the statistical analysis.
RESULTS
During the experiment, no significant difference (P > .05)
in animal weight and daily food intake between groups was
found (data not shown).
Oxidative stress
Our results have shown significantly increased liver
MDA level in MCD2 group (398.02 – 78.43 nmol/mg protein)
as compared with control (239.78 – 41.09 nmol/mg protein)
(P < .01). In contrast, MCD diet with LA treatment induced a
significant decrease in liver MDA level (93.56 – 22.06 nmol/
mg protein) as compared with control (P < .01) (Fig. 1A).
Similar to liver MDA level, MCD diet caused a signifi-
cant increase in liver NOx concentration (35.23 – 4.78 nmol/
mg protein) when compared with control group (19.45 –
6.02 nmol/mg protein) (P < .01). On the other hand, NOx
concentration was not significantly different between MCD2 +
LA group and control (P > .05) (Fig. 1B).
CAT activity in the liver was significantly decreased in
both MCD2 (63.77 – 13.85 U/mg protein) and MCD2 + LA
(56.36 – 15.00 U/mg protein) groups as compared with
control (133.10 – 40.54 U/mg protein) (P < .01), with no
significant difference (P > .05) between experimental groups
(Fig. 2).
The liver GSH content was significantly decreased 2
weeks after the initiation of MCD diet (102.44 – 10.12 nmol/
mg protein) as compared with control (123.23 – 12.32 nmol/
mg protein) (P < .05). In contrast to liver CAT activity, LA
treatment induced a significant increase in liver GSH con-
tent (154.87 – 18.66 nmol/mg protein) when compared with
control and MCD2 group (P < .01) (Fig. 3).
MCD diet alone caused a significant decrease in liver total
SOD activity (2.95 – 1.40 U/mg protein) as compared with
control (27.96 – 5.98 U/mg protein). However, in the group
treated with LA and MCD diet, total SOD activity was
significantly increased (55.08 – 8.04 U/mg protein) when
compared with control and MCD2 group (P < .01).
Changes in total SOD activity were accompanied by the
same changes in MnSOD and Cu/ZnSOD activity. While
MCD diet alone provoked a significant decline in the ac-
tivity of both izoenzymes (1.62 – 0.92 U/mg protein, and
1.33 – 0.69 U/mg protein, respectively) as compared with
control (16.09 – 2.49 U/mg protein and 13.16 – 2.46 U/mg
protein, respectively) (P < .01), the activities of MnSOD and
Cu/ZnSOD were significantly increased in MCD2 + LA
versus control group (29.60 – 9.06 U/mg protein, and
33.56 – 8.97 U/mg protein, respectively; P < .01) (Fig. 4).
Pathohistological analysis
No pathological changes were found in control group
(Fig. 5A). Mild hepatic steatosis with focal fatty change in
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the form of microvesicular steatosis was found in MCD2
group, accompanied with mild perivascular inflammation
(Fig. 5B). In MCD2 + LA group, steatosis and inflammation
were less pronounced than in MCD2 group with a few fat
droplets occasionally seen in hepatocytes (Fig. 5C).
FFA analysis
MCD diet induced a significant decrease in liver palmitic
(C16:0) and stearic acid (C18:0) proportion after 2 weeks as
compared with control (P < .01). Palmitic acid proportion
was, also, significantly lower in MCD2 + LA group versus
control, but to a significantly lesser extent than in MCD2
group (P < .01). On the other hand, stearic acid proportion
was significantly higher in MCD2 + LA versus. control
group (P < .05). While the proportion of oleic acid (C18:1
n9) was significantly higher, the proportion of oleic acid
isomer (C18:1 n7) was significantly lower in MCD2 group
when compared with control (P < .01). The combination of
LA and MCD diet induced no significant changes in liver
oleic acid isomer versus control group (P > .05). The pro-
portion of linoleic acid (C18:2 n6) was significantly higher
in MCD2 group versus control (P < .01), while in MCD2 +
LA group, the proportion of linoleic acid did not signifi-
cantly differ from the control (P > .05). When compared
with control group, arachidonic acid (C20:4 n6) was sig-
nificantly lower (P < .05) and docosapentaenoic acid (DPA,
C22:5 n3) was significantly higher (P < .01) in MCD2 group.
Similar to linoleic and oleic acid, in MCD2 + LA group, no
significant difference in liver arachidonic acid and DPA was
found when compared with control (P > .05). In contrast, the
proportion of liver docosahexaenoic acid (DHA, C22:6 n3)
was not significantly changed in MCD2 group as compared
with control (P > .05), while LA treatment in combination
with MCD diet induced a significant increase in DHA when
compared with control (P < .05) (Table 1).
FIG. 1. Liver MDA level (A) and NOx concentration (B) in MCD
diet-treated mice and mice on MCD diet with LA administration.
(MCD2 and MCD2 + LA respectively). Since the normal distribution
of parameters was confirmed by Kolmogorov–Smirnov test, signifi-
cance of the difference was estimated by using one-way ANOVA
with Tukey’s post hoc test (**P < .01 vs. control). MCD, methionine–
choline deficient; LA, a-lipoic acid; MDA, malondialdehyde; NOx,
nitrates + nitrites; ANOVA, analysis of variance.
FIG. 2. Liver CAT activity after MCD diet treatment and MCD diet
with LA administration. Since the normal distribution of parameters
was confirmed by Kolmogorov–Smirnov test, significance of the
difference was estimated by using one-way ANOVA with Tukey’s
post hoc test (**P < .01 vs. control). For further information, see
Figure 1. CAT, catalase.
FIG. 3. Liver GSH content in mice treated with MCD diet with or
without LA administration. Since the normal distribution of param-
eters was confirmed by Kolmogorov–Smirnov test, significance of the
difference was estimated by using one-way ANOVA with Tukey’s
post hoc test (*P < .05, **P < .01 vs. control; ##P < .01 vs. MCD2
group). For further information, see Figure 1. GSH, glutathione.
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DISCUSSION
It is well known that oxidative stress contributes to liver
injury regardless of its etiology. Recently, many studies
have pointed to the antioxidant effects of LA.25 In accor-
dance with other studies of NAFLD,26 lipid peroxidation
and nitrosative stress were also accompanied with mild
steatosis in our study after MCD diet (Fig. 1). NO promotes
oxidative stress-induced cell injury by formation of perox-
ynitrite anion, a potent prooxidant that causes protein ni-
tration and tissue injury.27 Oxidative injury in MCD diet
model of NAFLD may be due to GSH depletion, as well as
to decline in CAT and SOD activity (Figs. 2–4). Poor ac-
tivity of CAT in both experimental groups may be poten-
tially due to secondary activated alternative GSH-pathways,
so the CAT could be more active in the early phase of the
model. The role of GSH depletion in the pathogenesis of
NAFLD is supported by many other studies.8,26 A decrease
in GSH/GSSG ratio reflects the shift of liver redox balance
toward pro-oxidants as well as decreased synthesis of GSH
due to methionine deficiency in the food. In addition,
increased NO production may also contribute to a decline in
intracellular GSH level and aggravation of cellular injury.28
Studies in experimental models and in the human popu-
lation suggest that FFAs may play an important role in the
pathogenesis of NAFLD.29 Recent data suggested that satu-
rated fatty acids have more severe lipotoxic and proapoptotic
effects in the liver than do unsaturated fatty acids.30,31
However, changes in liver FFA profile in NAFLD still
remain controversial. Some studies on patients with NAFLD
and NASH have shown that hepatic FFAs were unchanged
across the spectrum of liver injury,32 while plasma FFA
levels were significantly increased in NAFLD and they were
suggested to be the primary source for triglyceride (TAG)
synthesis in hepatocytes.33 On the other hand, a high fat diet
was found to induce an increase in liver DHA level in
mice.34 Our study has shown a decrease in hepatic saturated
(palmitic and stearic acid) and arachidonic acid proportions
in the group treated with MCD diet for 2 weeks.29,35
LA was found to have antioxidant effects, as well as to
affect lipid metabolism in the liver. It has been shown in
cultured rat hepatocytes that LA treatment significantly
FIG. 4. The effects of MCD diet and
LA treatment on tSOD, MnSOD, and
Cu/ZnSOD activity in mice liver. Since
the normal distribution of parameters
was confirmed by Kolmogorov–Smir-
nov test, significance of the difference
was estimated by using one-way AN-
OVA with Tukey’s post hoc test
(*P < .05, **P < .01 vs. control;
##P < .01 vs. MCD2). For further in-
formation, see Figure 1. tSOD, total
superoxide dismutase; MnSOD, man-
ganese SOD; Cu/ZnSOD, cuprum/zinc
SOD.
FIG. 5. Histological findings of liver tissue (hematoxylin and eosin, · 10). Control (A) group shows normal morphology of the liver. In MCD2
group (B), microvesicular hepatic steatosis with focal fatty change was observed with mild perivascular inflammation. In MCD2 + LA group (C),
reduced steatosis with single fat droplets was evident with reduced inflammatory infiltrate. Color images available online at www.liebertpub.com/jmf
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inhibited FFA oxidation or reduced it even by 82%. In the
same study, it was also suggested that LA at therapeutic
concentrations increased pyruvate oxidation by activation of
the pyruvate dehydrogenase complex and decreased gluco-
neogenesis.36 In addition, LA treatment of insulin-resistant
rats for 14 weeks decreased plasma FFA concentrations and
this effect appears to be mediated, in part, by increased
hepatic PPAR-a expression, which may beneficially affect
insulin resistance.37
In our study, LA diminished MCD diet-induced lipid
peroxidation and nitrosative stress, probably due to in-
creased GSH level and SOD activity (Figs. 3 and 4). Similar
effects of LA were found in heart and kidney tissues,27 but
the effects on GSH level was found to be most marked in the
liver because of high activity of GSH-synthesizing enzymes
in this organ.38,39 However, the antioxidant effects of the LA
in NAFLD may be potentially due to its direct inhibition of
the free radicals (in the case of peroxinitrites), rather than
increased expression of the antioxidant enzymes. The anti-
oxidative effects of LA may be potentially mediated by
changes in fatty acid profile. n-3 Polyunsaturated fatty acids
may reduce oxidative damage and restore free radical ho-
meostasis by incompletely understood mechanisms.11 It has
been shown that linoleic, eicosapentaenoic acid (EPA), and
DHA have beneficial effects on oxidative stress in the kid-
neys by reducing MDA level, and increasing SOD and CAT
activity.40,41 However, our study suggests only the role of
DHA, and not of linoleic acid as a mediator of antioxidative
effects of LA in the liver, as only the proportion of DHA
increases after LA administration (Table 1). This possibly
indicates that supplementation of DHA, but not all poly-
unsaturated acids may potentiate the hepatoprotective ef-
fects of LA in NAFLD.
Other studies have also shown that supplementation with
DHA significantly reduced NO content and increased SOD
and CAT activity in the liver and brain. DHA supplemen-
tation improves cognitive functions and delays the onset of
pentylenetetrazole-induced seizures, at least partly through
attenuation of oxidative stress. In addition, DHA positively
modulates phosphatidylserine biosynthesis and accumula-
tion in neuronal cells, increases cell membrane fluidity, and
inhibits apoptosis in a phosphatidylserine-dependent man-
ner.42 The effects of DHA on membrane lipid composition
in the liver has to be further investigated, but these effects
may potentially contribute to modulation of oxidative stress
in NAFLD after LA treatment found in our study.
Arachidonic acid was, also, found to cause an increase in
MnSOD, Cu/ZnSOD, and CAT activities in rat hippocampal
slices.43 Since LA prevented MCD diet-induced decline in
arachidonic acid level in the liver, this can possibly be an
additional indirect mechanism of LA antioxidant effect.
However, this effect has to be further investigated by sup-
plementation with arachidonic acid using various models of
NAFLD.
Apart from influence on polyunsaturated fatty acids, an-
tioxidant effects of LA may be potentially further mediated
by an elevation of stearic acid proportion in the liver (Table
1). This may be surprising, as saturated fatty acids were
found to contribute to the apoptosis of hepatocytes and to the
progression of NAFLD, but stearic acid treatment has been
shown to increase the activity of SOD, especially Cu/
ZnSOD izoenzyme, CAT, and GSH peroxidase.44 This can
be considered one of the potentially beneficial effects of
stearic acid in NAFLD.
The effects of LA on liver fatty acid profile may, also, be
responsible for the anti-inflammatory effects of LA in
NAFLD found in the present study. n-3 Polyunsaturated fatty
acids reduce the inflammation in the liver through stimulation
of resolvin and protectin synthesis, as well as through inhi-
bition of phospholipase A2, an initial enzyme in the synthesis
of prostaglandins and leukotrienes. In addition, palmitic acid
increases the hepatocyte sensitivity to the cytotoxic effects of
TNF-a.45 DHA also exerts anti-inflammatory effect in the
brain through reduction of microglial secretion of proin-
flammatory cytokines such as IL-6 and TNF-a.46 A recent
study has shown that a-linoleic acid, EPA, and DHA reduce
inflammation in both the heart and the liver and prevent
cardiac fibrosis.40 The present study suggests that increased
liver DHA proportion may be a potential mechanism of anti-
inflammatory effects of LA in MCD-induced model of
NAFLD (Table 1).
Based on our results, it can be concluded that LA ame-
liorates lipid peroxidation and nitrosative stress in MCD
diet-induced hepatic steatosis through an increase in SOD
activity and GSH level. In addition, LA increases the pro-
portion of palmitic, stearic, arachidonic, and DHA in the
Table 1. The Effect of Methionine-Choline Deficient Diet and a-Lipoic Acid Treatment on Liver Free Fatty Acid Profile
Hepatic free fatty acid (%)
Group C16:0 C18:0 C18:1 n9 C18:1 n7 C18:2 n6 C20:4 n6 C22:5 n3 C22:6 n3
Control 22 – 0.73 13.11 – 0.67 10.25 – 0.57 2.40 – 0.32 18.40 – 0.74 15.45 – 0.59 0.55 – 0.05 10.04 – 0.43
MCD2 16.66 – 1.17** 9.00 – 1.65** 14.44 – 1.94** 0.91 – 0.19** 26.07 – 2.54** 12.20 – 2.21* 1.23 – 0.24** 9.13 – 0.76
MCD2 + LA 19.81 – 0.81*## 15.27 – 0.60* 9.87 – 1.01 0.84 – 0.08** 19.44 – 1.36 15.64 – 1.13 0.59 – 0.23 11.56 – 1.15*
Animals were treated with MCD diet and MCD + LA (100 mg/kg daily i.p.) for 2 weeks (MCD2 and MCD2 + LA groups, respectively). Since the normal
distribution of parameters was confirmed by Kolmogorov–Smirnov test, significance of the difference was estimated by using one-way ANOVA with Tukey’s post
hoc test (*P < .05, **P < .01 vs. control; ##P < .01 vs. MCD2 group).
C16:0, palmitic acid; C18:0, stearic acid; C18:1 n9, oleic acid; C18:1 n7, oleic acid isomer; C18:2 n6, linoleic acid; C20:4 n6, arachidonic acid; C22:5 n3,
docosapentaenoic acid (DPA); C22:6 n3, docosahexaenoic acid (DHA); LA, a-lipoic acid; MCD, methionine–choline deficient; ANOVA, analysis of variance.
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fatty liver. Increase in DHA may be considered a potential
mechanism of anti-inflammatory and antioxidant effects of
LA in MCD diet-induced NAFLD.
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Background and Aims. Methionine-choline deficient (MCD) diet duration necessary for
development of non-alcoholic fatty liver disease (NAFLD) and the dynamic of lipid pro-
file and fatty acids are not completely established. The study examined dynamics and as-
sociation between liver free fatty acids (FFA), serum lipid profile and liver morphological
changes on MCD diet-induced NAFLD in mice.
Methods. Male C57BL/6 mice (n 5 28) were divided into four groups (n 5 7 per group):
control: fed with standard chow, MCD diet-fed groups: 2, 4 or 6 weeks. After treatment,
liver and blood samples were taken for histopathology, serum lipid profile, and liver FFA
composition.
Results. Hepatic FFA profile showed a decrease in saturated acids, arachidonic and do-
cosahexaenoic acid, whereas proportions of docosapentaenoic, oleic and linoleic acid
were increased. Total cholesterol, HDL and triglycerides progressively decreased,
whereas LDL level progressively increased. Focal fatty change in the liver appeared after
2 weeks, whereas diffuse fatty change with severe inflammation and ballooned hepato-
cytes were evident after 6 weeks.
Conclusions. Six-week diet model may be appropriate for investigation of the role of lip-
otoxicity in the progression of NAFLD. Therefore, supplementation with n-3 polyunsat-
urated acid like DHA, rather than DPA, especially in the initial stage of fatty liver disease,
may potentially have preventive effects and alleviate development of NAFLD/NASH and
may also potentially reduce cardiovascular risk by moderating dyslipidemia.  2014
IMSS. Published by Elsevier Inc.
Key Words: Free fatty acids, Lipid status, Methionine-choline deficient diet, NAFLD, Mice.
Introduction
Nonalcoholic fatty liver disease (NAFLD) includes a wide
spectrum of liver diseases ranging from simple steatosis
through steatohepatitis to irreversible cirrhosis and in some
cases hepatocellular carcinoma. Simple hepatic steatosis is
the earliest stage of NAFLD and is characterized by deposi-
tion of triglycerides in O5% of hepatocytes. In some pa-
tients, hepatic steatosis can progress to nonalcoholic
steatohepatitis (NASH), which is characterized by the pres-
ence of hepatocyte ballooning and an inflammatory infil-
trate. Within 10 years, 10e30% of patients with NASH
develop cirrhosis, whereas |28% of patients with NASH-
induced cirrhosis develop hepatocellular carcinoma (HCC).
However, altered lipid and glucose metabolism in NAFLD
Address reprint requests to: Tatjana S. Radosavljevic, MD, PhD, Insti-
tute of Pathophysiology, Faculty of Medicine, University of Belgrade, Dr.
Subotica 9, 11000 Belgrade, Serbia; Phone/Fax: þ381 11 2685 340;
E-mail: tanjamm@med.bg.ac.rs
0188-4409/$ - see front matter. Copyright  2014 IMSS. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.arcmed.2013.12.010
Archives of Medical Research 45 (2014) 116e124
and metabolic syndrome may directly affect tumor suppres-
sor genes and contribute to HCC development directly from
NASH. Accordingly, recent study has shown that 41.7% of
individuals with NAFLD/NASH-HCC had no evidence of
cirrhosis (1). Prevalence of NAFLD increases nowadays par-
allel with obesity and diabetes and is rapidly becoming a
global health problem (2). The pathogenesis of NAFLD
and mechanisms involved in the progression of steatosis to
NASH are complex and not completely understood. Howev-
er, increased visceral adiposity and insulin resistance with
increased free fatty acids (FFA) release play a major role
in the development of liver steatosis (3). Further events that
contribute to liver injury include oxidative stress and lipid
peroxidation, decreased antioxidant defense, early mito-
chondrial dysfunction, iron accumulation, imbalance of
adipokines, adipose-derived cytokines with chronic inflam-
mation, and gut-derived microbial adducts (4).
Various animal models of NAFLD/NASH were used in
previous studies and they may be classified into genetic
models (sterol regulatory element binding protein
(SREBP)-1c transgenic mice, phosphatase and tensin ho-
mologue deleted on chromosome 10 (PTEN) null mice;
methionine adenosyltransferase-1A (MAT1A) null mice,
ob/ob, db/db, etc.), nutritional models (methionine- and
choline-deficient (MCD) diet, a high-fat diet) and combined
models that include genetic and nutritional modifications.
Although numerous animal models of NAFLD/NASH are
used, none completely reflects pathophysiology and liver
histopathology of human NAFLD/NASH (5). An ideal
model should demonstrate steatosis, intralobular inflamma-
tion (especially in acinar zone 3) and hepatocellular
ballooning. Furthermore, animals should develop metabolic
abnormalities such as dyslipidemia, increased FFA level,
elevated liver enzymes, obesity, insulin resistance and
altered adipokine profile (6). Although MCD diet was used
for induction of NAFLD, the precise time course of liver
injury in this model was not elucidated. Understanding
the dynamics of liver injury, especially hepatic FFA profile
and lipid status is important because of their possible role in
progression of NAFLD.
Accordingly, the objective of this study was to examine
the effects of MCD diet on liver FFA composition, serum
lipid profile, and liver morphology in order to evaluate
the time dependency of these parameters changes, and po-
tential association between hepatic FFAs and serum lipid
profile in NAFLD/NASH animal model.
Materials and Methods
Animals
The experiment was performed on male C57BL/6 mice
weighing on average 23  3 g and reared at the Military
Medical Academy in Belgrade. Animals were housed in
controlled laboratory environment (temperature 22 
2C, relative humidity 50  10%, 12/12 h light-dark cycle
with lights turned on at 9:00 a.m.) and had free access to
water and standard chow before the experiment. All exper-
imental procedures were in full compliance with Directive
of European Parliament and of the Council (2010/63EU)
and approved by the Ethics Committee of University of
Belgrade (No. 695/2). This study was performed in
September 2012.
All animals (n 5 28) at the age of 8 weeks were
randomly divided into the following groups: 1. control
(C; n5 7)econtinuously fed with standard chow; 2. groups
fed with MCD diet for 2 (MCD2; n 5 7), 4 (MCD4; n 5 7)
or 6 weeks (MCD6; n 5 7). MCD (MP Biomedicals, Santa
Ana, CA) diet composition is shown in Table 1. Control
diet has the same formulation as MCD diet, except it con-
tained 2 g/kg choline chloride and 3 g/kg methionine. Body
weight was measured weekly during the experiment and
compared to liver weight after sacrifice.
On the day prior to sacrifice mice were fasted overnight.
After the treatment, animals were sacrificed by exsanguina-
tions in ketamine (100 m g/kg i.p.) anesthesia. Blood sam-
ples were taken from the right side of the heart by cardiac
puncture for determination of lipid status and liver enzyme
(aminotransferases, alkaline phosphatase-ALP) activities.
Liver samples were taken for histopathology and FFA level
measurement.
Histopathological Analysis
Liver tissue was sectioned and incubated in 10% formalin
solution at room temperature. After fixation, liver samples
were processed by the standard method. Tissues were
Table 1. Methionine/choline deficient diet composition
Nutrient g/kg
Alphacel non-nutritive bulk 10


















Source: MP Biomedical, CA.
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incorporated in paraffin, sectioned at 5 mm and then
stained with hematoxylin-eosin (HE). They were then pre-
pared for light microscopy analysis. All samples were
evaluated by an experienced histopathologist who was
blinded to the experiment. Preparations were analyzed
and photographed using a combined photobinocular
BX51 light microscope (Olympus, Tokyo, Japan) equip-
ped with an Artcore 500 MI camera (Artray Co., Ltd.,
Tokyo, Japan).
Serum Biochemical Analysis
Liver damage was biochemically confirmed by determina-
tion of the activity of serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and ALP. Activ-
ities of these enzymes were measured spectrophoto-
metrically at photometer BTS-330 according to the
manufacturer’s instruction using special kits containing 2-
oxoglutarate (Sigma Aldrich, St. Louis, MO) for ALT and
AST and a kit containing 4-nitrophenyl phosphate (Sigma
Aldrich) for ALP activity.
Lipid concentrations in plasma (total cholesterol, triacyl-
glycerol [TAG] and high-density lipoproteins [HDL]) were
measured by enzymatic colorimetric methods. Cholesterol
and triglyceride assay kits were purchased from Abcam
(Cambridge, UK, Cholesterol Assay Kit, ab65390; Triglyc-
eride Quantification Kit, ab65336).
Plasma total cholesterol concentration was determined
by measuring hydrogen peroxide generated by chole-
sterol oxidase in oxidative coupling reaction with 4-
aminoantipyrine and phenol at 500 nm (7). Plasma LDL
concentration was calculated by a combination of ultracen-
trifugation and precipitation procedure by Friedewald et al.
(8). Plasma HDL concentration was determined by using
enzymatic colorimetric method (Roche Diagnostics, Basel,
Switzerland). In the presence of double positively charged
anions, the HDL fraction was measured after selective
LDL precipitation by polyanion sulfates. In our experi-
mental protocol, dextran sulfate and magnesium sulfate
were used in accordance with the Centers of Disease Con-
trol and Prevention (Atlanta, GA: Lipid Reference Section).
After centrifugation, HDL fraction was determined directly
in the supernatant by the PAP method (9).
Modified cholesterol-oxidase reagent by inclusion of
2,4,6-tribromo-3-hydroxybenzoic acid (TBHBA) was used
to measure plasma TAG concentration according to the
enzymatic colorimetric method.
Free Fatty Acid Analysis
Lipids for further fatty acid analysis were extracted accord-
ing to the method of Bligh and Dyer (10). The methyl esters
of the fatty acids (FAMEs) from the lipid extract were
transesterified with HCl in methanol according to the
method described by Ichihara and Fukubayashi (11).
FAMEs were quantified using Agilent Technologies
(7890A Gas Chromatograph, Santa Clara, CA) with a flame
ionization detector. Separation of the FAMEs was per-
formed on a 112e88A7, HP-88 capillary column (100 m
 0.25 mm  0.2 mm) using He as a carrier gas at a flow
rate of 105 ml/min. The samples were injected at a starting
oven temperature of 175C, injector temperature was
250C and detector temperature was 280C. The oven tem-
perature was programmed to increase from 175C to 220C
at 5C/min. Fatty acids were identified by their retention
time with reference fatty acid standards (Supelco, FAME
Mix, Sigma Aldrich) and were expressed as a percentage
of total fatty acids in the liver.
Statistical Analysis
Results are expressed as mean  SD. As the normal distri-
bution of parameters was confirmed by Kolmogorov-
Smirnov test, one-way analysis of variance (ANOVA) with
Tukey’s post hoc test was used for testing the difference
among groups. Association between parameters was deter-
mined using Pearson’s correlation coefficient; p !0.05 was
considered statistically significant. SPSS (v.15.0) was used
for statistical analysis.
Results
MCD diet induced a significant decrease in body weight af-
ter 2 (17.29  1.41g), 4 (15.86  1.16 g) and 6 weeks
(15.00  1.00 g) compared with control (22.86  1.77 g)
( p !0.01). The lowest body weight was observed in the
MCD6 group. Also, the liver/body weight ratio was signif-
icantly lower in all MCD diet-treated groups in comparison
with control. However, after an initial decline in MCD2
group (4.08  0.45%) vs. control (5.58  0.60%) ( p !
0.01), the most prominent decrease in this ratio was evident
in the MCD4 group (4.21  0.47%) (Figure 1).
Figure 1. Effects of methionine choline deficient (MCD) diet on animal
body weight and body/liver weight ratio 2, 4 and 6 weeks after beginning
of treatment (MCD2, MCD4 and MCD6 groups, respectively). Signifi-
cance of the difference was estimated by using one-way analysis of
variance (ANOVA) with Tukey’s post hoc test was used (*p !0.05,
**p !0.01 vs. control). Data are presented as mean  SD.
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Histopathological Findings
No pathological changes were found in the control group
(Figure 2A). MCD diet caused hepatic steatosis in mice,
which was evident in all experimental groups. Mild hepatic
steatosis with focal fatty change was found in the MCD2
group in the form of microvesicular steatosis (Figure 2B).
Within 4 weeks, MCD diet induced moderate steatosis with
diffuse fatty change in mice liver (Figure 2C). In MCD6
group the presence of severe macrovesicular steatosis with
intralobular inflammatory infiltrate indicates NASH.
Ballooning degeneration of hepatocytes and cell swelling
was observed as a result of fat accumulation. Apoptotic
bodies may be occasionally seen in the MCD6 group
(Figure 2D).
Biochemical Analysis
Our study has shown that serum ALT activity was signifi-
cantly increased in all experimental groups (MCD2:
492.32  61.10 U/L, MCD4: 510.15  63.51 U/L and
MCD6: 537.09  77.32 U/L) in comparison with control
group (66.05  19.22 U/L) ( p !0.01). No significant dif-
ference in ALT activity was evident among MCD diet-
treated groups. AST activity was significantly increased in
MCD2 (642.87  42.24 U/L), MCD4 (669.65  86.21 U/
L) and MCD6 (896.45  121.22 U/L) group in comparison
with control (69.43  16.01 U/L). However, the most
pronounced increase was observed in the MCD6 group,
whereas between MCD2 and MCD4 groups no significant
difference was evident. On the other hand, MCD diet did
not cause the change in serum ALP activity in all experi-
mental groups when compared with control (Figure 3A).
Accordingly, AST/ALT ratio was significantly increased
in MCD diet-treated groups (MCD2: 1.30  0.04, MCD4:
1.31  0.05) in comparison with control (1.04  0.05) ( p
!0.05). However, the highest ratio was evident in MCD6
group (1.67  0.08) ( p !0.01) (Figure 3B).
Serum total cholesterol level was significantly decreased
in MCD diet-treated group at all timepoints in comparison
with control (2.34  0.25 mmol/L) ( p !0.01). The most
prominent decrease was observed in MCD6 group (1.16
 0.14 mmol/L) compared with MCD2 (1.57  0.15
mmol/L) and MCD4 groups (1.33  0.16 mmol/L) ( p !
0.01).
Analysis of serum cholesterol fractions has shown that
MCD diet induced a progressive decline in serum HDL
level. Although an initial decline was evident in MCD2
(1.17  0.09 mmol/L) when compared with control group
(1.57  0.20 mmol/L) ( p !0.01), serum HDL level was
significantly lower in MCD4 (0.28  0.07 mmol/L) and
MCD6 (0.18  0.08 mmol/L) groups in comparison with
MCD2 group ( p !0.01).
In contrast, serum LDL level was significantly elevated
in MCD4 (0.49  0.10 mmol/L) and MCD6 (0.73  0.10
Figure 2. Histological findings of liver tissue (hematoxylin & eosin). (A) Control group shows normal morphology of the liver (magnification 40). (B) In
MCD2 group focal fatty changes were evident (mild steatosis). (C) In MCD4 group diffuse fatty change was evident (more severe steatosis). (D) The most
prominent morphological changes were evident in MCD6 group with more extensive steatosis, prominent inflammatory infiltrate, cell swelling and
ballooning degeneration of hepatocytes. Apoptotic bodies may also be seen (magnification 100). For further information see Figure 1.
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mmol/L) groups in comparison with control (0.07  0.03
mmol/L) ( p !0.01). Difference in serum LDL level be-
tween MCD6 and MCD4 group was also highly significant
( p !0.01) (Figure 4).
Serum triglyceride level was significantly decreased in
all experimental groups (MCD2: 0.75  0.10 mmol/L,
MCD4: 0.7  0.14 mmol/L and MCD6: 0.48  0.05
mmol/L) in comparison with control group (1.52  0.12
mmol/L) ( p !0.01). The decrease was more prominent
in MCD6 group compared to MCD4 and MCD2 groups
( p !0.05) (Figure 4).
FFA Analysis by Gas Chromatography
MCD diet induced a significant decrease in liver palmitic
acid (C16:0) proportion at all timepoints and in stearic acid
(C18:0) proportion only 2 and 4 weeks after beginning of
the diet in comparison with control group ( p !0.01).
Whereas oleic acid (C18:1 n9) was significantly higher,
oleic acid isomer (C18:1 n7) was significantly lower in
all experimental groups when compared with control ( p
!0.01). Linoleic acid (C18:2 n6) was significantly higher
in all experimental groups vs. control with the highest
proportion in MCD2 group. After this period linoleic acid
(C18:2 n6) proportion progressively declined and in
MCD6 group it was significantly lower than in MCD2
group ( p !0.05). When compared with control
group, arachidonic acid (C20:4 n6) was significantly lower
( p !0.05) and docosapentaenoic acid (DPA, C22:5 n3)
was significantly higher ( p !0.01) only 2 weeks after
the beginning of the MCD diet. At other timepoints no sig-
nificant change was found. In contrast, liver docosahexae-
noic acid (DHA, C22:6 n3) proportion was significantly
decreased in MCD4 and MCD6 group in comparison with
control ( p !0.01) (Table 2).
Association Between FFA and Lipid Status
Assessments by the Pearson correlation coefficients re-
vealed significant correlation between liver DHA propor-
tion and serum LDL (r 5 866, p !0.001), total
cholesterol (r 5 813, p !0.001) and triglyceride level
(r 5 695, p !0.001), (Figure 5).
Discussion
NAFLD has an increasing prevalence and is strongly associ-
ated with obesity, diabetes and metabolic syndrome. For
studying NAFLD/NASH, animal models are essential tools.
A large number of rodent models of steatohepatitis have
recently been described, but no single animal model can
completely reflect the range of histopathological and patho-
physiological features associated with human NASH. Obese
and diabetic ob/ob mice develop steatohepatitis, but fibrosis
is missing due to leptin deficiency. On the other hand, hy-
perleptinemic db/db mice develop obesity and severe type
2 diabetes due to a functional defect in the long-form leptin
receptor. High fat diet-fed mice are obese with hyperinsuli-
nemia and glucose intolerance with developed insulin resis-
tance, similar to NAFLD in humans. However, other studies
reported that high-fat diet models failed to develop histolog-
ical evidence of steatohepatitis (12).
The MCD diet model is commonly used for NASH
because changes in the liver are reproducible, rapid and
similar to those observed in human NASH (4,11). By using
this model in our study, the results have shown initial fatty
changes in the mice liver after 2 weeks of MCD diet with
progressive deterioration to evident NASH 6 weeks after
the beginning of treatment (Figure 2). Because initial sim-
ple steatosis was found to progress into NASH within 6
weeks (Figure 2), it may be suggested that FFAs are
involved in this progression and this model may be suitable
for investigation of the possible role of FFAs in the patho-
genesis of NASH and liver fibrosis and cirrhosis. The model
used in our study can be considered as an advantage
compared to high-fat diet model that requires a longer time
period to develop fatty liver disease (13). Otherwise, the
Figure 3. Effects of MCD diet on serum enzymes (ALT, AST and ALP)
activity (A), and AST/ALT ratio (B). Significance of the difference was
estimated using one-way analysis of variance (ANOVA) with Tukey’s post
hoc test was used (*p !0.05, **p !0.01 vs. control; yyp !0.01 vs.
MCD4). ALT, alanine aminotransferase; AST, aspartate aminotransferase;
ALP, alkaline phosphatase. For further information see Figure 1.
120 Stankovic et al./ Archives of Medical Research 45 (2014) 116e124
major disadvantage of the MCD diet model is its associa-
tion with significant weight loss, often 20% of body weight
after 2e3 weeks, found in the present and other studies and
also the absence of insulin resistance and metabolic syn-
drome (14). Whereas a decline of liver/body weight ratio
was evident 2 and 4 weeks after beginning of treatment, this
ratio was higher after 6 weeks than in MCD2 and MCD4
group (Figure 1) due to an increase in liver weight. This in-
crease is a consequence of fat accumulation, evident on his-
topathology (Figure 2) due to methionine and choline
deficiency, which impairs very low-density lipoprotein
(VLDL) efflux from the liver. Methionine is necessary for
ApoB100 synthesis, whereas choline is required to make
the phosphatidylcholine portion in VLDL particles (15).
In addition, fat accumulation may be a consequence of
decreased b-oxidation of fatty acids and increased de novo
lipogenesis due to upregulation of SREBP-1c. TAG reten-
tion in the liver may also be responsible for decreased
serum triglyceride level found in the present study (Figures
2 and 4B). Park et al. found that after only 1 week of MCD
diet, serum triglyceride level decreased (16).
Apart from reduction of serum triglyceride level, results
of our study have shown that MCD diet induced a signifi-
cant decrease in serum total cholesterol level. However, this
diet does not seem to have protective effect because LDL/
HDL ratio reveals atherogenic lipid serum profile in MCD
diet-induced NAFLD (Figure 4) as found in other studies
(17). This represents an advantage of this model when
compared with mice nullizygous for acyl-CoA oxidase
(ACOX) model because NAFLD is also associated with
atherogenic serum lipid profile in obese humans (18).
Keeping in mind that high levels of FFA can result in
increased intracellular TAG synthesis and formation of lipid
droplets (19), this study is one of the first that determined
fatty acid profile in MCD diet model of NAFLD. Our study
has shown a decrease in hepatic saturated acid proportion
Table 2. Effect of MCD diet on liver free fatty acid profile*
Group
Free fatty acid (%)
C 16:0 C 18:0 C 18:1 n9 C 18:1 n7 C 18:2 n6 C 20:4 n6 C 22:5 n3 C 22:6 n3
Control 21.9  0.78 13.24  0.73 10.11  0.67 2.33  0.37 18.47  0.76 15.53  0.62 0.54  0.05 10.09  0.44
MCD2 16.66  1.17** 9.00  1.65** 14.44  1.94** 0.91  0.19** 26.07  2.54** 12.20  2.21* 1.23  0.24** 9.13  0.76
MCD4 15.66  0.49** 10.47  1.08** 15.43  2.22** 0.89  0.27** 22.86  1.87* 14.51  1.90 0.44  0.15 7.16  0.95**
MCD6 16.74  0.68** 12.29  0.68 13.44  1.80** 0.90  0.18** 21.77  1.20*a 16.00  1.02 0.43  0.08 6.46  0.73**
C 16:0, palmitic acid; C 18:0, stearic acid; C 18:1 n9, oleic acid; C 18:1 n7, oleic acid isomer; C 18:2 n6, linoleic acid; C 20:4 n6, arachidonic acid; C 22:5 n3,
docosapentaenoic acid (DPA); C 22:6 n3, docosahexaenoic acid (DHA).
*Duration of MCD diet was 2, 4 or 6 weeks (MCD2, MCD4 and MCD6, respectively).
Significance of the difference was estimated by using one-way ANOVA with Tukey’s post hoc test (**p !0.01, *p !0.05 vs. control).
ap !0.05 vs. MCD2 group.
Figure 4. Time-dependent effects of MCD diet on serum lipid profile: total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL)
and triglyceride level. Significance of the difference was estimated by using one-way analysis of variance (ANOVA) with Tukey’s post hoc test was used (*p
!0.05, **p !0.01 vs. control; #p !0.05, ##p !0.01 vs. MCD2; yp !0.05, yyp !0.01 vs. MCD4). For further information see Figure 1.
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(palmitic and stearic acid), oleic acid isomer, arachidonic
acid and DHA, whereas the proportions of hepatic oleic,
DPA and linoleic acid were elevated. In addition, increase
in hepatic DPA and linoleic acid proportion was most pro-
nounced in MCD2, whereas the highest oleic acid propor-
tion was evident in MCD4 group (Table 2). Because the
hepatotoxic effect of saturated acids are well known, a sig-
nificant decrease in C 16:0 and C 18:0 proportions may
potentially alleviate liver injury caused by MCD diet. On
the other hand, n-3 PUFAs are known to have many bene-
ficial effects on the liver. MCD diet induced a progressive
decrease in DHA. Supplementation with this fatty acid
may possibly have protective effects for NAFLD rather than
DPA, whose proportion was not significantly changed in
this NAFLD model.
Time-dependent changes in liver FFAs may be explained
by variable degrees of FFA esterification in the hepatocytes
to form TAGs. Other human or experimental studies have
shown contradictory findings related to FFA profile in the
liver and serum. In contrast to our model, high-fat diet
was found to induce an increase in liver DHA level (20).
Studies on patients with NAFLD and NASH have shown
that hepatic FFAs were unchanged across the spectrum of
liver injury (21), whereas plasma FFA levels were signifi-
cantly increased in NAFLD and were suggested to be the
primary source for TAG synthesis in hepatocytes (22),
Within TAGs and diacylglycerols, the saturated palmitic
acid and the monounsaturated oleic acid were elevated, re-
flecting, perhaps, their greater availability in the circulating
FFA pool (23). Other studies have demonstrated elevated
levels of circulating oleic and palmitic acid in patients with
NAFLD (24). This discrepancy between our study and
other studies can be explained by different mechanisms of
NAFLD development in humans and MCD diet model
due to the absence of obesity and metabolic syndrome in
MCD-diet fed mice (5,16).
Although MCD diet does not provoke insulin resistance,
which is important in the pathogenesis of NAFLD in
humans, this model may be potentially used for the inves-
tigation of lipotoxic effects of FFA. FFA lipotoxicity in
NAFLD has been described in many studies so far
(24,25). In vitro exposure of liver cells (HuH7) to high con-
centrations of FFA results in fat overload, which promotes
inflammatory and fibrogenic response similar to those
observed in patients with NAFLD and NASH (25). Also,
Jun et al. recently showed that FFA treatment of HepG2
cells resulted in hepatic lipotoxicity due to disrupted fatty
acid oxidation in hepatocytes (26). Intracellular FFA accu-
mulation is also associated with an inflammatory response
elicited by an increased gene expression of IL-6, IL-8 and
TNF-alpha (27,28) as well as in fibrosis (29). However,
the role of FFAs in NAFLD progression appears to be com-
plex because ob/ob mice (leptin deficient) develop steatohe-
patitis, but not liver fibrosis (12).
Recent studies have pointed to a possible association be-
tween serum FFAs and cardiovascular risk factors such as
dyslipidemia, insulin resistance and body mass index, also
present in NAFLD (30,31). However, in our animal NAFLD
model, a significant negative correlation between hepatic
DHA and serum LDL level may indicate a potential role
of DHA supplementation in prevention of atherogenic lipid
profile in NAFLD patients. In addition, DHA þ EPA diet
was found to decrease hepatic total cholesterol content
(32), whereas our study suggests that DHA may have an
opposite influence on serum cholesterol level because there
was a significant positive correlation found. Supplementation
with n-3 polyunsaturated fatty acids in humans showed a sig-
nificant decrease in serum triglyceride level (33). A signifi-
cant decrease in serum triglycerides in our animal NAFLD
model probably is not caused directly by decreased hepatic
DHA despite their positive correlation, but due to specific
lipid metabolism in rodents than in a human population.
Apart from inflammation, MCD diet induced apoptosis
in a 6-week period (Figure 2). Hepatocyte apoptosis is a
frequent histological finding in NAFLD and correlates with
progressive inflammation and fibrosis. In addition, in obese
Figure 5. Association between hepatic DHA and serum LDL (A), total cholesterol (B) and triglycerides (C). Correlation was estimated using Pearson’s cor-
relation coefficient r.
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humans with NAFLD, anti-apoptotic process is found to
inhibit FFA toxicity in fatty liver (34). The role of FFA in
apoptosis was confirmed by FFA treatment of cultured he-
patic cells (24). In accordance with these findings, it may be
suggested that oleic and linoleic acids, which were found to
increase during MCD diet, may contribute to apoptosis
found in MCD6 group. In addition, the magnitude of hepa-
tocyte apoptosis correlates with liver injury with higher
rates of apoptosis in patients with AST/ALT ratio O1
(35). This is consistent with the findings of our study. Ac-
cording to histology findings and liver FFA composition,
MCD diet treatment for 4 weeks may be used as a suitable
model of steatosis, whereas MCD diet treatment for 6
weeks may be used as a model of NASH as well as for
investigation of the role of lipotoxicity in the progression
of NAFLD.
Based on our results, it can be concluded that MCD diet
induces initial fatty change within 2 weeks with progression
to more diffuse fatty change at 4 weeks and NASH in 6
weeks accompanied by apoptosis and inflammation. MCD
diet induced a progressive decrease in serum triglyceride,
total cholesterol and HDL followed by a progressive in-
crease in serum LDL level. Palmitic and stearic acids,
DPA and DHA proportions were decreased after MCD diet
treatment, whereas oleic and linoleic acid proportion
increased. Therefore, supplementation with n-3 polyunsatu-
rated acids such as DHA, especially in initial stages of fatty
liver disease, may potentially have preventive effects and
alleviate development of NAFLD/NASH and reduce cardio-
vascular risk by moderating dyslipidemia, but this potential
effect of DHA needs to be further investigated on this and
other NAFLD animal models.
Based on differing mechanisms of NAFLD/NASH
development in humans and in MCD, MCD is a strongly
limited model appropriate for histological studies on
NASH, whereas metabolic processes, contribution of adi-
pose tissue and many other factors are not reflected.
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